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ABSTRACT
The maintenance of cellular protein homeostasis, or proteostasis, is dependent upon a complex
network of molecular chaperones, degradation machinery and other regulatory factors, which
together act to keep the proteome soluble and functional. Disturbances to proteostasis can lead to
protein aggregation and inclusion formation, processes associated with a variety of
neurodegenerative disorders. The heat shock proteins (Hsps) are a superfamily of molecular
chaperones that are dramatically upregulated in response to cellular stress. The Hsps can bind
aggregation-prone proteins and either refold or traffic them for degradation. One class of Hsps,
the DNAJBs, act as co-factors of the Hsp70 machine and have been previously identified as potent
suppressors of disease-related protein aggregation. This has raised the potential of targeting
DNAJB chaperone action in the context of protein aggregation associated with disease.

In the work described in this thesis, a destabilised isoform of the protein firefly luciferase
(R188Q/R261Q Fluc; FlucDM) was overexpressed in cells to assess how components of the
proteostasis machinery engage with aggregation-prone proteins to prevent them from forming
intracellular inclusions. In Chapter 3, FlucDM was used as a model aggregation-prone protein to
screen for the generic capacity of the major human Hsps to suppress intracellular inclusion
formation by destabilised proteins. This work marks the first use of the quantitative flow
cytometric analysis of inclusions and trafficking (FloIT) technique to conduct an Hsp
overexpression screen for modulators of inclusion formation in cells. Of the small Hsps, HspB4
HspB6, HspB7 and HspB9, reduced inclusion formation by FlucDM in cells. The major nucleotide
exchange factors, including members of the Bcl-2-associated athanogene and Hsp110 families,
did not modulate FlucDM aggregation. Of the HspA (Hsp70) family members tested, HspA1A and
HspA2 reduced inclusion formation by FlucDM. Significantly, all of the DNAJBs tested were
effective at reducing the aggregation of FlucDM into inclusions in cells, with DNAJB1, DNAJB5,
DNAJB6 and DNAJB8 being the most potent suppressors.
iv

Experiments investigating the exact molecular mechanism by which specific DNAJBs prevent
inclusion formation by destabilised proteins in cells are described in Chapter 4. DNAJBs suppress
inclusion formation by supporting the Hsp70-dependent degradation of FlucDM via the
proteasome. The serine-rich stretch in DNAJB6 and DNAJB8, essential for preventing fibrillar
aggregation, is not involved in the suppression of FlucDM inclusion formation. Conversely,
deletion of the C-terminal TTK-LKS motif in DNAJB6 and DNAJB8, a region not required to
suppress polyQ aggregation, abolished its ability to inhibit inclusion formation by FlucDM. Thus,
DNAJB6 and DNAJB8 possess two distinct regions for binding substrates, one that is responsible
for binding β-hairpins that form during amyloid formation and another that interacts with exposed
hydrophobic patches in aggregation-prone clients.

Finally, the aggregation propensity of FlucDM was exploited in order to measure the ability of
mouse neuroblastoma (Neuro-2a) and mouse neuroblastoma × spinal cord (NSC-34) motor neuron
hybrid cells to prevent inclusion formation. As part of the work presented in Chapter 5, a first step
towards a robust and quantitative method to measure the proteostasis capacity of a cell was
established. Using this method, it was demonstrated that NSC-34 cells were more susceptible to
FlucDM inclusion formation than Neuro-2a cells. Investigation into the major arms of the
proteostasis network indicated that heat shock transcription factor 1 (HSF1) activation remains a
valid therapeutic target for the treatment of neurodegenerative diseases, as overexpression of wildtype HSF1 reduced inclusion formation by FlucDM in both Neuro-2a and NSC-34 cells. The
mechanism by which HSF1 overexpression inhibits inclusion formation by FlucDM is dependent
upon proteostasis networks other than the Hsps and this likely involves presentation of destabilised
proteins for processing by the degradation machinery.

This work highlights the dynamic nature of the proteostasis network. This study validates the use
of FlucDM as a destabilised model protein that can be used as a sensor to elucidate how components
v

of the protein quality control network act together to maintain the conformational stability of
aggregation-prone proteins. The development of FlucDM as a protein folding sensor, along with
the diverse applications of flow cytometry described throughout this thesis provide a foundation
towards measuring the proteostasis capacity of a cell. This work identified that the Hsps have
unique client specificities and that DNAJBs possess distinct substrate binding regions for the
suppression of amyloidogenesis versus amorphous inclusion formation in cells. Future work
should investigate the potential of pharmacologically or genetically targeting molecular
chaperones and arms of the proteostasis network to treat neurodegenerative diseases.
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Chapter 1 – Introduction
Protein homeostasis, or proteostasis, refers to the maintenance of the conformational and
functional integrity of the proteome. The term proteostasis therefore encompasses all of the
pathways that regulate the synthesis, concentration, folding, trafficking and degradation of
proteins. Molecular chaperones are a key component of proteostasis as they play a central role in
facilitating the correct folding of nascent polypeptides and stabilising misfolded proteins to
prevent aggregation. Heat shock proteins (Hsps) are a family of molecular chaperones; when cells
are exposed to stress, the expression of some Hsps is dramatically upregulated. Hsps can bind
aggregation-prone proteins and either refold them or traffic them for degradation. Disturbances to
proteostasis are associated with many age-related diseases including neurodegenerative
conditions, with studies linking age to a subsequent decline in cellular proteostasis capacity (BenZvi et al., 2009). Consequently, the proteostasis network appears to be a promising therapeutic
target for the treatment of neurodegenerative diseases (Balch et al., 2008, Powers et al., 2009).
This literature review will discuss the association of cellular protein aggregation with disease
before highlighting the emerging evidence to suggest that different cell types display a differential
capacity to prevent protein aggregation. The role of Hsps in proteostasis will be discussed, due to
their proposed roles in minimising protein aggregation. Finally, this review will highlight current
methods used to investigate protein aggregation in cells and identify how these may be adapted
for use as potential methods to measure the proteostasis capacity of a cell.

1.1

Protein folding

The ability of a protein to adopt its correct three-dimensional structure depends upon the linear
sequence of amino acids of the polypeptide chain (Anfinsen, 1973). Following translation, most
proteins fold into a biologically active or functional conformation, termed the native state
(Broadley and Hartl, 2009). However, throughout their lifetime, certain factors may cause a
protein to unfold, misfold or reside in an intermediate (partially-folded) state. Schubert et al.
(2000) estimate that under physiological conditions, one third of all newly synthesised
2
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polypeptides never reach their native state. This is due, at least in part, to random errors in
translation and post-translational modifications that would normally aid in ensuring correct protein
folding (Allan Drummond and Wilke, 2009).

A further hindrance to protein folding is macromolecular crowding. The intracellular environment
is crowded by the presence of high concentrations of macromolecules throughout the cytosol.
These macromolecular constituents, which include lipids, carbohydrates and proteins, are vital for
cellular function. Generally, protein folding must occur under conditions in which
macromolecules are present at concentrations of ~300–400 g/L (Hartl and Hayer-Hartl, 2009),
which limits the space available for a protein to fold (Van Den Berg et al., 1999, Ellis and Minton,
2006). Under conditions of cellular stress, this crowded environment increases the probability of
unfavourable associations between partially-folded protein intermediates (Ecroyd and Carver,
2008). Despite the many hurdles that proteins must overcome in order to fold correctly, most do
so rapidly and without difficulty (Dobson, 2003). The processes that facilitate and regulate the
folding of a polypeptide chain into its functional native conformation are described below.

1.1.1

The thermodynamics of protein folding

Anfinsen (1973) was the first to describe the underlying mechanisms of protein folding, often
termed Anfinsen’s dogma or the “thermodynamic hypothesis”. Anfinsen postulated that all
requirements for a protein to fold correctly (and become biologically active) are contained within
the amino acid sequence of the polypeptide chain (Anfinsen, 1973). This led to the thermodynamic
hypothesis of protein folding which states that the three-dimensional structure of a protein in its
normal environment occurs when the Gibbs free energy of the entire system is at its lowest
(Anfinsen, 1973). Theoretically, due to the freedom of rotation of the bonds that link individual
amino acids in an unfolded polypeptide chain, even a short polypeptide can sample an almost
infinite number of conformations. Thus, if a protein with 100 amino acid residues were to sample
3
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every possible conformation before reaching its native state, the length of time taken for it to fold
would be astronomical (Dobson, 2003). Despite this, most proteins fold into their native state
within a matter of milliseconds.

The ability of a protein to fold so rapidly relies on the cooperation of many weak, non-covalent
interactions between side chains (e.g. hydrogen bonds and hydrophobic forces). Hydrogen bonds
between amino acid residues provide most of the directional and selective interactions that
facilitate correct protein folding (Myers and Pace, 1996). At some stage during folding, most
proteins undergo hydrophobic collapse (i.e. the burial of hydrophobic side chains inside the protein
structure), resulting in the formation of compact molten globular intermediates (Brockwell and
Radford, 2007, Hartl et al., 2011). The formation of these thermodynamically favourable globular
intermediates is a key process in the folding of a protein towards its native, biologically active
conformation. Proteins that form these partially-folded intermediates prior to reaching their native
state must overcome energy barriers that dictate the kinetic and thermodynamic properties that
allow the protein to fold correctly. This concept has led to the energy landscape model of protein
folding, in which polypeptide chains explore funnel-shaped potential energy surfaces as they fold
towards their native conformation (Figure 1.1) (Hartl et al., 2011). Under normal conditions,
native proteins are in equilibrium with partially-folded intermediate states and completely
unfolded (denatured) conformations, as part of the on-folding pathway (Hartl and Hayer-Hartl,
2002). However, under conditions of stress (e.g. increases in temperature or changes in pH),
partially-folded intermediates can persist at higher than normal concentrations, leading to
increased exposure of hydrophobic side chains (Wang et al., 2010).
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Figure 1.1. The funnel-shaped energy landscape model of protein folding. The model describes the funnel-shaped
energy landscape that polypeptide sequences explore as they fold into their native state. The representative unfolded
polypeptides first must progress through these potential energy surfaces (green) and are essentially funnelled towards
a state of lower free energy, resulting in the formation of folding intermediates (transition states). The transition state
represents the energy barrier which all intermediates must overcome in order to progress to the conformation in which
the Gibbs free energy is lowest, termed the native state. This process of transitioning into the native state can occur
via the assistance of chaperones. Alternatively, proteins unable to transition to the native state, either during de novo
synthesis or unfolding following exposure to cell stress, can adopt partially-folded intermediate conformations. These
partially-folded intermediates are prone to hydrophobically-driven self-association, causing them to leave the onfolding pathway and enter off-folding pathways (red). The two irreversible off-folding pathways result in the
formation of either disordered amorphous aggregates or highly ordered amyloid fibrils. Chaperones are important in
preventing these hydrophobically-driven, non-native interactions. Figure adapted from Hartl et al. (2011).

1.2

Protein misfolding

When a protein is subjected to conditions of cellular stress, such as oxidative stress (Papp et al.,
2003), heat shock (Feder and Hofmann, 1999), exposure to heavy metals (Richter-Landsberg and
Goldbaum, 2003) or endoplasmic reticulum (ER) stress (Kawahara et al., 1997), the bonds which
maintain the native conformation may be disrupted. As a result, hydrogen bonds and hydrophobic
5
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interactions between side chains are broken and proteins begin to partially unfold into intermediate
conformations (Smith et al., 2007). Exposed hydrophobic regions are attracted to similar
hydrophobic surfaces on neighbouring molecules and thus, these partially-folded intermediates
are prone to self-association and aggregation (Fink, 1998, Ecroyd and Carver, 2008). This process
results in proteins exiting the protein on-folding pathway and entering off-folding pathways (Shea
and Brooks, 2001, Stefani, 2008), leading to the formation of amorphous (disordered) aggregates
or amyloid fibrils (Dobson, 2004, Stranks et al., 2009, Greenwald and Riek, 2010).

The mechanism of disordered protein aggregation proceeds following the rapid unfolding and
association of protein intermediates, whereby aggregation results from the addition of individual
monomers that are randomly incorporated into growing clumps. This process is associated with
the formation of amorphous aggregates that, when large enough, precipitate out of solution
(Stranks et al., 2009). Alternatively, aggregation can occur via a slower but highly ordered process
that starts with the formation of soluble, β-sheet rich oligomeric forms of the protein, which
associate to form a stable nucleus. This nucleus creates a ‘seed’ which acts as a template to
sequester other protein intermediates into the growing chain of aggregated protein, termed a
protofibril. The growth and association of protofibrils eventually leads to the formation of highly
ordered and insoluble protein deposits that are referred to as amyloid fibrils. Whether a protein
proceeds to aggregate via an amorphous or fibrillar mechanism is thought to depend upon the
structure and stability of the partially-folded intermediate. For example, protein intermediates
which have little loss of secondary structure and a high degree of exposed hydrophobicity tend to
rapidly form disordered amorphous precipitates (Uversky and Ptitsyn, 1994, Khurana et al., 2001,
Cheung and Truskett, 2005, Stranks et al., 2009). Conversely, protein intermediates that are more
significantly unfolded, and therefore have lost most of their secondary structure and have a low
degree of exposed hydrophobicity, preferentially associate to form fibrils via a slow, but highly
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ordered mechanism (Lai et al., 1996, Harper and Lansbury Jr, 1997, Chamberlain et al., 2000,
Khurana et al., 2001, Quintas et al., 2001).

1.2.1

Protein aggregation and human disease

Amyloid fibrils have long been implicated in a variety of debilitating diseases, some of the most
notable being neurodegenerative disorders, including Alzheimer’s disease (Kidd, 1963),
Parkinson’s disease (Duffy and Tennyson, 1965), amyotrophic lateral sclerosis (ALS) (Abarbanel
et al., 1986) and the prion diseases (Ishii et al., 1984). The common pathological hallmark of these
and other neurodegenerative diseases is the presence of aggregated protein in the form of amyloid
fibrils, which have self-assembled into large tangled deposits in the brain (Selkoe, 2004).
Depending on the location of the aggregated protein, amyloid fibrils can deposit into intracellular
protein inclusions or extracellular plaques (Westermark et al., 2005). Many age-related
neurodegenerative diseases, including Alzheimer’s disease, Huntington’s disease and ALS, are
associated with the expression of aggregation-prone proteins or polypeptide fragments that
oligomerise and deposit into inclusions. For example, the deposition of the tau protein and
amyloid-β peptide into intracellular and extracellular deposits, respectively, are pathological
hallmarks of Alzheimer’s disease (Bucciantini et al., 2002, Hardy and Selkoe, 2002, Haass and
Selkoe, 2007, Iqbal et al., 2009). Proteins containing expanded polyglutamine (polyQ) repeats
aggregate to form amyloid precursors and mature fibrils which have been linked to Huntington’s
disease and various ataxias (Zoghbi and Orr, 2000, Chiti and Dobson, 2006).

Although many diseases are characterised by the formation of amyloid fibrils, not all proteins
aggregate through an ordered mechanism. For example, mutations in superoxide dismutase 1
(SOD1), which are causative of some familial forms of ALS, lead to the formation of highly
disordered and hydrophobic amorphous precipitates (Banci et al., 2007, Prudencio et al., 2009).
In addition, recent studies have demonstrated that almost all cases of sporadic ALS and
7
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frontotemporal dementia share a common neuropathology of predominantly amorphous,
intracellular deposits that contain transactive response DNA-binding protein 43 (TDP-43)
(Neumann et al., 2006, Adachi et al., 2009, Scotter et al., 2015). Furthermore, some proteins are
known to adopt intermediate conformations before forming amyloid fibres (Dobson, 2003,
Stathopulos et al., 2003). Finally, amorphous aggregation is associated with protein misfolding
that occurs during conditions of cellular stress (Chiti and Dobson, 2006, Ecroyd and Carver, 2008).
Thus, protein aggregation can lead to amyloid-fibril and/or amorphous forms, each with their own
unique characteristics (Kampinga and Bergink, 2016). Different mechanisms or protein quality
control machinery is likely to be required to maintain each of these forms of aggregation-prone
proteins in a soluble state.

The deposition of protein into aggregates is associated with progressive neuronal loss, reduced
synaptic transmission and neuro-inflammation. The death of neurons has been suspected to occur
by programmed cell death (apoptosis) (Mattson, 2000), however, the specific mechanism by which
this occurs is still not completely understood. There have been at least three hypotheses proposed
to describe how protein misfolding and aggregation cause neuronal loss and subsequent
neurodegeneration. Cattaneo et al. (2001) proposed the ‘loss-of-function’ hypothesis, which states
that neuronal loss is a result of reduced protein activity due to unfolding and aggregation.
However, such a mechanism has been refuted by research into Huntington’s disease, which
demonstrates that patients that are either homozygous or heterozygous for mutations in the
huntingtin protein both present with similar clinical features (Wexler et al., 1987). These results
imply that mutant huntingtin is capable of performing the same function as non-mutated (wildtype) huntingtin, and thus, the loss-of-function hypothesis does not correctly describe the
pathogenesis associated with Huntington’s disease. Another strong argument against the loss-offunction hypothesis pertains to research into SOD1, the aggregation of which is associated with
some familial forms of ALS (Turner and Talbot, 2008). Studies involving the knockout of SOD1
8
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in mice have shown that this does not lead to degeneration of motor neurons (Reaume et al., 1996).
In addition, there is no correlation between enzyme activity and disease severity with regard to
disease-associated mutations of SOD1 (Borchelt et al., 1995).

The ‘brain inflammation’ hypothesis proposes that protein aggregates and deposits cause a chronic
inflammatory response in the brain, leading to neuronal loss and synaptic decline (McGeer and
McGeer, 1995). Several in vitro studies have demonstrated that protein aggregates can activate
microglia and astrocytes, causing them to release pro-inflammatory proteins (e.g. cytokines and
chemokines) (Peyrin et al., 1999, Yates et al., 2000). In addition, clinical trials in animal models
and humans have shown that treatment with nonsteroidal anti-inflammatory drugs slows the
progression of Alzheimer’s disease (McGeer et al., 1996). Other studies have indicated a
beneficial role for neuro-inflammation in these diseases (Wyss-Coray and Mucke, 2002). For
example, immune-boosting vaccinations with amyloid-β resulted in a pronounced decrease in the
prevalence of cerebral amyloid plaques (Schenk et al., 1999) and improved behavioural and
cognitive function in mouse models of Alzheimer’s disease (Janus et al., 2000, Morgan et al.,
2000). However, when this vaccination was trialled in humans, cases of brain encephalopathies
and subsequent increased inflammation were observed, including an elevated white blood cell
count in the cerebrospinal fluid, indicative of a central inflammatory response (Schenk, 2002).
These studies suggest that brain inflammation resulting from neurodegenerative conditions may
have simultaneous positive and negative effects.

The final and most widely accepted hypothesis regarding the mechanism by which protein
misfolding and aggregation lead to neurodegeneration is the ‘gain-of-toxic-activity’ hypothesis.
This hypothesis is based on the concept that the presence of aggregates induces neuronal apoptosis.
Seminal in vitro studies undertaken by Forloni et al. (1993), Loo et al. (1993) and Lunkes and
Mandel (1998) demonstrated that increased aggregation directly promotes the neurotoxic effects
9
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of misfolded proteins. Additional evidence to support this hypothesis is based on more recent
experiments involving TDP-43, in which overexpression of both mutant and wild-type TDP-43
induces disease phenotypes in mouse models of ALS (Wils et al., 2010, Xu et al., 2010). These
results suggest that TDP-43 gains toxic properties as the disease progresses. It has also been
postulated that in some diseases, a combination of these hypothesised mechanisms may be
involved in neurodegeneration (Soto, 2003).

1.2.2

Inclusion formation in cells

An evolutionarily conserved action of cells in response to stress is the localisation of misfolded or
aggregated proteins into subcellular protein deposits, termed protein inclusions (Wigley et al.,
1999, Kaganovich et al., 2008, Kirstein et al., 2008). Cells can develop different types of
inclusions depending upon the nature of the misfolded protein. These inclusions include
aggresomes (Johnston et al., 1998), juxtanuclear quality control compartments (JUNQ) and
insoluble protein deposits (IPOD) (Figure 1.2) (Kaganovich et al., 2008). Aggresomes are a type
of insoluble inclusion body generated in the cytoplasm of mammalian cells, the formation of which
is initiated by small protein aggregates that form at the periphery of the cell (Tyedmers et al.,
2010). The aggregates are then transported, in a dynein/dynactin-dependent manner, along the
microtubule cytoskeleton until they are delivered to a juxtanuclear, pericentriolar site at the main
microtubule organising centre (centrosome) (Johnston et al., 1998, Kopito, 2000).

Work undertaken by Kaganovich et al. (2008) identified two other inclusion structures in the
cytoplasm of mammalian and yeast cells that have been proposed to act as quality control
compartments, JUNQ and IPOD inclusions. JUNQ inclusions harbour misfolded (but soluble)
proteins, which are still mobile and can readily exchange with proteins in the surrounding
cytoplasm. The proteins in JUNQ compartments are ubiquitinated, indicative of them having been
targeted for degradation by the proteasome (Kaganovich et al., 2008). The accumulation of
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ubiquitinated protein in JUNQ inclusions perhaps suggests that when the capacity of the
proteasome is limited (as observed in aged cells), ubiquitinated substrates can be reversibly held
in JUNQ compartments (Bagola and Sommer, 2008). In contrast, proteins deposited in IPOD
compartments typically cannot diffuse out of the inclusions and are terminally unfolded
(aggregated), not ubiquitinated and therefore, presumably not intended for degradation by the
proteasome (Kaganovich et al., 2008).

Figure 1.2. The distinct quality control compartments formed in cells when misfolded proteins are localised
into inclusions. Cells can localise misfolded proteins into discrete cytosolic compartments depending on the features
of the aggregating protein. There are currently three types of inclusions that have been identified in mammalian and
yeast cells; aggresomes, and JUNQ and IPOD inclusions. Aggresome formation is initiated by small protein
aggregates at the perimeter of the cell. The aggregates are transported along the microtubule cytoskeleton until they
are delivered to the microtubule-organising centre (MTOC). JUNQ inclusions, which are found close to the nucleus,
contain misfolded (but soluble) proteins that can still associate with proteins in the surrounding cytoplasm. Proteins
in JUNQ compartments are ubiquitinated and are associated with proteasomes. IPOD compartments are usually
located at the periphery of the cell and contain terminally unfolded (aggregated) proteins that are not ubiquitinated
and cannot associate with proteins in the cytoplasm.
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Whilst the intracellular and extracellular proteinaceous deposits found in patients who suffer from
neurodegenerative diseases contain one dominant aggregated protein (Alexandrescu, 2005, Chiti
and Dobson, 2006), other proteins and molecules, including chaperones and co-chaperones, are
also found in these deposits (Sherman and Goldberg, 2001). The exact reason why these other
proteins are associated with these deposits remains unclear, but it is assumed to be, at least in part,
due to the functional roles these proteins have in the rescue of misfolded proteins found in
inclusions (Bergemalm et al., 2010). Moreover, it has been postulated that inclusions may play a
protective role in the cell by sequestering non-functional proteins into discrete entities (Bucciantini
et al., 2002, Walsh et al., 2002, Tanaka et al., 2004, Miller et al., 2011). However, whilst inclusions
appear to protect cells over short time periods, eventually cells with inclusions die as a result of
the associated toxicity (Lang-Rollin et al., 2003, Ramdzan et al., 2017). This effect has been
hypothesised to represent a failure of the systems in cells that act to maintain the solubility and
function of aggregation-prone proteins. In any case, it is evident that neuronal degradation is
related to protein aggregation and subsequent inclusion formation (Chiti and Dobson, 2006,
Ticozzi et al., 2010, Ormsby et al., 2013). Thus, further research into the mechanisms by which
proteins aggregate and factors that prevent inclusion formation is extremely important, as this will
likely provide promising therapeutic targets for treating neurodegenerative conditions.

1.2.3

Are some cells more susceptible to the formation of inclusions than others?

It has been reported that different cell types have varying susceptibilities to inclusion formation
(Wyttenbach et al., 2002, Cecchi et al., 2005). However, there remains a substantial gap in
knowledge surrounding the molecular basis of resistance or susceptibility to inclusion formation
between cell types. The innate ability of the cell to maintain aggregation-prone proteins in a
soluble state is known to vary significantly among different cell types (Lim and Yue, 2015). For
example, neurons appear to be particularly susceptible to inclusion formation since many
debilitating neurodegenerative conditions are characterised by the accumulation of misfolded
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proteins into inclusions in neurons. This raises the question as to why neurons are so susceptible
to inclusion formation, given that many aggregation-prone proteins are also expressed (sometimes
at higher concentrations) in other cells of the body? The reason why neurons are so vulnerable to
inclusion formation is not well understood at the molecular level, but it has been proposed to be
as a result of their limited capacity to divide (and therefore dilute toxic protein aggregates) and
low turnover rate, stemming from their increased longevity compared to other cell types (Saxena
and Caroni, 2011, Lim and Yue, 2015, Smith et al., 2015). It may also be that the cellular pathways
that maintain an aggregation-prone protein in a soluble state are regulated differently in neurons
compared to other cell types (Lim and Yue, 2015). Therefore, intrinsic differences in the pathways
that regulate the intracellular environment and act to prevent protein aggregation may also explain
the susceptibility of certain cell types to inclusion formation.

1.3

Protein homeostasis (proteostasis)

Anfinsen’s (1973) dogma of protein folding, whilst significant, is limited as it mostly relates to
the folding of small, single domain polypeptide chains in vitro. Thus, the in vivo folding of
proteins, particularly large and/or multi-domain proteins, is not accurately described by
Anfinsen’s thermodynamic hypothesis. In addition, once a protein successfully folds into its native
state, this does not signal the end of the folding events that it may endure during its lifetime.
Proteins can partially unfold when subjected to cellular stress and then refold back into their
biologically active states (Dobson, 2003), whilst other proteins must be unfolded and refolded as
part of their normal trafficking within the cell, for example when being transported across
intracellular membranes or undergoing cellular secretion (Schnell and Hebert, 2003). Moreover,
protein folding in vivo is much more complex than in solution, primarily due to the effect of
macromolecular crowding in cells. Therefore, cells possess regulatory networks that assist in
folding proteins and maintaining protein homeostasis (proteostasis) in order to prevent protein
aggregation and inclusion formation (Roth and Balch, 2011). For recent published reviews on the
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systems involved in maintaining cellular proteostasis, see Kaushik and Cuervo (2015), Labbadia
and Morimoto (2015), Yerbury et al. (2016), Dikic (2017), Gomez-Pastor et al. (2018), Klaips et
al. (2018), Hipp et al. (2019), Hetz et al. (2020), Hetz (2021).

The proteostasis network refers to the pathways that help to maintain a stable and functional
proteome. The integrity of the proteome is maintained by a network of approximately 800 proteins
that are involved in processes that include the synthesis, folding, trafficking and degradation of
proteins. Of these, 332 function as molecular chaperones or co-chaperones (Brehme et al., 2014,
Balchin et al., 2016). This network of proteins act to maintain proteostasis in the intracellular and
extracellular environments by responding and adapting to internal and external changes. Under
normal physiological conditions, the proteostasis network can successfully maintain the proteome
in a functional state. However, certain factors, such as gene mutations, epigenetic factors, aging
and cell stress, can act to disrupt proteostasis and therefore reduce cell viability (Balch et al., 2008,
Morimoto, 2008). When the cell is exposed to conditions that promote protein misfolding and
aggregation, non-native or partially-folded proteins can self-associate to form aggregates
(described above), be rescued by molecular chaperones or be directed for degradation by
proteases.

1.4

Chaperone-mediated protein handling

A cell may be exposed to a variety of environmental conditions, including macromolecular
crowding (Ellis and Minton, 2006), an increase in temperature (Feder and Hofmann, 1999) and
suboptimal pH (Fink et al., 1994), which result in an increase in partially-folded or misfolded
proteins. This is counterbalanced by the upregulation of some molecular chaperones that occur as
a result of cellular stress (Hartl et al., 2011). Molecular chaperones are a ubiquitous family of
extracellular and intracellular proteins that stabilise aberrantly folded polypeptides and target them
for refolding or degradation, thereby minimising protein aggregation (Hartl, 1996, Broadley and
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Hartl, 2009, Hartl et al., 2011, Wyatt et al., 2013). The term ‘chaperone’ encompasses many
different families of proteins. The best described is the heat shock protein (Hsp) superfamily,
which includes Hsp40, Hsp60, Hsp70, Hsp90, Hsp110 and the small Hsps (sHsps) (Bukau et al.,
2006, Hartl et al., 2011).

1.4.1

The heat shock response

The heat shock response is a primary pathway that is activated in cells during periods of stress.
The heat shock response was first identified in Drosophila busckii by Ritossa (1962). The
accumulation of partially-folded protein intermediates that form following proteotoxic stress can
activate transcription factors and induce the heat shock response, a response that acts to protect
the cell and re-establish proteostasis. The human genome encodes four heat shock transcription
factors (HSF), HSF1 – HSF4, with HSF1 identified as the ‘master regulator’ of transcriptional
responses during cell stress (Åkerfelt et al., 2010). Under normal conditions, HSF1 resides as an
inactive monomer in the cytoplasm via weak and transient interactions with chaperone proteins,
Hsp90, Hsp40, Hsp70 or the chaperonin TriC/CCT (Shi et al., 1998, Bharadwaj et al., 1999, Guo
et al., 2001, Gómez et al., 2008, Neef et al., 2014, Vihervaara and Sistonen, 2014). Under
conditions of cellular stress, the chaperone-HSF1 equilibrium is altered due to the rapid formation
of partially-folded proteins, which are substrates for the chaperones (Zuo et al., 1994, Zuo et al.,
1995). Thus, HSF1 is released from chaperone-HSF1 complexes and undergoes self-association
to form trimers that can then translocate into the nucleus. (Morimoto, 2011). Activated HSF1
trimers are then able to bind heat shock elements in the promotor region of heat shock genes,
leading to the transcription and upregulation of these Hsps (Trinklein et al., 2004).

HSF1-mediated transcription is attenuated by a negatively regulated feedback mechanism,
whereby elevated levels of HSF1-induced Hsps competitively inhibit HSF1 trimer activity in the
nucleus to promote its inactive, monomeric form (Anckar and Sistonen, 2011, Zheng et al., 2016).
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This negative feedback loop ensures that the concentration and expression of Hsps is proportional
to the pool of non-native proteins present in the cell. Thus, modulation of HSF1 activity has been
suggested as a potential therapeutic approach for the treatment of diseases associated with protein
aggregation (Neef et al., 2010, Neef et al., 2011, Gomez-Pastor et al., 2018). Despite this, the
majority of Hsps are not stress-inducible and instead are constitutively expressed, performing
general ‘house-keeping’ functions for the maintenance of cell viability. The extensive roles of
Hsps in proteostasis have been well documented in recent comprehensive reviews (Winkler et al.,
2012, Priya et al., 2013, Kakkar et al., 2014, Tóth et al., 2015, Treweek et al., 2015, Kampinga
and Bergink, 2016, Zarouchlioti et al., 2018, Rosenzweig et al., 2019) and are therefore only
briefly summarised below.

1.4.2

Hsp70 chaperone machinery

Chaperones can be broadly categorised as adenosine triphosphate (ATP)-dependent ‘foldase’ or
ATP-independent ‘holdase’ proteins, depending on the type of interaction they have with client
proteins. ATP-dependent foldase chaperones can fold newly synthesised proteins and refold
unfolded or misfolded proteins via a process known as kinetic partitioning. These foldases, which
includes the Hsp70 family, bind to exposed hydrophobic regions in unfolded proteins to prevent
aggregation, and exploit the energy of ATP to promote folding of the protein into the native state
(Langer et al., 1992, Lin et al., 2008, Hartl et al., 2011). The functional diversity of Hsp70
members is rather striking considering Hsp70 chaperones are among the most evolutionarily
conserved proteins in humans and participate in diverse functions within the cell (Kampinga and
Craig, 2010, Hageman et al., 2011). The major members of the human Hsp70 family and their
previously reported roles within the cell are outlined in Table 1.1.
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Table 1.1. Human Hsp70 proteins, their reported stress inducibility, subcellular localisation and proposed roles within the cell.

Name

Synonyms

HspA1A

Hsp70
Hsp70-1
Hsp72
Hsp70-1A

HspA1L

Hsp70hom
Hsp70-1L

No

Heat
shock

No

HspA2

Stress
inducible
Yes

Subcellular
localisation
Cytosol,
nucleus, cell
membrane,
extracellular
exosomes

Suggested cellular roles

References

Most widely studied and the major stress-inducible member
of the Hsp70 family. Expression is upregulated upon HSF1
activation following a variety of cellular assaults, for
protection against harmful protein aggregation. Known to
participate in the refolding of denatured proteins. Can inhibit
substrate accumulation, thereby removing the trigger of
programmed cell death. Stabilises the lysosomal membrane
to inhibit release of lysosomal hydrolases into the cytosol to
prevent cell death via apoptosis. Participates cooperatively
with Hsp110 and Hsp40 to form the disaggregase machinery
to solubilise aggregated proteins. Participates in protein
translocation across the ER and mitochondrial membranes.
With the assistance of co-chaperones, can pass on misfolded
proteins for degradation via autophagy or the proteasome.

(Chirico et al., 1988, Deshaies
et al., 1988, Li et al., 1991,
Jäättelä and Wissing, 1993,
Mestril et al., 1994, Bellmann
et al., 1996, Wissing and
Jäättelä, 1996, Michels et al.,
1997, Kwak et al., 1998,
Nollen et al., 1999, Mosser et
al., 2000, Leist and Jäättelä,
2001, Nylandsted et al., 2004,
Kroemer and Jäättelä, 2005,
Carra et al., 2008b,
Gamerdinger et al., 2009,
Rampelt et al., 2012, Nillegoda
et al., 2015)
(Milner and Duncan Campbell,
1990, Warrick et al., 1999,
Hageman et al., 2011)

Cytosol,
nucleus

Lacks the heat shock binding element in its promoter region,
and therefore is less heat-inducible than HspA1A. Expressed
endogenously at low levels in most tissues, with high
abundance in the testis. Evidence suggests that, under
normal conditions, HspA1L acts to mitigate deleterious
effects of mutant protein aggregation, thereby providing
cells with basal protection against the continual assault of
protein misfolding.
Cytosol,
Primarily expressed in the testis. Within spermatocytes, it is
nucleus, cell the main chaperone for the CyclinB1/Cdk1 complex during
17
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1997, Rohde et al., 2005,
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HspA5

70kD
protein 2
Hsp70-2
BiP
GRP78
Mif2

No

HspA6

Hsp70-6
Hsp70B

Yes

HspA8

Hsp70-8
Hsc70
Hsc71
Hsp71
Hsp73

No

HspA14

Hsp70-14
Hsp70L1

Yes

membrane,
extracellular
exosomes
ER

meiotic cell division. Involved in packaging DNA proteins
for post-meiotic genome reorganisation. Essential for the
proliferation and survival of human cancer cells.
ER-resident Hsp70 member that possesses a C-terminal
retention signal which prevents its secretion out of the ER
lumen. Involved in the general folding of proteins and
maintenance of proteostasis following stress in the ER. Is
recruited in the post-translational translocation of substrates
through the translocon into the cytosol.
Cytosol,
Strictly only induced proceeding severe stress insults.
extracellular Functions as a component of the general stress-response.
exosomes
Compared to related Hsp70 members, HspA6 has enhanced
N-terminal ATPase activity and is believed to have evolved
a distinct functional role in the maintenance of cell
reproduction and viability under conditions of cellular stress.
Cytosol,
Constitutively expressed housekeeping member of the
nucleus, cell Hsp70 family. Has been reported to participate in a plethora
membrane, of cellular functions, including folding of nascent
extracellular polypeptides, promoting correct protein translocation across
exosomes
membranes, chaperone-mediated degradation by the
proteasome or autophagy, protection against protein
aggregation under stress conditions, and disassembly of
clathrin cages for recycling.
Cytosol,
Functions in the cell are currently unclear. Lacks the
membrane
canonical substrate binding domain and instead participates
in protein translation.
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Govin et al., 2006, Daugaard et
al., 2007a)
(Munro and Pelham, 1987,
Brodsky and Schekman, 1993,
Matlack et al., 1997, Lee,
2005, Oka et al., 2013)

(Parsian et al., 2000, Noonan et
al., 2007, Hageman et al.,
2011)

(Lindquist and Craig, 1988,
Beckmann et al., 1990,
Demand et al., 2001, Albanèse
et al., 2006, Kettern et al.,
2010, Morgan et al., 2013)

(Huang et al., 2005, Kampinga
and Craig, 2010)
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Despite the functional diversity of members of the Hsp70 family, they share a common molecular
mechanism of action: a cycle of ATP-dependent client-binding and release that facilitates
interaction with client proteins. The diverse roles that Hsp70s have in the cell is likely a result of
them not acting in isolation; rather, Hsp70 ‘machines’ are regulated by co-factors, such as other
chaperones and nucleotide exchange factors (NEFs).
1.4.3

Hsp40 proteins – drivers of the Hsp70 machine

The activity of Hsp70 chaperones is driven by interactions with Hsp40 proteins (also known as
DNAJs, J proteins, or J-domain proteins), whereby DNAJs deliver misfolded clients to the Hsp70
machinery and, in turn, stimulate Hsp70 ATPase activity (Bukau et al., 2006). The DNAJs are so
named as they have a highly conserved J-domain which contains the histidine-proline-aspartate
(HPD) motif for interaction with the Hsp70 machinery. The human genome encodes 53 DNAJ
proteins that can be divided into three separate subfamilies, the DNAJA, DNAJB and DNAJC
proteins, based upon intrinsic structural features (Figure 1.3A) (Cheetham and Caplan, 1998,
Kampinga and Craig, 2010). The DNAJAs are comprised of an N-terminal J-domain, a
glycine/phenylalanine (G/F)-rich linker region and two C-terminal domains (CTD-I and CTD-II),
with a zinc-finger-like region (ZFLR) inserted into CTD-I. The two barrel topology contained in
the C-terminal region forms a hydrophobic pocket with the ZFLR extruding from it to create a
substrate binding domain (Linke et al., 2003, Kota et al., 2009). The ZFLR in DNAJAs is thought
to contribute to client binding since mutation of the first of the two Zn2+ -binding sites renders the
DNAJA-Hsp70 complex unable to prevent the aggregation of misfolded proteins in bacteria
(Linke et al., 2003) and yeast (Lu and Cyr, 1998, Fan et al., 2005). The second Zn2+-binding site
is important for the transfer of DNAJA-bound clients to Hsp70 (Linke et al., 2003, Baaklini et al.,
2012). There is some evidence to suggest that members of the mammalian DNAJA family have a
differential capacity to bind client proteins. For example, a complex of DNAJA2-Hsp70, but not
DNAJA4-Hsp70, can support refolding of denatured luciferase, despite both DNAJAs being able
to stimulate Hsp70 ATPase activity (Hafizur et al., 2004).
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Figure 1.3. The divergence of DNAJ proteins based on their structural features. (A) Schematic representation of
the domain organisation of class A (top), class B (middle) and class C (bottom) DNAJ proteins. The histidine-prolineaspartate (HPD) motif lies within the J-domain, which is highly conserved among the three classes of DNAJs. Class
A DNAJs have an N-terminal J-domain, a glycine/phenylalanine (G/F)-rich linker region and two C-terminal domains
(CTD-I and CTD-II), with a zinc-finger-like region (ZFLR) in CTD-I and a dimerisation domain (DD). Class B DNAJ
proteins are comprised of an N-terminal J-domain, an internal G/F-rich linker region, diverse C-terminal domain(s)
for binding clients and in some cases, a DD. Class C DNAJs contain a J-domain (which can be located anywhere
within the protein) and are heterogeneous in terms of their C-terminal domains. (B) Combined phylogenetic
distribution of aligned DNAJB primary amino acid sequences using the neighbour-joining algorithm and Blosum
matrixes. Scale bar represents phylogenetic distance of 0.1 amino acids substitutions per position. Numbers on the
branch-points indicate bootstrap values of 1000 trials.

Structurally, DNAJB proteins are defined by an N-terminal J-domain, an internal G/F-rich linker
region and a C-terminal domain that is thought to bind clients (Cheetham and Caplan, 1998,
Kampinga and Craig, 2010). The DNAJB proteins can be further divided into two subfamilies,
based on their C-terminal structure (Hageman and Kampinga, 2009, Kampinga and Craig, 2010,
Rosenzweig et al., 2019) and phylogenetic classification following sequence analysis (Figure
1.3B) (Hageman et al., 2010, Hageman et al., 2011). The first subclass (termed DNAJB1-like)
includes DNAJB1, DNAJB4 and DNAJB5, whereas the second (termed DNAJB6-like) includes
DNAJB2, DNAJB6, DNAJB7 and DNAJB8. In contrast to DNAJB6-like proteins, which possess
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one (albeit diverse) C-terminal domain, DNAJB1-like proteins have two distinct C-terminal
regions for binding clients. Of the DNAJs, the DNAJB proteins are the most extensively studied
due to them being previously identified as potent suppressors of aggregation associated with many
disease-related proteins, including polyQ, amyloid-β and SOD1 proteins (Howarth et al., 2007,
Hageman et al., 2010, Labbadia et al., 2012, Gillis et al., 2013, Månsson et al., 2014a, Kakkar et
al., 2016b, Serlidaki et al., 2020). The proposed cellular roles of the major human DNAJB
members and their previously reported capacity to prevent the aggregation of a variety of
aggregation-prone proteins is outlined below (Table 1.2).
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Table 1.2. Human DNAJBs, their reported stress inducibility, subcellular localisation, reported capacity to suppress the aggregation of client proteins and proposed roles
within the cell.

Name

DNAJB1

Synonyms

Hsp40
Hdj-1

Stress
inducible
Yes

Subcellular
localisation
Cytosol

Reported chaperone activity

Suggested cellular
roles
Acts with Hsp70 to reduce amyloid-β
Participates in
aggregation in vitro. Prevents the nucleation downstream stages in
of polyQ-expanded huntingtin tracts to
the folding of proteins
reduce the formation of mature toxic fibrils
directly off the
in vitro. Decreases the rate of assembly of α- ribosome.
synuclein fibrils and increases the capacity
of Hsp70 to bind α-synuclein in vitro.
Interacts alongside
Suppresses tau aggregation in a doseHsc70, Hsp90 and the
dependent manner in vitro. Cooperates in
co-chaperones Bag1,
vitro with Hsp110 and Hsp70 to solubilise
HIP and HOP to
amorphous aggregates formed by both
traffic substrates for
denatured firefly luciferase and α-synuclein degradation via
as part of the disaggregase machinery.
chaperone-mediated
autophagy.
Has mild suppressive activity against
inclusion formation by polyQ-expanded
Expression is
huntingtin, but does not suppress toxicity in upregulated upon
cells. When expressed in combination with
HSF1 activation
Hsp70 can increase cellular proliferation and following cell stress to
reduce the cytotoxicity associated with
protect against
polyQ-expanded huntingtin inclusion
accumulation of
formation. Reduces the misfolding and
misfolded proteins.
aggregation of mutant Parkin in cells.
Increases the solubility of polyQ-expanded
androgen receptor and enhances its
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References

(Jana et al., 2000,
Kazemi-Esfarjani
and Benzer, 2000,
Kobayashi et al.,
2000, Muchowski
et al., 2000,
Agarraberes and
Dice, 2001, Bailey
et al., 2002,
McLean et al.,
2002, Takeuchi et
al., 2002, Evans et
al., 2006, Hageman
et al., 2010,
Kampinga and
Craig, 2010,
Pemberton et al.,
2011, Shorter,
2011, Rampelt et
al., 2012, Kuo et
al., 2013, Ormsby
et al., 2013,
Vihervaara and
Sistonen, 2014,
Nillegoda et al.,
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proteasomal degradation in a cellular model
of spinal and bulbar muscular atrophy.
Overexpression decreases intracellular
inclusion formation in α-synuclein cell
culture model of disease. Reduces
cytoplasmic inclusion formation by mutant
SOD1 to improve neurite outgrowth in cells.

DNAJB2a/b

Hsjla
Hsj1b

Yes

Cytosol,
nucleus, ER

Suppresses toxicity of aggregation and
reduces eye degeneration in Drosophila
melanogaster models of polyQ-expanded
disease.
Regulates proteasomal degradation to reduce
the aggregation associated with a polyQexpanded form of ataxin-3 in cells. Reduces
polyQ-expanded huntingtin aggregation in
vitro, in cells, in mice and rats. Inhibits the
misfolding of mutant Parkin in cells to
reduce protein aggregation and promote
functional refolding. Prevents mutant SOD1
aggregation in cells. Inhibits the aggregation
of SOD1 in mice and, in turn, increases
muscle function, motor neuron survival and
body weight. Overexpression reduces TDP43 aggregation in cells. Inhibits polyQexpanded huntingtin-induced death of
striatal neurons and promotes neuronal
function in Caenorhabditis elegans.
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2015, Kakkar et al.,
2016a, Nillegoda et
al., 2017, Serlidaki
et al., 2020,
Tittelmeier et al.,
2020)

Contains ubiquitininteracting motifs
(UIMs) that bind
ubiquitinated proteins
and shuttles them for
degradation via the
proteasome.

(Chapple and
Cheetham, 2003,
Chapple et al.,
2004, Westhoff et
al., 2005, BorrellPagès et al., 2006,
Howarth et al.,
2007, Hageman et
al., 2010,
Kampinga and
Craig, 2010, Gao et
al., 2011, Hageman
et al., 2011, Rose et
al., 2011, Blumen
et al., 2012,
Labbadia et al.,
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2012, Novoselov et
al., 2013, Chen et
al., 2016, Kakkar et
al., 2016a,
Serlidaki et al.,
2020)
(Abubaker et al.,
2013, Abu-Farha et
al., 2015)

DNAJB3

HCG3
Hsj3
Msjl

No

Cytosol,
nucleus

None reported

DNAJB4

Hlj1
Hsc40

Yes

Cytosol

Suppresses intracellular inclusion formation
of mutant Parkin.

24

Marker for risk of
obesity and insulin
resistance as its
expression is reduced
at the mRNA and
protein levels in both
blood and adipose
tissue of obese
individuals. May play
a role in insulin
signalling and glucose
uptake by modulating
the c-Jun NH2terminal kinase (JNK).
Has close homology
(Chen et al., 1999,
to DNAJB1 and is the Kakkar et al.,
non-heat inducible
2016a)
and constitutively
expressed member of
the DNAJ family.
Proposed to act as a
housekeeping Hsp40
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DNAJB5

DNAJB6a/b

Hsc40
Hsp40-3

Yes

Cytosol

Inhibits polyQ aggregation in certain cell
types.

Hsj2a
Mrja
Hsj2b
Mrjb

Yes

Cytosol,
nucleus

Prevents the primary nucleation of amyloidβ and polyQ-expanded huntingtin peptides
into mature fibrils in vitro. Suppresses the
aggregation of many disease-related polyQexpanded proteins, including huntingtin,
ataxin-3 and the androgen receptor in cells.
Inhibits mutant Parkin inclusion formation
in cells. Reduces intracellular amyloid-β
aggregation, but this activity is dependent
upon interaction with Hsp70. Suppresses
prion-like aggregation of a nuclear TDP-43
mutant protein in cells.
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member, much like
HspA8 (Hsc70) of the
Hsp70 family.
Structurally is near
identical to DNAJB4.
Associates with class
II histone deacetylases
(HDACs) in a redoxdependent manner in
response to
hypertrophic stimuli,
suggesting it may
participate as a redoxregulated chaperone.
Mediates keratin
turnover in placental
development and
participates in stem
cell self-renewal.
Mutations in the
protein have been
implicated in severe
forms of inheritable
myopathies that are
distinguished by
myofibrillar
disintegration along

(Ago et al., 2008,
Oka et al., 2009,
Hageman et al.,
2011)

(Chan et al., 2000,
Hanai and
Mashima, 2003,
Fayazi et al., 2006,
Watson et al.,
2007, Watson et
al., 2009, Hageman
et al., 2010,
Hageman et al.,
2011, Sarparanta et
al., 2012, Gillis et
al., 2013, Månsson
et al., 2014a,
Månsson et al.,
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Restores eye structure in a mutant ataxin-3
Drosophila melanogaster model.
Overexpression significantly reduces
inclusion formation of polyQ-expanded
huntingtin and alleviates associated toxicity
in transgenic Xenopus laevis tadpole and
Drosophila melanogaster models of disease.
Overexpression of human DNAJB6 in
transgenic mice reduces polyQ aggregation
in the brain, increases neurological
performance and lifespan and slows overall
rate of disease progression.

DNAJB7

DJ-5
Hsc3

No

Cytosol,
nucleus

Prevents intracellular inclusion formation by
mutant SOD1 and Parkin.

DNAJB8

mDj6

No

Cytosol,
nucleus

Delays the fibrillation of polyQ expanded
huntingtin in vitro. Inhibits the intracellular
aggregation of disease-related polyQexpanded proteins, such as huntingtin,
ataxin-3 and the androgen receptor. Inhibits
26

with DNAJB6
accumulation. This
may suggest a role for
DNAJB6 in the
maintenance of
muscle structure
and/or as a chaperone
which normally
functions to prevent
the accumulation of
misfolded sarcomeric
proteins in the muscle.
However, the role of
DNAJB6 in muscle
and these inheritable
diseases is yet to be
determined.
Cellular function not
well understood. May
participate in
intermediate filament
organisation.
Functional homologue
of DNAJB6. Required
for the survival of
cancer stem cells and
controls tumourinitiating processes.

2014b, Udan-Johns
et al., 2014,
Hussein et al.,
2015, Kakkar et al.,
2016a, Kakkar et
al., 2016b)

(Kakkar et al.,
2016a, Chiarelli et
al., 2019, Serlidaki
et al., 2020)
(Hageman et al.,
2010, Hageman et
al., 2011,
Nishizawa et al.,
2012, Gillis et al.,
2013, Månsson et
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intracellular inclusion formation of mutant
Parkin in an Hsp70-dependent manner.

DNAJB9

ERdj4
Mdg1

Yes

ER

Reduces inclusion formation of polyQexpanded huntingtin and attenuates toxicity
in a transgenic Xenopus laevis tadpole
model.
Mediates the clearance of the mutant
transmembrane-conductance regulator
membrane protein, implicated in cystic
fibrosis, via ER-associated degradation in
cells and mice. Promotes the turnover of
misfolded surfactant protein C (associated
with interstitial lung disease in humans) via
ER-associated degradation in cells.
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Identified as a
cancer/testis antigen.

al., 2014b, Kakkar
et al., 2016a)

The ER-resident
member of the DNAJ
family. Plays a
primary role in
binding client proteins
throughout the ER and
transfers them to
Hsp70/BiP for ERassociated
degradation.

(Dong et al., 2008,
Lai et al., 2012,
Behnke et al.,
2016, Huang et al.,
2019)
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The DNAJC family is highly diverse and includes any DNAJs that do not fit within the
specifications outlined for DNAJA and DNAJB proteins, instead only sharing the conserved Jdomain. In contrast to DNAJA and DNAJB members, in which the J-domain is always located at
the N-terminus, DNAJCs contain a J-domain that can be located anywhere within the protein. The
DNAJC members are heterogeneous in terms of their C-terminal domain structure and no mode
of action has currently been defined for their interaction with substrates. These proteins differ
drastically in length (from ~100 amino acids in DNAJC19 to ~4,600 amino acids in DNAJC29)
and contain variable structural domains/motifs (e.g. thioredoxin boxes, GTP binding sites,
transmembrane helices, tetratricopeptide repeat domains, coiled coils, ISU-1 binding domains,
clathrin-binding regions and protein kinase domains) (Kampinga and Craig, 2010). The
intracellular roles of the DNAJC members are currently not well understood (Kampinga et al.,
2019); those that have been studied have been shown to participate in diverse cellular functions,
including protein translocation into the mitochondria and ER (Craig, 2018), ER-associated
degradation (Ushioda et al., 2016) translation (Sahi et al., 2010) and endocytosis and exocytosis
(Ungewickell et al., 1995, Rapoport et al., 2008, Vos et al., 2008).

1.4.4

The Hsp70/Hsp40-mediated protein folding cycle

Molecular chaperones of the Hsp70 family have a 40 kDa N-terminal nucleotide binding (ATPase)
domain and a 25 kDa C-terminal domain for the binding of unfolded clients. Hsp70 members also
contain a short, flexible hydrophobic linker region, which separates the N- from the C-terminal,
as well as a far C-terminal helical ‘lid’ that closes over the substrate binding domain to capture
client proteins (Figure 1.4A). Hsp70 chaperone activity is defined by the rapid association and
release of client proteins to prevent subsequent protein aggregation and to promote protein folding.
The Hsp70 cycle begins when DNAJs bind client proteins via the C-terminal substrate binding
region to then interact with the Hsp70 ATPase domain via the conserved HPD motif located in the
J-domain (Figure 1.4B). The client protein rapidly, but transiently, interacts with the ‘open’
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conformation of the Hsp70 substrate binding region. The J-domain and client protein stimulate
ATP hydrolysis to cause a conformational change in Hsp70, which in turn closes its lid over the
substrate binding domain to stabilise the interaction with the client protein. The DNAJ then
dissociates from the complex (Kampinga and Craig, 2010). Following ATP hydrolysis, Hsp70 in
the ADP-bound state has high affinity for substrate (Rosenzweig et al., 2019). A NEF (outlined
briefly below), which has higher affinity for the ADP-bound state than the ATP-bound
conformation, binds to Hsp70, inducing ADP to dissociate from Hsp70. This allows ATP to rebind, reverting Hsp70 back to its low-affinity substrate binding state, which triggers substrate
release. The released substrate can then fold into its native state or, if it is unable to do so, DNAJs
can re-bind exposed regions of hydrophobicity in the substrate such that it re-enters the Hsp70
cycle.
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Figure 1.4. The Hsp70/Hsp40 chaperone cycle. (A) Cartoon representation of Hsp70 with the subdomains (IA/B
and IIA/B) of the nucleotide binding (ATPase) domain indicated. The flexible linker region separates the N- and Cterminal domains. The C-terminal substrate binding domain is split into a β-sandwich-containing region for the
binding of misfolded client proteins. Once substrate is bound, the C-terminal α-helical ‘lid’ closes over the substrate
binding domain to capture and stabilise client proteins. (B) Canonical model of the handling of client proteins by the
Hsp70 machinery. (1) DNAJs bind client proteins via the C-terminal substrate binding domain and then (2) interact
with the Hsp70 nucleotide binding domain via the conserved HPD motif in the J-domain. (3) The client protein
interacts with the ‘open’ conformation of the Hsp70 substrate binding domain. A conformational change induced by
the J-domain and client protein stimulates ATP hydrolysis and the α-helical lid in the Hsp70 substrate binding domain
closes over the substrate. The DNAJ dissociates from the complex and the Hsp70 substrate binding domain is left in
the ‘closed’ conformation. (4) A NEF then binds the ADP-bound form of Hsp70, (5) inducing ADP to dissociate. (6)
This allows ATP to re-bind, triggering substrate release. (7) The NEF is released from the complex and the client
protein can fold into its native state. Alternatively, if the native state is not reached, DNAJs can re-bind non-native
proteins and the cycle begins again.
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1.4.5

Small heat shock proteins (sHsps)

The sHsps are ATP-independent holdase chaperones. Similar to DNAJs, the sHsps bind solventexposed hydrophobic rich regions in partially-folded states of proteins. The sHsps act to stabilise
these partially-folded protein intermediates by forming soluble, high molecular weight complexes
with them, thus preventing their aggregation (Frydman et al., 1994, Eyles and Gierasch, 2010,
Johnston et al., 2021). This process creates a pool of protein intermediates which, once conditions
are favourable, are released and allowed to spontaneously refold, passed on to foldase chaperones
for ATP-dependent chaperone-mediated refolding, or targeted for degradation (Hartl et al., 2011).
The sHsp molecular chaperones possess a conserved α-crystallin domain, which is flanked by
variable N- and C-terminal regions. The human genome encodes ten sHsps (HspB1 - HspB10)
(Kappé et al., 2003, Kampinga et al., 2009) and whilst the monomeric subunits of sHsps are of
low molecular mass (12 to 43 kDa), some of these sHsps form large polydisperse oligomers in
solution (Aquilina et al., 2013). The sHsps play a primary role in minimising protein aggregation
in cells and their proposed roles within the cell are described below (Table 1.3).
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Table 1.3. Human sHsps, their reported binding partners, subcellular localisation and proposed roles within cells.

Name

Synonyms

HspB1

Hsp27
Hsp25
(mouse)

HspB2

MKBP

HspB3

HspL27

Reported binding
partners
HspB5; HspB8;
HspB4;
CRYBB2;
CRYGC; Rif1;
TP53; AKT1;
CYCS; MED31;
ILK; Daxx;
MAGED1;
TGFB1I1;
MGC15730;
SERPINH1
DMPK; HspB2;
HspB8; HspB3;
HspB5; Ubl5;

Subcellular
localisation
Cytosol, cell
membrane

Cytosol, nucleus,
mitochondria

ANP32A;
Cytosol, nucleus
MED31;
OLFML3;
MED8; MRPL38;
NELF; Ramp3;
BBOX1; Rif1;
SETDB1;

Suggested cellular roles

References

Participates in cytoskeletal stabilisation
and acts as an antioxidant by regulating
intracellular redox homeostasis. Has
chaperone and pro-refolding functions.
Confers anti-apoptotic function.

(Jakob et al., 1993, Lavoie et
al., 1993, Lavoie et al., 1995,
Charette et al., 2000, Lee and
Vierling, 2000, Pandey et al.,
2000, Arrigo et al., 2005,
Outeiro et al., 2006, Bryantsev
et al., 2007, Minoia et al.,
2014b, Cox and Ecroyd, 2017)

Acts in concert with HspB3 to function in
muscle cell differentiation and myofibrillar
integrity. Inhibits the extrinsic apoptotic
pathway. Activates, chaperones and
enhances kinase activity of the myotonic
dystrophy protein kinase (DMPK).
Forms complexes with HspB2 to
participate in muscle cell differentiation.

(Suzuki et al., 1998, Sugiyama
et al., 2000, Nakagawa et al.,
2001, Vos et al., 2009, Oshita
et al., 2010)
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ZZEF1; UNC119;
HspB2
HspB1; CRYZ;
Cytosol
MIP; ALB;
HspB4; HspB5

HspB4

αAcrystallin

HspB5

αBcrystallin

HspB1; PSMA3;
CS; HspB2;
HspB5; BMPR2;
HspB4

Cytosol, nucleus, cell
membrane,
mitochondria

HspB6

Hsp20
p20

Bag3

Cytosol, nucleus

HspB7

cvHsp

HspB8

Cytosol, nucleus,
cytoskeleton,
mitochondria

HspB8

Hsp22
H11
E2IG1

HspB1; HspB8;
HspB7; HspB2;
Bag3

Cytosol, nucleus

Maintains the proper refractive index in the
eye lens. Has chaperone activity and acts
with ATP-dependent chaperones to assist
in protein refolding.
Maintains the proper refractive index in the
eye lens. Plays a role in cytoskeleton
stabilisation. Effective anti-aggregation
chaperone and acts with ATP-dependent
chaperones to assist in refolding.

(Jakob et al., 1993, Andley et
al., 1998, Mackay et al., 2003,
Bhagyalaxmi et al., 2009)

(Jakob et al., 1993, Iwaki et al.,
1994, Nicholl and Quinlan,
1994, Morrison et al., 2003,
van Rijk et al., 2003, Jin et al.,
2008, Noh et al., 2008, Vos et
al., 2008, Vos et al., 2010, Cox
and Ecroyd, 2017)
Acts in cytoskeletal stabilisation. Has some (Fan et al., 2004, Dreiza et al.,
anti-aggregation capacity. Evidence
2005, Zhu et al., 2005,
suggests it plays a role in autophagy
Islamovic et al., 2007, Qian et
regulation. Has cardio-protective
al., 2009, Fuchs et al., 2010,
properties and functions in smooth muscle Vos et al., 2010, Ke et al.,
relaxation.
2011)
Maintains myofibrillar integrity. Can
(Krief et al., 1999, Golenhofen
protect against protein aggregation and
et al., 2000, Vos et al., 2009,
associated toxicity. Involved in dynamic,
Carra et al., 2010, Vos et al.,
stress-induced translocation to SC35
2010)
splicing speckles.
Can inhibit protein synthesis and is an
(Chowdary et al., 2004, Irobi et
effective anti-aggregation chaperone.
al., 2004, Carra et al., 2005,
Targets Hsp-loaded substrates for
Carra et al., 2008a, Carra et al.,
degradation via macroautophagy.
2008b, Carra, 2009, Carra et
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HspB9

CT51

-

Cytosol, nucleus

HspB10

ODFP
ODF1

SPAG4; SPAG5;
TRIP6; ODF1

Cytosol

al., 2009, Crippa et al., 2010,
Fuchs et al., 2010,
Gamerdinger et al., 2011,
Crippa et al., 2016)
(de Wit et al., 2004, Vos et al.,
2010)

Expressed exclusively in the testis.
Involved in cytoskeletal stabilisation. Has
chaperone activity. Has been identified as
a cancer/testis antigen.
Expressed exclusively in the testis. Role in (Fontaine et al., 2003, Vos et
the cell currently not well understood. May al., 2009)
participate in cytoskeletal stabilisation.
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Most work that has been conducted to study the chaperone function of the sHsps has involved
recombinant proteins tested in solution-based assays. Thus, the precise molecular mechanism(s)
by which sHsps prevent protein aggregation in cells is still not understood (Hilton et al., 2013).

1.4.6

Bcl-2 associated athanogene (Bag) proteins

The actions of maintaining, refolding and repairing damaged proteins by molecular chaperones
are thought to be essential for maintaining cell viability. In addition, it requires far less energy to
refold proteins than it does to degrade them and synthesise new ones (Richter et al., 2010).
However, when proteins become severely or irreversibly damaged, thus making refolding
impossible, the proteostasis mechanisms which manage these proteins switch and chaperones
present unfolded substrates for degradation (Spiess et al., 1999). Co-chaperones play a central role
in determining the route through which Hsp-loaded substrates are degraded (Gamerdinger et al.,
2011). The Bcl-2 associated athanogene (Bag) proteins (Bag1–6) are a ubiquitous family of cochaperones and function as NEFs. Bag proteins are so named because they share an evolutionarily
conserved region of ~50 amino acids, known as the BAG domain. The BAG domain facilitates
their interaction with Hsp70. Bag proteins bind to the ATPase domain of Hsp70 with high affinity
(Doong et al., 2002) and, as such, modulate interactions of the Hsp70 C-terminal substrate binding
domain with unfolded polypeptides. Thus, by binding to Hsp70, Bag proteins regulate substrate
binding and release (Takayama and Reed, 2001, Gamerdinger et al., 2011). Their proposed
contribution to the maintenance of proteostasis has sparked recent interest into the interactions
that dictate their cellular function (Fuchs et al., 2010). However, the precise role(s) of the Bag
isoforms within the cell are still relatively unclear. The suggested roles of Bag proteins in the cell
are summarised below (Table 1.4).
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Table 1.4. Human Bag proteins, their reported binding partners, subcellular localisation and proposed roles
within cells.

Name

Synonyms

Bag1

RAP46
HAP46
HAP50

Bag2

-

Bag3

Reported
binding
partners
Bcl-2; Raf1,
Siah1,
HGFR;
PDGFR;
steroid
receptors;
RAR;
Hsc70/Hsp70

Subcellular
localisation

Suggested cellular
roles

Cytosol

Accelerates ATPtriggered substrate
release by Hsc70/
Hsp70. Plays a role
in trafficking Hsploaded substrates to
the proteasome.

-

Nucleus

CAIR-1
Bis

PLCγ; Bcl-2;
HspB5;
HspB6;
HspB8;
Hsc70/Hsp70

Cytosol

Bag4

SODD

TNFR1;
DR3;
Hsc70/Hsp70

Cytosol,
nucleus

Bag5

-

-

Vesicles

Bag6

Scythe
BAT3

Hsc70/Hsp70

Cytosol,
nucleus

Inhibits the ubiquitin
ligase activity of
CHIP (C-terminus of
the Hsc70interacting protein)
and regulates the
Hsc70/Hsp70
complex.
Prevents the
accumulation of
unfolded
polypeptides by
trafficking Hsploaded substrates for
degradation by
macroautophagy.
Recruits
Hsc70/Hsp70 to
receptors which
participate in the
initiation of
apoptosis.
May regulate the
Hsc70/Hsp70
complex in a similar
manner to Bag1.
Nuclear apoptosis
regulator.
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1.4.7

Hsp110 proteins

Another group of proteins which participate as NEFs in the Hsp70 substrate binding and release
cycle are the Hsp110 (HspH) family (Dragovic et al., 2006, Raviol et al., 2006). In humans, there
are four known Hsp110 proteins and they belong to the eukaryotic Hsp70 superfamily. The
nucleotide-binding domains of Hsp110 and Hsp70 members share high sequence similarity, with
Hsp110 proteins differing mainly through having a more divergent substrate binding (ATPase)
domain. The structure of the Hsp110s is similar to that of the ‘open’ conformation of Hsp70s, with
the addition of a β-stranded sandwich of variable length inserted into the C-terminal helical lid of
the Hsp110 substrate binding domain (Schuermann et al., 2008, Rosenzweig et al., 2019).
Hsp110s modulate nucleotide release from Hsp70s in a manner that is distinct from the Bag
proteins; Hsp110s first bind ATP, which induces a conformational change that allows them to
interact with Hsp70 (Shaner et al., 2006). Hsp110s can then catalyse nucleotide exchange through
a direct interaction of the Hsp110 and Hsp70 nucleotide-binding domains. This facilitates the
formation of a stable Hsp110-Hsp70 complex which, in turn, dissociates when ATP binds to
Hsp70 (Andréasson et al., 2008). Whilst Hsp110 proteins do not participate directly in substrate
refolding (Polier et al., 2008), they have been reported previously to bind aggregation-prone
proteins, such as amyloid-β, tau and mutant SOD1 and, in some cases, suppress their aggregation
(Oh et al., 1999, Yamashita et al., 2007, Wang et al., 2009, Eroglu et al., 2010, Polier et al., 2010,
Olzscha et al., 2011, Serlidaki et al., 2020). However, unlike Hsp70s, the interaction of Hsp110s
with client proteins is not modulated by a nucleotide-dependent, substrate binding release cycle.
It is therefore believed that Hsp110s can only act as holdases that pass client proteins onto the
Hsp70 chaperone machinery for processing (Hideyuki et al., 1993, Dragovic et al., 2006, Raviol
et al., 2006, Polier et al., 2008, Schuermann et al., 2008). The suggested roles of the four human
Hsp110 members within the cell are outlined briefly below (Table 1.5).
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Table 1.5. Human Hsp110 proteins, their reported binding partners, expression patterns and proposed roles
within cells.

Name

Synonyms

HspH1

Hsp105

HspH2

Apg-2,
Hsp110,
HspA4

HspH3

Apg-1,
HspA4L

HspH4

HYOUI,
Grp170

Reported binding
Subcellular
partners
localisation
Hsc70/Hsp70; HspA2; Cytosol,
HspA4; DNAJA1;
nucleus,
HspA9; DNAJB1;
vesicles
DNAJB4; HspA12a;
GrpEL1; HspA5/BiP

Hsc70/Hsp70;
DNAJB1; Hsp90AA1;
Bag3; Bag1; Stip1;
Stub1; HspH1;
HspA9; DNAJB4
Hsc70/Hsp70;
DNAJB1; HspA9;
HspA12a; DNAJC2;
DNAJB6; HspA5/BiP;
DNAJC7; HspA12b

Cytosol,
nucleus,
extracellular
exosomes

Hsp90B1; DNAJC10;
DNAJB11; DNAJC3;
SEC63; CALR;
P4HB; DNAJB11;
HspA5/BiP; PDIA4;
ERP29; SIL1

ER

1.5

Protein degradation pathways

1.5.1

Ubiquitin-proteasome system

Cytosol,
nucleus

Suggested
cellular roles
Implicated in
cancer
signalling.
Protects against
stress-induced
apoptosis.
Participates as a
NEF and has
holdase activity.
Implicated in
spermatogenesis.

Participates as a
NEF and has
putative holdase
activity.
Implicated in
leukaemia.
Participates as a
NEF and has
holdase activity.
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Behnke et
al., 2016)

If chaperones are unable to refold a protein substrate, they can maintain the folding intermediate
in a soluble state for recognition by degradation machinery (Esser et al., 2004). There are two
major pathways for the degradation of aggregation-prone proteins in eukaryotic cells; the
ubiquitin-proteasome system and autophagy (Lilienbaum, 2013). Under normal cellular
conditions, the ubiquitin-proteasome system is thought to degrade up to 90% of aberrant, shortlived, denatured or damaged proteins (Rock et al., 1994, Hershko and Ciechanover, 1998,
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Glickman and Ciechanover, 2002, Luo and Le, 2010). Once Hsps present substrates to the
ubiquitin-proteasome system, degradation proceeds via recognition of exposed hydrophobicity in
non-native proteins by cytosolic enzymes called ubiquitin ligases. Non-native proteins are then
covalently tagged with ubiquitin, a structurally conserved polypeptide made up of 76 amino acids.
Ubiquitin possesses free lysine residues which can become ligated to another ubiquitin molecule
to form polyubiquitin chains (Xu et al., 2009). Typically, polyubiquitin chains direct the misfolded
protein to the proteasome, a multi-subunit barrel-shaped structure containing several proteolytic
enzymes to ensure specificity to a diverse range of proteins. Proteolysis of the misfolded substrate
results in the release of small peptides or single amino acids from the proteasome back into the
cytosol to be recycled. Free ubiquitin polypeptides are also released and are then able to bind
nearby unfolded substrates (Nassif et al., 2014).

1.5.2

Autophagy

Autophagy also facilitates the degradation of partially-folded protein intermediates or protein
aggregates. There are three forms of autophagy; microautophagy, macroautophagy and chaperonemediated autophagy. Macroautophagy is the major inducible autophagic pathway for the
degradation of aggregated proteins and cytoplasmic components (Klionsky and Emr, 2000,
Lilienbaum, 2013). Chaperone-assisted selective autophagy (CASA) is a specialised form of
macroautophagy in which non-native proteins bound to chaperones are targeted for degradation
by co-chaperones. Mammalian macroautophagy (including CASA) occurs via an integrated and
regulated set of processes (Lilienbaum, 2013). Upon presentation of unfolded polypeptides by
Hsps, macroautophagy is initiated via nucleation of the phagophore, a small membranous vesicle
which elongates and closes in on itself to form the autophagosome. The autophagosome
selectively engulfs non-native proteins and other cytoplasmic organelles and then fuses with
lysosomes to form autophagolysosomes (Johansen and Lamark, 2011). The acidic environment
inside the autophagolysosome activates lysosomal enzymes called hydrolases, which degrade non39
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native proteins and other macromolecules (Klionsky and Emr, 2000, Rubinsztein, 2006,
Lilienbaum, 2013). The proteostasis mechanisms outlined above, including protein folding and
aggregation, degradation by the ubiquitin-proteasome system or autophagy, and the heat shock
response, are summarised in Figure 1.5.
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Figure 1.5. The proteostasis network in cells. The proteostasis network is responsible for maintaining proteins in
their native conformation, in the correct location and concentration. In most cases, nascent protein synthesis and
folding requires attention from molecular chaperones. Under conditions of cell stress, partially-folded intermediates
can accumulate and potentially self-associate (aggregate). Cytosolic misfolded proteins and aggregates can be bound
by molecular chaperones (such as the Hsps) and shuttled for refolding (not shown) or degradation. There are two
major pathways that exist in the cell for the degradation of terminally misfolded and aggregated proteins; the
ubiquitin-proteasome system and autophagy. Degradation via the ubiquitin-proteasome system proceeds once
partially-folded or misfolded proteins are covalently tagged with ubiquitin molecules, which in turn form a
polyubiquitin chain. The polyubiquitin chain directs the complex through the proteasome where proteolysis occurs
and the broken down peptides are released back into the cytosol to be recycled. Autophagy is initiated by the
nucleation of the phagophore, which in turn elongates and closes in on itself, engulfing aggregated or misfolded
proteins. The autophagosome fuses with the lysosome to form the autophagolysosome and the internal environment
activates lysosomal enzymes to mediate degradation. Under normal conditions, HSF1 resides as an inactive monomer
in the cytoplasm via interactions with the molecular chaperones Hsp90, Hsp40, Hsp70 and TriC/CCT. Under
conditions of cellular stress, partially-folded intermediates accumulate and the chaperones dissociate from chaperoneHSF1 complexes. HSF1 undergoes trimerisation and can then translocate into the nucleus. Activated HSF1 trimers
bind heat shock elements in the promotor region of heat shock genes for the transcription and upregulation of inducible
target genes, which include the Hsp molecular chaperones.

1.6

Investigating proteostasis in cells

Uncovering the roles that the heat shock response, autophagy and the ubiquitin-proteasome system
have in the proteostasis network is essential, as these may be therapeutic targets to treat diseases
associated with protein misfolding and aggregation. Unfortunately, the methods available for
monitoring pathways that affect proteostasis in cells are still somewhat limited. Whilst many
studies have utilised genetic or pharmacological approaches to reveal the mechanisms involved in
protein folding and misfolding in cells (Seglen and Gordon, 1982, Lee and Goldberg, 1998,
Yamamoto et al., 1998, Taylor et al., 2007, Lee et al., 2010, Oslowski and Urano, 2011, Hou et
al., 2012, Wang et al., 2017), it remains to be determined which (if any) pathway(s) of the protein
quality control network is/are responsible for one cell type being more susceptible to protein
aggregation compared to another. Thus, there is a need to further characterise the role of
proteostasis-related pathways in preventing protein

aggregation in the context of

neurodegenerative disease phenotypes. Drugs that target important components of the proteostasis
network may assist in uncovering the mechanisms by which proteins aggregate and/or the
pathways that prevent protein aggregation in response to cellular stress (Kampinga and Bergink,
2016). The currently available bioanalytical and chemical methods to investigate proteostasis
pathways in cells have been reviewed recently (Sebastian and Shoulders, 2020, Zhang et al., 2021).
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Understanding the status, function and regulation of the proteostasis network within cells is
extremely important and requires the use of various biological tools. In this respect, the protein
firefly luciferase (Fluc) has been used extensively to assess chaperone activity in vitro (Schröder
et al., 1993, Heyrovská et al., 1998, Naylor, 1999, Hageman et al., 2007). Moreover, destabilised
(i.e. aggregation-prone) forms of Fluc have been exploited to study proteostasis in cells and to
detect proteostasis imbalance or dysfunction (Gupta et al., 2011). By tagging Fluc with a
fluorescent protein, such as green fluorescent protein (GFP), its aggregation state can be monitored
in cells and organisms (Gupta et al., 2011). In this way, destabilised mutants of Fluc serve as
protein folding sensors that can be used to assess the capacity of cells (or organisms) to maintain
an aggregation-prone protein in a soluble state. Another advantage of using Fluc to study protein
aggregation in cells is that the protein has no biological function in commonly used mammalian
cell and animal models. This makes it an ideal model to study generic aspects of protein
aggregation in cells since its misfolding and aggregation is not due to endogenous interactions that
could confound analyses. Moreover, inhibition of aggregation of Fluc-based proteostasis sensors
relies on engagement of the aggregation-prone protein with components of the cellular protein
quality control network that generically act to solubilise or degrade aggregated proteins.

Whilst previous studies have employed Fluc as a model aggregation-prone protein to study protein
aggregation in cells (Gupta et al., 2011, Whiten et al., 2016, San Gil et al., 2017, San Gil et al.,
2020), the role the protein quality control network has in preventing the aggregation of mutant
Fluc into inclusions is yet to be definitely characterised. Furthermore, the aggregation propensity
of Fluc is yet to be exploited in order to comparatively ascertain the relative capacity of different
cell types to inhibit inclusion formation by aggregation-prone proteins. Doing so would be a first
step towards delineating why some cells are more susceptible to the formation of protein
inclusions than others.
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1.6.1

Analysis of inclusion formation in cells using flow cytometry

Cellular models of protein aggregation have previously been used to investigate the role(s) of
chaperones and other proteostasis-related pathways in preventing the accumulation of misfolded
proteins into inclusions (Ramdzan et al., 2012). Earlier approaches to detect the formation of
inclusions in cells primarily involved microscopy-based techniques; however, even with the
advancement of automated microscopy systems, these techniques are limited in their ability to
provide high-throughput and quantitative analyses. Another common method used to assess the
formation of inclusions in cells is the fractionation of lysates into insoluble and soluble material
for analysis by traditional bulk-based biochemical analyses, such as the filter trap assay (Hageman
et al., 2010, Kakkar et al., 2016a, Serlidaki et al., 2020). However, when screening many different
samples, these types of assays can be time consuming, laborious and, when it comes to counting
inclusions in individual cells, subjective. More recently, two flow cytometry-based approaches for
the detection of inclusions in cells have been described, both of which afford high-throughput and
quantitative analysis of cells with inclusions.

Pulse-shape analysis (PulSA) is a flow cytometry-based technique that can detect inclusions
formed by some aggregation-prone proteins in intact cells (Ramdzan et al., 2012). PulSA relies on
the aggregation-prone protein to be fluorescently tagged so that its localisation into inclusions can
be observed (and quantified) in cells. For example, this technique can differentiate diffuse nonaggregated huntingtin from aggregated forms of huntingtin in protein inclusions due to differences
in the fluorescent pulse shapes as a cell passes through the laser of the flow cytometer (Figure
1.6A). Ramdzan et al. (2012) reported that cells containing huntingtin inclusions exhibit a reduced
pulse width and an increased pulse height compared to cells containing non-aggregated huntingtin
(Figure 1.6B). Thus, cells with inclusions can be identified and quantified in a plot of fluorescent
pulse width versus pulse height. PulSA has been used to assess the impact of chaperones on
huntingtin aggregation in cells (Ramdzan et al., 2012) and may therefore provide a valuable tool
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to characterise chaperone function and the regulation of degradation pathways in other cell-based
models of protein aggregation.

Figure 1.6. The flow cytometric technique pulse-shape analysis (PulSA) used to monitor the aggregation of
proteins into inclusions in cells. (A) The principle behind PulSA. Cells in which the fluorescently-tagged protein is
in inclusions have increased pulse heights and narrower pulse widths compared to cells in which the protein remains
soluble and diffuse throughout the cytoplasm, a phenomenon which can be monitored by flow cytometry. (B) Flow
cytometric analysis, in arbitrary fluorescence units (AFU), of inclusion formation by non-aggregating (25Q) and
aggregation-prone (46Q) forms of mCherry-tagged huntingtin (i.e. polyglutamine (polyQ) stretches of 25 and 46
glutamines; here referred to as 25Q and 46Q) expressed in mouse neuroblastoma cells following transfection. Htt25Q is diffusely distributed throughout the cell and Htt-46Q aggregates into inclusions. Two distinct populations can
be identified by PulSA, cells with no inclusions (ni) and cells with inclusions (i). The cells with inclusions have a
narrower pulse width and higher pulse height than cells without inclusions.

Whilst PulSA is effective at identifying cells with large inclusions, the technique cannot be reliably
used to identify cells that contain smaller punctate inclusions, such as those formed by SOD1
(Whiten et al., 2016). To address this, a technique known as flow cytometric analysis of inclusions
and trafficking (FloIT) was developed (Whiten et al., 2016). FloIT can identify intracellular
inclusions of various sizes in cell lysates, including those less than 200 nm in diameter (Whiten et
al., 2016). The FloIT technique is based on an earlier study in which yeast were mechanically
lysed in order to analyse fluorescently-tagged protein aggregates by quantitative flow cytometry
(Shiber et al., 2014). Whilst the basic principle behind methods such as the filter trap assay and
FloIT are the same (Figure 1.7A) (i.e. analysis of insoluble protein in a cell lysate), FloIT is
advantageous due to the high-throughput and quantitative capacity of flow cytometry. In FloIT,
the nuclei within a cell lysate are stained and enumerated using a nuclear marker (e.g. RedDot1)
and quantified based upon forward scatter (FSC) and RedDot1 fluorescence signals in the flow
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cytometer (Figure 1.7B), before being excluded from further analyses. Inclusions produced by
fluorescently-tagged (e.g. enhanced green fluorescent protein; EGFP) aggregation-prone proteins
within a cell lysate are detected and enumerated using signals from the FSC and EGFP
fluorescence (Figure 1.7C). Finally, the number of inclusions is normalised against the number of
nuclei present to enable a quantitative analysis between samples.

Figure 1.7. Flow cytometric analysis of inclusions and trafficking (FloIT) used to quantify the number of
inclusions in a cell lysate. (A) Schematic representation depicting the preparation of cells for FloIT. Following
transient transfection with the fluorescently-tagged aggregation-prone protein of interest, the cells are lysed and nuclei
stained prior to analysis by flow cytometry. (B) Two parameter, pseudo-colour flow cytometry plots gating nuclei
and non-nuclear particles (indicated) from lysates prepared from mouse neuroblastoma × spinal cord motor neuron
hybrid cells transiently transfected to express EGFP-tagged aggregation-prone SOD1G93A (SOD1G93A-EGFP; glycine
substituted to alanine at position 93). Nuclei and non-nuclear particles are identified based on FSC (in arbitrary units;
AU) and RedDot1 fluorescence (in arbitrary fluorescence units; AFU) (leſt: unstained, right: stained with RedDot1).
(C) Non-nuclear particles (gated in (A)) analysed for the presence of inclusions based on EGFP fluorescence (in AFU)
and FSC of lysates prepared from cells transiently expressing EGFP (leſt) or SOD1G93A-EGFP (right). Inclusions
formed by SOD1G93A-EGFP have been indicated.
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FloIT can be used to count and characterise the inclusions within a given cell population and, by
exploiting fluorescence-activated cell sorting methods, can even be used to facilitate the physical
recovery of protein inclusions from a cell lysate. FloIT can be used to detect inclusions formed by
a range of aggregation-prone proteins that differ in size and granularity (Whiten et al., 2016),
making FloIT broadly applicable to most (if not all) model systems of protein aggregation .

1.7

Measuring the proteostasis capacity of cells

The proteostasis capacity of a cell can be defined as the ability to prevent protein accumulation
and aggregation through the regulation of its protein quality control network. The ability to
quantitatively measure the proteostasis capacity of a cell is an important step towards deciphering
why some cell types are more susceptible to the formation of inclusions than others. This is
especially true given that the proteostasis capacity of a cell is known to influence the rate at which
misfolded proteins accumulate (Gidalevitz et al., 2006, Hutt et al., 2009, Powers et al., 2009,
Gidalevitz et al., 2010). Thus, a decline in proteostasis capacity is linked to an impaired ability of
a cell to prevent protein aggregation, which can lead to the onset and progression of toxicity
associated with disease (Brehme et al., 2014, Hipp et al., 2014). At present there is no definitive
method to quantitatively measure the proteostasis capacity of cells.

One major challenge in the field is determining the baseline efficiency with which different cell
types can maintain proteostasis. There have been recent publications describing potential methods
which could be used to measure the proteostasis capacity of different cell types. Liu et al. (2015)
utilised a conformationally metastable retroaldolase protein with thermo-labile properties as a
marker for the decline of proteostasis. The protein was labelled with a small-molecule fluorogenic
probe as a folding sensor to monitor the proteostasis network capacity proceeding stress. However,
the system was only used to assess the effects of heat stress and it is unclear whether it has the
capacity to report on protein “foldedness” after other types of cellular insults or following
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interactions with proteins such as chaperones. Ebbinghaus et al. (2010) described a method which
examined the biomolecular dynamics and folding rates of a probe-labelled phosphoglycerate
kinase protein in human cells following rapid temperature-induced jumps and tracked the reestablishment of equilibrium. However, this technique does not quantitatively report on the
capacity of cells to re-establish proteostasis or define the ability of the protein quality machinery
to engage with these client proteins.

Wood et al. (2018) described a biosensor system that utilises metastable barnase isoforms as bait
proteins that then report on foldedness and aggregation state in cells via fluorescence resonance
energy transfer (FRET) and quantitative flow cytometry methods. Briefly, this method involves
flanking the barnase moiety with two fluorescent proteins, such that both the folded state of
barnase and chaperone-unfolded client complexes can be monitored simultaneously. However,
this method assumes that the holdase activity of the protein quality control network is an overall
indicator of proteostasis health. A method described by Chen et al. (2017), which utilises a cellpermeable fluorogenic dye called tetraphenylethene maleimide (TPE-MI), was used to measure
the levels of unfolded protein in cells. Fluorescence from the TPE-MI occurs when it reacts with
free cysteine thiols in proteins that become exposed during protein unfolding. This technique
demonstrated that TPE-MI fluorescence is enhanced upon reaction with cellular proteomes under
conditions that promote the accumulation of unfolded proteins (Chen et al., 2017). However, it is
yet to be determined whether this method can be used to decipher the ability of cells to prevent
protein aggregation. A molecular rotor-based fluorophore technique developed by Fares et al.
(2018) aimed to detect changes in the conformation of a protein in live cells, including misfolded
or unfolded states of monomers, as well as the formation of soluble oligomers that occurs during
the early stages of proteome stress (prior to the formation of insoluble aggregates). This work
highlights the ability of molecular rotor-based Halo tags to be used to visualise the aggregation of
proteins in live cells and may enable the real-time analysis of cellular proteostasis capacity in
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different cell types. However, further characterisation of the method is required to test its
suitability, for example, upon exposure to different types of cellular stress.

1.8

Summary and aims

There is now overwhelming evidence demonstrating the important role that the protein quality
control network plays in preventing inclusion formation by aggregation-prone proteins. However,
fundamental questions remain as to the role(s) specific components of this network have in this
process. For example, whilst it is well known that some DNAJBs are potent inhibitors of
amyloidogenesis (Hageman et al., 2010, Hageman et al., 2011, Månsson et al., 2014a, Månsson et
al., 2014b, Kakkar et al., 2016b, Månsson et al., 2018), it remains to be determined whether DNAJs
have a generic capacity to engage destabilised amorphously aggregating client proteins, and, if so,
whether this occurs via the same mechanism. Moreover, the relative importance of the ubiquitinproteasome system, autophagy and chaperone network in maintaining proteostasis in cells remains
to be established. Identification of pathways important in preventing protein aggregation, along
with approaches to assess the susceptibility of cell types to inclusion formation, would provide a
basis for the development of effective therapies against diseases associated with protein
aggregation.

The work described in this thesis primarily involved the investigation of the role of proteostasis
pathways, and in particular molecular chaperones, in preventing intracellular inclusion formation
of destabilised proteins. To do so, a double mutant (DM; R188Q, R261Q) form of Fluc (FlucDM)
was exploited in this work as it readily aggregates in cells and has been previously identified to be
an effective proteostasis sensor (Gupta et al., 2011). In addition, as Fluc is not endogenously
expressed in mammalian cells, it has no natural binding partners, so cellular components only
interact with it as a result of its aggregation-prone state and to prevent it forming inclusions in the
cell (Gupta et al., 2011).
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The specific aims of the work described in this thesis were to:
i.

Perform a comprehensive Hsp overexpression screen to identify modulators of FlucDM
inclusion formation in mammalian cells.

ii.

Characterise the mechanism by which DNAJBs inhibit the aggregation of destabilised
client proteins into intracellular inclusions.

iii.

Exploit the aggregation propensity of FlucDM in order to quantitatively assess the relative
proteostasis capacity of two mammalian neuronal cell lines.

iv.

Modulate pathways in the protein quality control network to identify those that play a
key role in inhibiting the formation of inclusions in cells.
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Methods used in multiple chapters of this thesis are outlined in this chapter. Methods specifically
pertaining to work presented in Chapters 3 – 5 are provided in the relevant chapters.

2.1

Materials

All common laboratory chemicals and materials used in this work were purchased from SigmaAldrich (St. Louis, MO, USA) or Amresco (Solon, OH, USA), unless otherwise indicated.
Dulbecco’s Modified Eagle Medium/Ham’s F-12 (DMEM/F-12), foetal calf serum (FCS), Lglutamine and 0.05% trypsin/EDTA were obtained from Gibco (Carlsbad, CA, USA). The
transfection reagents Lipofectamine® LTX/PLUS™ or Lipofectamine™ 3000 were purchased from
Life Technologies (Carlsbad, CA, USA) and linear (MW 25,000) polyethylenimine was obtained
from BioScientific (Gymea, Australia). The PureYield™ Plasmid Midiprep System was purchased
from Promega (Madison, WI, USA). Tetracycline, poly-L-lysine, dimethyl sulfoxide (DMSO),
paraformaldehyde (PFA), thapsigargin and azoramide were purchased from Sigma-Aldrich and
RedDot1 was obtained from Biotium (Hayward, CA, USA). The bicinchoninic acid (BCA) protein
assay kit, Halt™ Protease and Phosphatase Inhibitor Cocktail, Nonidet™ P-40 (NP-40) and Triton
X-100 were purchased from Thermo Fisher Scientific (Glen Burnie, MD, USA). Zeocin and
blasticidin were purchased from InvivoGen (San Diego, CA, USA). MG132 was obtained from
SelleckChem (Boston, MA, USA) and 3-methyladenine (3-MA) was purchased from AdipoGen
(San Diego, CA, USA). Bafilomycin A1 and rapamycin were obtained from Sapphire Bioscience
(Sydney, Australia). Precision Plus Protein™ dual colour standards and ImmunoBlot™
polyvinylidene difluoride (PVDF) membrane used for immunoblotting were purchased from BioRad (Hercules, CA, USA).

Human embryonic kidney (HEK293) cells and mouse neuroblastoma (Neuro-2a) cells were
purchased from the American Type Culture Collection (Manassas, VA, USA). HEK293 cells
stably expressing the tetracycline (tet) repressor (Flp-In T-REx) were obtained from Invitrogen
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(Carlsbad, CA, USA). Mouse neuroblastoma × spinal cord (NSC-34) motor neuron hybrid cells,
originally described by Cashman et al. (1992), were generously donated by Professor Justin
Yerbury (University of Wollongong, Australia). The heat shocked HeLa cell lysate was prepared
and donated by Dr Rebecca San Gil (University of Wollongong, Australia). Cell lines were
routinely tested for mycoplasma contamination (~ every 6 months) and the identity of the humanderived cell lines were verified via short tandem repeat profiling (Garvan Institute of Medical
Research, Australia).
2.2

Antibodies

Antibodies were sourced from Abcam (Cambridge, MA, USA), unless otherwise indicated, and
their specifications, including the dilutions used for immunoblotting, are outlined in Table 2.1.
Table 2.1. Primary and secondary antibodies used for immunoblotting

Primary antibodies
Product name
Anti-GFP antibody
Anti-GRP78 antibody
Anti-Hsc70 antibody
Anti-HSF1 antibody
Anti-Hsp40 antibody
Anti-Hsp70 antibody
Anti-Hsp90 antibody
Anti-LC3II antibody

Description
Rabbit polyclonal
Rabbit polyclonal
Mouse monoclonal
Rat monoclonal
Mouse monoclonal
Mouse monoclonal
Mouse monoclonal
Rabbit polyclonal

Anti-SQSTM1/p62
Anti-Ubiquitin antibody

Mouse monoclonal
Mouse monoclonal

Anti-V5 antibody

Mouse monoclonal

Secondary antibodies
Goat anti-rabbit IgG
horse radish peroxidase
(HRP)-conjugated
antibody
Rabbit anti-mouse IgG
HRP-conjugated
antibody
Rabbit anti-rat IgG
HRP-conjugated
antibody

Supplier
Abcam
Abcam
Abcam
Abcam
Abcam
Abcam
Abcam
Cell Signalling
Technology (Danvers,
MA, USA)
Abcam
Santa Cruz
Biotechnology
(Dallas, TX, USA)
Thermo Fisher
Scientific

Product #
ab290
ab21685
ab2788
ab81279
ab78437
ab47455
ab13492
2775

Dilution
1:2500
1:1000
1:1000
1:1000
1:5000
1:1000
1:1000
1:1000

ab56416
sc-8017

1:2000
1:1000

46-0705

1:5000

Goat polyclonal

Thermo Fisher
Scientific

31466

1:5000

Rabbit polyclonal

Sigma-Aldrich

A9044

1:5000

Rabbit polyclonal

Abcam

ab6734

1:5000
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2.3

Preparation of mammalian expression constructs

2.3.1

Plasmid constructs

The pN3-enhanced green fluorescent protein (EGFP) plasmid was kindly donated by Dr Darren
Saunders (University of New South Wales, Australia). Plasmids encoding wild-type (WT) and
double mutant (DM; R188Q, R261Q) Fluc with an N-terminal EGFP tag (FlucWT-EGFP and
FlucDM-EGFP) (Gupta et al., 2011) were kindly gifted by Professor Ulrich Hartl (Max Planck
Institute of Biochemistry, Munich, Germany) and were cloned into pcDNA4/TO/myc/hisA for
mammalian expression by GenScript (Piscataway, NJ, USA). The pCDNA5/FRT/TO-monomeric
red fluorescent protein (mRFP) and pCDNA5/FRT/TO/V5-tagged heat shock protein (Hsp)
plasmid library, including all mutational variants, were generously donated by Professor Harm
Kampinga (University of Groningen, The Netherlands) and are outlined in more detail in the
relevant chapters of this thesis.

2.3.2

Preparation of chemically competent Escherichia coli (E. coli)

Chemically competent DH5α E. coli were prepared by inoculating 10 mL of lysogeny broth (LB;
5% (w/v) yeast, 10% (w/v) NaCl, 10% (w/v) tryptone, pH 7.4) with a single colony. The culture
was incubated overnight at 37°C with shaking at 180 rpm. Cells were centrifuged at 5,000 × g for
5 min at room temperature, washed in ice-cold 100 mM CaCl2 and incubated on ice for 30 min.
The cells were centrifuged again (5,000 × g for 5 min at 4°C) and washed in ice-cold 100 mM
CaCl2 containing 15% (v/v) glycerol and snap frozen in liquid nitrogen for storage at -80°C.

2.3.3

Transformation of chemically competent E. coli

To transform cells, 100 ng/µL of plasmid DNA was mixed gently with an aliquot (100 μL) of
chemically competent DH5α E. coli and incubated on ice for 30 min. Cells were then heat shocked
at 42°C for 30 sec and immediately returned to ice. Cells were diluted 1:7 in LB broth and the
transformation mixture was incubated at 37°C for 1 h on an orbital shaker (180 rpm).
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Transformation cultures were then plated onto selective LB agar media (LB with 15% (w/v) agar)
supplemented with ampicillin (100 μg/mL) or kanamycin (50 μg/mL) as required, and incubated
at 37°C overnight. A single colony was then used to inoculate LB media containing the appropriate
antibiotic, which was incubated overnight at 37°C. This culture was then mixed 1:1 with sterile
30% (v/v) glycerol and stored in sterile cryovials at -80°C until required.

2.3.4

Bacterial culture and preparation of plasmid DNA

Single colonies of chemically competent DH5α E. coli, containing the plasmid sequence of
interest, were used to inoculate cultures consisting of 100 mL LB supplemented with the
appropriate antibiotic, i.e. either ampicillin (100 μg/mL) or kanamycin (50 μg/mL). The cultures
were incubated at 37°C overnight with shaking at 180 rpm. Cultures were pelleted by
centrifugation at 5,000 × g for 10 min at room temperature and the supernatant discarded.
Transfection-quality plasmid DNA was purified from the bacterial cell pellets by centrifugation
using the PureYield™ Plasmid Midiprep System, as per the manufacturer’s instructions.
Concentrations and purity of plasmid DNA were determined using a NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientific) by measuring the absorbance at 260 and 280 nm.

2.4

Mammalian cell culture

2.4.1

Passaging and plating

HEK293, Neuro-2a and NSC-34 cells were cultured in DMEM/F-12 supplemented with Lglutamine (2.5 mM) and 10% FCS (v/v) at 37°C under 5% CO2/95% air in a Heracell 150i CO2
incubator (Thermo Fisher Scientific). Stably transfected Flp-In T-REx HEK293 cells were
cultured as above with the addition of zeocin (50 μg/mL) and blasticidin (5 μg/mL) to the culture
medium weekly to ensure maintenance of the tet-repressor. Flp-In T-REx HEK293 cells contain
a single stably integrated flippase recognition target (FRT) site at a transcriptionally active
genomic locus for homogenous expression from a tetracycline-inducible expression vector, such
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as the pCDNA5/FRT/TO/V5-tagged constructs used in this work. Following transient transfection
of Flp-In T-REx HEK293 cells, the expression of the gene of interest from a FRT-tagged plasmid
can be induced using tetracycline. A major benefit of using this system is that, if required, the
expression of a protein of interest can be induced in a time-dependent manner.

Cells were sub-cultured into fresh CELLSTAR® culture flasks or plates (Greiner Bio-One,
Frickenhausen, Germany) every three days or when they were deemed to be ~80% confluent.
Briefly, culture media was removed and replaced with sterile phosphate buffered saline (PBS; 135
mM NaCl, 2.7 mM KCl, 1.75 mM KH2PO4, 10 mM Na2HPO4, pH 7.4) to remove excess serum.
The PBS was pipetted off and a sufficient volume of 0.05% (v/v) trypsin/EDTA was added to
cover the bottom of the flask. Cells were incubated at 37°C for 5 min and the flask was gently
tapped to dislodge cells. An aliquot of DMEM/F-12 containing 1% (v/v) FCS was used to wash
the bottom of the flask (~20 times) in order to collect cells. For passaging purposes, ~15% of the
cells were collected and centrifuged at 300 × g for 5 min at room temperature. The supernatant
was discarded and cells were resuspended in the appropriate volume of culture medium before
being transferred to a fresh culture flask. For plating purposes, the remaining cell suspension was
collected and centrifuged as above prior to being resuspended in DMEM/F-12 containing 10%
(v/v) FCS for counting. A sample of the cell suspension was combined 1:1 with trypan-blue
(Sigma-Aldrich) and the cell density determined using a BLAUBRAND® Neubauer-improved
counting chamber (Marienfeld 50 Superior, Lauda-Königshofen, Germany). Cells were then
diluted with culture medium and seeded in the appropriate plate at the desired cellular density.

2.4.2

Storage

Cell lines were maintained in liquid nitrogen for long-term storage. To generate stocks for storage,
cells were harvested as above before being resuspended in DMEM/F-12 supplemented with 40%
(v/v) FCS and 10% (v/v) DMSO. The suspension was then aliquoted (1 mL) into sterile cryovials
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and placed in a pre-cooled Nalgene® Mr. Frosty Freezing Container (Thermo Fisher Scientific)
containing isopropanol. Cells were stored at -80°C overnight prior to transfer to liquid nitrogen.
When removing stocks from liquid nitrogen for use, cells were thawed slowly in 70% ethanol and
then immediately diluted 1:10 into DMEM/F-12 containing 10% (v/v) FCS. Cells were
centrifuged at 300 × g for 5 min at room temperature and resuspended in full culture medium
before being transferred to a flask. After 24 h, the culture medium was discarded and replaced
with fresh media and the cells were allowed to reach 80% confluency prior to being passaged.
Thawed cells were allowed to grow as normal with regular passaging for a minimum of two weeks
prior to use in subsequent experiments. Details regarding the transient transfection, co-transfection
or treatment of established cells lines are outlined in the relevant chapters of this thesis.

2.5

Immunocytochemistry and confocal microscopy

In some experiments, HEK293, Neuro-2a or NSC-34 cells were grown to 60-70% confluency in
8-well chamber µ-Slides (Ibidi, Martinsried, Germany) and were transfected as outlined in the
relevant chapters of this thesis. At 48 h post-transfection, cells were pre-fixed with warmed (37°C)
2% (v/v) PFA for 5 min, prior to fixing with 4% (v/v) PFA for 15 min at room temperature. Cells
were washed twice with 100 mM Tris-HCl (pH 8.0) for 10 min with gentle rocking to quench
residual PFA. Cells were then permeabilised with 0.1% (v/v) Triton X-100 in PBS for 10 min and
blocked for 1 h at room temperature in blocking buffer (1% (v/v) FCS, 1% (w/v) bovine serum
albumin (BSA), 0.1% (v/v) Triton X-100 in PBS, pH 7.4). Cells were incubated with the primary
antibody of interest diluted (dilutions specified in relevant chapters) in blocking buffer for 1 h at
37°C and then washed 3 times (each for 10 min) with gentle rocking in 0.1% (v/v) Triton X-100
in PBS. Cells were then incubated with the appropriate secondary antibody diluted in blocking
buffer for 30 min at 37°C in the dark, prior to 3 washes (each for 10 min) in 0.1% (v/v) Triton X100 in PBS with rocking. Finally, cells were stained with 0.1 µg/mL Hoechst 33342 nucleic acid
stain (Thermo Fisher Scientific) for 5 min at room temperature, washed twice in PBS, and imaged
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in ~150 µL PBS/well using a SP8 TCS confocal microscope (Leica Microsystems, Wetzlar,
Germany), the 20× objective lens or the 63× oil objective lens and, where required, the 4× zoom
function in the Leica Application Suite (LAS)-X software (Leica Microsystems). To eliminate
spectral overlap, fluorescent images were acquired by sequential scanning, where Hoechst 33482
was excited with a 405 nm laser, EGFP was excited with a 488 nm laser, mRFP or Dylight® 550
were excited with a 552 nm laser and Alexa Fluor 647 was excited with a 638 nm laser. Images
were prepared using the LAS-X Version 3 software.

2.6

Flow cytometry

In some experiments, 48 h post-transfection, cells were prepared for flow cytometric analysis.
Cells were harvested with 0.05% (v/v) trypsin/EDTA, then diluted with DMEM/F-12 containing
1% (v/v) FCS and centrifuged at 300 × g for 5 min at room temperature. Cells were then washed
twice in PBS and resuspended in 500 μL PBS. Cells were kept on ice throughout this process to
minimise cell death. In all experiments, flow cytometry was performed using a BD LSRFortessa
X-20 or BD LSR-II analytical flow cytometer (BD Biosciences, San Jose, CA, USA) and FCS
files were analysed using FlowJo version 10 (Tree Star, Ashland, OR, USA).

2.6.1

Pulse-shape analysis (PulSA)

An aliquot of the cell suspension (250 μL) was taken and analysed by flow cytometry. The
percentage of cells containing inclusions was identified by the previously described technique
known as PulSA (Ramdzan et al., 2012), using the excitation wavelength and emission collection
window for EGFP (488 nm, 525/50 nm, respectively). In all experiments a minimum of 50,000
events were acquired, unless otherwise specified. Briefly, in addition to fluorescence area, the
width and height parameters of the EGFP fluorescence signal of each event were recorded and
used to determine the number of cells with inclusions. The PulSA technique facilitates (in some
cases) the identification of cells with inclusions as a result of a shift in their EGFP fluorescence
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profile, such that they have a narrower EGFP fluorescence pulse width and increased EGFP
fluorescence pulse height compared to cells expressing EGFP alone. The transfection efficiency
of cells was also quantified by flow cytometry in these experiments for use in later analyses.

2.6.2

Flow cytometric analysis of inclusions and trafficking (FloIT)

The remaining 250 μL of cells were centrifuged as above (section 2.6) and analysed by FloIT as
previously described (Whiten et al., 2016). To do so, cells were resuspended in PBS containing
0.5% (v/v) Triton X-100 to facilitate cell lysis. Except in control samples used to set gates,
RedDot1 was diluted (1:1000) into PBS and then diluted further (1:500) upon addition to cell
lysates. Following a 2 min incubation on ice to stain nuclei, flow cytometry was performed as
previously described (Whiten et al., 2016). Forward scatter (FSC) and side scatter (SSC), together
with RedDot1 fluorescence (640 nm excitation, 670/30 nm collection) and EGFP fluorescence
(section 2.6.1) of particles present in cell lysates were measured. The FSC threshold was set to
200 (minimum possible) in order to include small inclusions in analyses. In all experiments, axes
were set to log10 and a minimum of 100,000 events were acquired. Nuclei were identified based
on FSC and RedDot1 fluorescence and were excluded from further analyses. Inclusions were
counted based on their FSC and EGFP fluorescence, in comparison to untransfected or EGFPonly expressing cells. Unless otherwise stated, voltages of 300 (FSC), 200 (SSC), 300, (EGFP),
290 (mRFP; 561 nm excitation, 586/15 nm collection) and 520 (RedDot1) were used in all
experiments. The number of inclusions identified within the population was normalised against
the number of nuclei present and values are reported as the number of inclusions/100 cells
according to the equation:
𝑛𝑛𝑖𝑖
𝑖𝑖 = 100 �
�
𝛾𝛾. 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛

Equation 2.1

Where ni is the number of inclusions present, nnuc is the number of nuclei, and γ is the transfection
efficiency.
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2.7

Immunoblotting

2.7.1

Cellular protein extraction and quantification by the bicinchoninic acid (BCA) assay

In some experiments, transfected cells were trypsinised, harvested, washed twice in PBS (300 × g
for 5 min at room temperature) and cellular protein was extracted by lysis with NP-40 lysis buffer
(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40 supplemented with 0.5% (v/v)
Halt™ Protease and Phosphatase Inhibitor Cocktail, pH 8.0). Cell lysates were then sonicated using
the Sonifer® 250 Digital cell disruptor and a double step micro-tip (Branson Ultrasonics, CT, USA)
at 50% amplitude for 5 sec. The total protein concentration for each sample was then determined
using a BCA assay. The assay was carried out using a standard 96-well plate format, as described
previously (Redinbaugh and Turley, 1986), and BSA was used as a standard for determining
protein concentrations in cell lysates. The concentration in each sample was adjusted with NP-40
lysis buffer to generate cell lysates with a total protein concentration of 1 mg/mL to ensure equal
loading onto SDS polyacrylamide gel electrophoresis (SDS-PAGE) gels for subsequent
immunoblotting.

2.7.2

Cellular fractionation by centrifugation

A 45 µL aliquot of total protein (total fraction) was taken and kept on ice until use. The remaining
155 µL lysate was centrifuged at 20,000 × g for 30 mins at 4°C and the supernatant (soluble
fraction) carefully collected and placed on ice. The pellet was washed in ice-cold TNE buffer (50
mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0) and centrifuged again at 20,000 × g for 30
mins at 4°C. The supernatant was carefully removed and discarded and the pellet resuspended in
50 µL NP-40 lysis buffer. The insoluble pellet was vortexed to dislodge it from the tube and the
fraction was sonicated at 50% amplitude for 5 sec (insoluble fraction) and remained on ice until
required.
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2.7.3

SDS-PAGE

SDS-PAGE loading buffer (final concentrations: 500 mM Tris-HCl, 2% (w/v) SDS, 25% (v/v)
glycerol, 0.01% (w/v) bromophenol blue, 15% (v/v) β-mercaptoethanol, pH 6.8) was added to cell
lysate samples and they were then heated at 95°C for 5 min before being loaded onto an SDSPAGE gel. SDS-PAGE was undertaken using polyacrylamide resolving gels (12% (w/v)
acrylamide/bis, 375 mM Tris (pH 8.8), 0.1% (w/v) SDS, 0.25% (v/v) tetramethylethylenediamine,
0.02% (w/v) ammonium persulfate) with polyacrylamide stacking gels (4% (w/v) acrylamide/bis,
330 mM Tris (pH 6.8), 0.1% (w/v) SDS, 0.4% (v/v) tetramethylethylenediamine, 0.04% (w/v)
ammonium persulfate) following standard procedures (Laemmli, 1970). The gels were run in a
Mini-Protean® Tetra Cell system (Bio-Rad) filled with SDS-PAGE running buffer (25 mM Tris
base, 192 mM glycine, 0.5% (w/v) SDS, pH 8.3). Samples were electrophoresed for 15 min at 100
V until proteins had migrated through the stacking gel, at which point, the voltage was increased
to 150 V and was allowed to run until the bromophenol blue dye front had migrated off the end of
the gel (~1 h). When required, gels were stained with Coomassie Blue staining solution (40% (v/v)
methanol, 10% (v/v) acetic acid, 0.02% (w/v) Coomassie Brilliant Blue R-250) and de-stained in
de-staining solution (40% (v/v) methanol, 10% (v/v) acetic acid), otherwise gels were used for
immunoblotting.

2.7.4

Immunoblotting and detection

Samples were separated by SDS-PAGE as described above prior to transfer onto a PVDF
membrane using a standard technique (Towbin et al., 1979). Briefly, proteins were transferred
onto a PVDF membrane at 100 V for 1 h in ice-cold transfer buffer (25 mM Tris base, 192 mM
glycine, 20% (v/v) methanol, pH 8.3). The membrane was blocked at 4°C overnight with 5% (w/v)
skim milk powder in Tris-buffered saline (TBS; 50 mM Tris base, 150 mM NaCl, pH 7.6).
Membranes were incubated with primary antibodies of interest (refer to Table 2.1 above for the
dilutions used for specific antibodies) in 5% (w/v) skim milk powder in TBS containing 0.05%
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(v/v) Tween 20 (TBS-T) for 2 h at room temperature. The membrane was washed four times (each
for 10 min) in TBS-T before being incubated with the appropriate HRP-conjugated secondary
antibody, diluted 1:5000 into 5% (w/v) skim milk powder in TBS-T (see Table 2.1). The
membrane was rocked at room temperature for 1 h before being washed four times (each for 10
min) in TBS-T. Proteins of interest were detected with SuperSignal® West Pico Chemiluminescent
Substrate or SuperSignal® West Dura Extended Duration Chemiluminescent Substrate (Thermo
Fisher Scientific) using an Amersham Imager 600RGB (GE Healthcare Life Sciences, Little
Chalfont, UK) or ChemiDoc™ Imaging System (Bio-Rad), with exposure times ranging from 1–
15 min.

2.8

Statistical analyses

Histograms were generated and statistical analyses were performed using GraphPad Prism v8
(GraphPad Software, La Jolla, CA, USA). Unless otherwise stated, results are reported as the mean
± standard error of the mean (S.E.M) and the number of independent (biological) replicates (n) of
each experiment is specified. Data were analysed by one-way (or two-way) analysis of variance
(ANOVA) and Tukey’s, Bonferroni's or Dunnett’s post-hoc test or, where appropriate, assessed
assuming unequal variance using the unpaired two-tailed Student’s t-test. In all analyses, P < 0.05
was considered statistically significant.
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for suppressors of FlucDM inclusion
formation
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3.1

Introduction

Cell-based and in vivo studies investigating the role and function of the Hsps have demonstrated
their remarkable ability to prevent the aggregation of disease-associated proteins. For example,
overexpression of Hsp70 has been shown to reduce α-synuclein aggregation and the associated
toxicity in a cell culture and transgenic mouse model of Parkinson’s disease (Klucken et al., 2004).
Overexpression of Hsp70 in a transgenic mouse model of spinocerebellar ataxia type 1 reduced
neurodegeneration and repaired motor function (Cummings et al., 2001). In addition,
overexpression of Hsp70 can reduce the toxicity associated with mutant α-synuclein aggregation
in Drosophila melanogaster models of Parkinson’s disease (Auluck et al., 2002), whilst its
interaction with aggregation-prone huntingtin in vitro has been shown to supress the formation of
amyloid-like fibrillar aggregates (Muchowski et al., 2000). Furthermore, the upregulation of
Hsp70, Hsp40 and Hsp60 in combination, protects neurons against the toxicity associated with
amyloid-β aggregation both in vitro and in vivo (Evans et al., 2006). Previous work has
demonstrated that overexpression of Hsp27 (HspB1) inhibits the aggregation of SOD1 in vitro
(Yerbury et al., 2013) and α-synuclein in cell culture models (Outeiro et al., 2006, Cox and Ecroyd,
2017). Similarly, αB-crystallin (HspB5) can suppress the aggregation of SOD1 (Yerbury et al.,
2013) and α-synuclein (Cox and Ecroyd, 2017) in vitro and has been identified to be important in
maintaining the solubility of misfolded proteins (Ghosh et al., 2006, Eyles and Gierasch, 2010,
Kampinga and Garrido, 2012, Treweek et al., 2015). The identification of mutations in molecular
chaperones linked to familial cases of neurodegenerative disease further demonstrates their
importance in the maintenance of proteostasis (Hansen et al., 2002, Irobi et al., 2004, De Mena et
al., 2009, Selcen et al., 2009).

Interestingly, in some cases different Hsps appear to be required to impede the aggregation of
disease-associated proteins, suggesting a degree of specificity in the interaction of chaperones with
these client proteins (Kampinga and Bergink, 2016). For example, HspA1A was the only member
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of the Hsp70 family capable of preventing intracellular inclusion formation by a disease-related
SOD1 mutant (Serlidaki et al., 2020). To-date, the majority of cell-based screens of the capacity
of chaperones to prevent protein aggregation have involved proteins whose aggregation is disease
related (Hageman et al., 2010, Vos et al., 2010, Hageman et al., 2011, Minoia et al., 2014b, Kakkar
et al., 2016a, Serlidaki et al., 2020). However, since these proteins are endogenously expressed in
cells, their misfolding and aggregation may be associated with disruptions to functional
interactions. To avoid this, in this work a previously described mutant isoform of Fluc,
FlucR188Q/R261Q (herein referred to double mutant Fluc, FlucDM) (Gupta et al., 2011) was chosen in
order to assess the generic capacity of Hsp molecular chaperones and co-chaperones to engage
with a highly destabilised, aggregation-prone protein in cells to prevent its aggregation into
inclusions. This FlucDM isoform therefore acts as a proteostasis sensor by reporting on the capacity
of Hsps to maintain aggregation-prone proteins in a soluble state. Fluc has no biological role in
the human cell model used in this study; thus, its aggregation is not influenced by interaction with
endogenous ligands or binding partners. Moreover, since Fluc forms amorphous-type aggregates
(Schröder et al., 1993, Buchberger et al., 1996, Rampelt et al., 2012) this work sought to test
whether Hsps previously identified to suppress the fibrillar aggregation of proteins (Vos et al.,
2010, Månsson et al., 2014a, Kakkar et al., 2016b) also inhibit the amorphous aggregation of
destabilised proteins in cells.
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3.2

Methods

3.2.1

Plasmid constructs

Construction of the V5-tagged Hsp (HspA, HspB, DNAJ and HspH) plasmid library used in this
study was previously described by Hageman and Kampinga (2009). Plasmids encoding HA-Bag1,
FLAG-Bag2, FLAG-Bag3, pcDNA5/FRT/TO-V5-Bag4 and FLAG-Bag5 were donated by
Professor Harm Kampinga (University of Groningen, The Netherlands).

3.2.2

Cell culture and transfection of HEK293 and Flp-In T-REx HEK293 cells

HEK293 and Flp-In T-Rex HEK293 cells were cultured as described in section 2.4.1. For transient
transfections, cells were grown to 60-70% confluence in CELLSTAR® 6-well plates (Greiner BioOne) coated with 0.001% poly-L-lysine. Cells were co-transfected 24 h post-plating with linear
polyethylenimine according to the manufacturer’s instructions, using 0.2 µg of plasmid encoding
for FlucDM and 0.8 µg of plasmid DNA encoding for either mRFP (as a negative control) or a Hsp
isoform. For transfection of Flp-In T-REx HEK293 cells, 1 µg/mL tetracycline was added to the
culture medium 4 h post-transfection to induce expression. To test the luciferase activity of cells
expressing FlucWT or FlucDM, Flp-In T-REx HEK293 cells were transfected with FlucWT-EGFP or
FlucDM-EGFP DNA at amounts of 0.1, 0.2 or 0.3 µg, with linear polyethylenimine as stated above.

3.2.3

Epifluorescence microscopy

The formation of inclusions following expression of FlucWT-EGFP or FlucDM-EGFP was assessed
directly in 6-well plates 48 h post-transfection by epifluorescence microscopy. Green fluorescence
was detected by excitation at 488 nm. All images were taken at 20× magnification using a Leica
DMi8 fluorescence microscope (Leica Microsystems). Images were prepared with the LASAdvanced Fluorescence (LAS-AF) Version 3 software (Leica Microsystems).
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3.2.4

Cellular protein fractionation and subsequent immunoblotting

Cells were fractionated and protein was extracted and quantified as outlined in section 2.7.2.
Subsequent SDS-PAGE and immunoblotting was undertaken as described in sections 2.7.3 and
2.7.4, respectively.

3.2.5

Antibodies

See Table 2.1 in section 2.2 for antibodies and dilutions used for immunoblotting.

3.2.6

Flow cytometry assays to assess inclusion formation

See section 2.6 for methods pertaining to standard flow cytometry, PulSA and FloIT analyses of
cells.

3.2.7

Flow cytometry to assess relative FlucDM-EGFP levels in cells

To account for any differences in the level of FlucDM-EGFP being expressed between treatment
groups and for use in the luciferase assays (see section 3.2.8), the EGFP geometric mean was
determined for live cells transfected as described above and analysed by flow cytometry. Data in
Figure 3.9 and Figure 8.1 in Appendix I are presented as the raw EGFP geometric means of each
treatment group. The average EGFP geometric mean was taken from three independent
experiments and used to calculate the relative EGFP fluorescence. In some experiments, the data
was analysed using the following equation:
Relative EGFP fluorescence =

Average EGFP geometric mean of Hsp sample
Average EGFP geometric mean of mRFP

Equation 3.1

The relative EGFP fluorescence was then used to normalise between treatment groups for the
relative amount of FlucDM in the luciferase assay (see section 3.2.8).
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3.2.8

Luciferase activity measurements

The ability of the chaperones to maintain FlucDM-EGFP in a functional state was assessed using a
luciferase activity assay. Cells were transfected in a 6-well plate as per section 3.2.2 and cell lysis
and luciferase assays were performed 48 h post-transfection as described previously (Michels et
al., 1995). Briefly, cells were lysed on ice in 1.0 mL Triton X-100 lysis buffer (25 mM Tris/H3PO4,
10 mM MgCl2, 1% (v/v) Triton X-100, 15% glycerol, 1 mM EDTA, pH 7.8) prior to being
transferred to -80°C overnight to facilitate total cell lysis. Samples were thawed on ice and 100
µL was added to a cuvette. Luciferase activity was measured for 10 sec following injection of 100
µL substrate (1.25 mM ATP, 0.087 mg/mL D-luciferin) using a Sirius Luminometer (Berthold
Technologies, Baden-Württemberg, Germany). Untransfected cells were plated and treated as
above and the average relative light units (RLUs) of these cells was subtracted (as a baseline
activity) from other treatment groups. Measurements from three separate wells (technical
replicates) of each sample were performed and data are presented as the mean ± S.E.M of these
technical replicates. In addition, the RLUs of each sample was normalised to the relative levels of
FlucDM-EGFP as per the following equation:
RLUs/Fluc DM levels =

3.2.9

Luciferase activity in RLUs
Relative EGFP fluorescence

Equation 3.2

Sequence alignment and structural modelling

Sequence alignment of HspA1A and HspA1L were performed with the Clustal Omega (EMBLEBI, Cambridgeshire, UK) Needle (EMBOSS) pairwise sequence alignment tool and the
Needleman-Wunsch algorithm. Structural modelling of the HspA1A nucleotide binding domain
was undertaken using PyMOL version 2 (PyMOL Molecular Graphics System, Schrödinger, Inc.,
NY, USA). The nucleotide binding domains of HspA1A (PDB ID: 3JXU) and HspA1L (PDB ID:
3GDQ) were first aligned in PyMOL using the alignment command and then non-conserved
regions in HspA1L were identified manually using the above sequence alignment. Non-conserved
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regions in HspA1L were mapped onto the HspA1A structure and were chosen to be presented as
main chain spheres.

3.2.10 Statistics
Statistical tests were performed as described in section 3.2.10.
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3.3

Results

3.3.1

Characterisation of mutant Fluc as a suitable client protein to screen for Hsp

chaperone activity
Prior to conducting an Hsp overexpression screen to identify modulators of FlucDM aggregation in
cells, the intracellular aggregation propensity of FlucDM into inclusions in HEK293 cells was first
confirmed by transfecting cells so they expressed FlucDM-EGFP or the less aggregation-prone
FlucWT-EGFP (Figure 3.1A). Some cells expressing FlucDM-EGFP contained green fluorescent
puncta throughout the cytoplasm (~15% of transfected cells), corresponding to the aggregation
and formation of inclusions by this protein. Whilst inclusions were occasionally observed in cells
expressing FlucWT-EGFP (less than 5%), most of these cells exhibited diffuse green fluorescence
throughout the cytoplasm and the nucleus. The significantly enhanced aggregation propensity of
FlucDM-EGFP compared to FlucWT-EGFP was confirmed by examining the distribution of
detergent soluble and insoluble protein between cells expressing either of these two Fluc isoforms
(Figure 3.1B). There was approximately triple the amount of insoluble protein detected in cells
expressing FlucDM compared to those expressing FlucWT, whilst the soluble protein formed by
cells expressing FlucDM was two-fold higher than that observed in cells expressing FlucWT.

Figure 3.1. FlucDM readily aggregates to form inclusions in cells, which can be assessed using traditional
analyses. HEK293 cells were transfected with FlucWT-EGFP or FlucDM-EGFP and analysed 48 h post-transfection by
(A) epifluorescence microscopy or (B) NP-40 cell fractionation followed by immunoblotting. In (A) green
fluorescence was detected by excitation at 488 nm. Examples of cells containing inclusions are denoted by the arrows.
All images were taken at 20× magnification using a Leica DMi8 fluorescence microscope and scale bars represent 60
μm. Images are representative of three experiments. In (B) an anti-GFP antibody was used to detect FlucWT or FlucDM
in the soluble (S) or insoluble pellet (P) fraction. A section of the gel showing the total protein was used as a loading
control. The blots shown are representative of three experiments.
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The percentage of HEK293 cells with inclusions was then analysed by the previously described
flow cytometric, pulse shape analysis (PulSA) technique (Ramdzan et al., 2012). First, polygonal
gating of the forward scatter (FSC) and side scatter (SSC) signals was used to identify viable, live
cells and to remove dead cells, cellular debris and cell doublets from subsequent analyses (Figure
3.2A). Transfected cells were selected based upon EGFP fluorescence, using untransfected cells
as a control; cells that did not fluoresce were excluded from further analyses (Figure 3.2B).
Finally, live, single, EGFP-positive cells were analysed, plotting the pulse width (W) versus height
(H) of the EGFP fluorescence signal (Ramdzan et al., 2012). Cells expressing EGFP, which rarely
contain inclusions (Figure 3.2C; left), were used to set the gate to identify cells with inclusions
formed by FlucDM-EGFP (Figure 3.2C; right). PulSA demonstrated that there was a significantly
higher percentage of FlucDM-expressing cells with inclusions (9.0 ± 1.1%) compared to cells
expressing FlucWT (2.1 ± 0.2%) (Figure 3.2D).

71

Chapter 3 – Hsp overexpression screen

Figure 3.2. The formation of inclusions by Fluc in HEK293 cells can be assessed by PulSA. HEK293 cells were
transiently transfected to express FlucWT-EGFP or FlucDM-EGFP (or EGFP as a control) and were analysed by PulSA
48 h post-transfection. EGFP fluorescence was detected using a 488 nm laser and 525/50 nm emission filter and
100,000 events were collected for each cell population. Values within plots represent the percentage of cells within
each gate. (A) Forward scatter (FSC) and side scatter (SSC) pseudo-colour plot of untransfected cells. The polygonal
gate encompasses the viable, live cells in the population which were selected for subsequent analyses. (B) Frequency
histogram of the relative EGFP fluorescence of untransfected (grey) and transiently transfected cells expressing EGFP
(green). Cells expressing EGFP (gate shown) were selected for subsequent analyses. (C) Pulse-shape analysis (PulSA)
of cells transiently transfected with EGFP (left) or FlucDM-EGFP (right) used to identify cells with inclusions based
upon the EGFP pulse width (W) and pulse height (H) signals. (D) The proportion of HEK293 cells expressing FlucWTEGFP or FlucDM-EGFP with inclusions. Data in (D) are presented as the mean ± S.E.M (n=3) of the percentage of
cells containing inclusions. Significant differences between group means were determined using an unpaired twotailed Student’s t-test (** = P < 0.01).

Cells expressing EGFP-tagged Fluc were also analysed by the FloIT assay, a technique that readily
enumerates the number of inclusions formed in cells (Whiten et al., 2016). Thus, cells were lysed
in PBS containing 0.5% (v/v) Triton X-100 and analysed by flow cytometry. Nuclei and nonnuclear particles were identified (and quantified) based on the FSC signal and RedDot1
fluorescence (left: unstained, right: stained with RedDot1) (Figure 3.3A) and nuclei were excluded
from subsequent analyses. The EGFP fluorescence of cells expressing Fluc was exploited to
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identify cytoplasmic inclusions containing Fluc based on their FSC and EGFP fluorescence signals
(untransfected or EGFP-expressing cells were used as a negative control) (Figure 3.3B). The
number of inclusions measured by FloIT was significantly higher (~3 fold) in cells expressing
FlucDM compared to those expressing FlucWT (Figure 3.3C), in accordance with the results from
the fluorescence microscopy, detergent insolubility analyses and PulSA of these proteins. Taken
together, these data show that FlucDM readily aggregates in cells and that FloIT can be used as a
rapid and non-subjective method to assess this aggregation into inclusions.

Figure 3.3. The formation of inclusions by Fluc in HEK293 cells can be assessed by FloIT. HEK293 cells were
transiently transfected to express EGFP, FlucWT-EGFP or FlucDM-EGFP and were analysed by FloIT 48 h posttransfection. Prior to analysis, cells were lysed in PBS with 0.5% (v/v) Triton X-100. RedDot1 was added (1:1500
dilution) to cell lysates immediately prior to performing flow cytometry and 100,000 events collected for each
population. RedDot1 fluorescence was analysed using a 640 nm laser and 670/30 nm collection window. EGFP
fluorescence was detected using a 488 nm laser and 525/50 nm emission filter. (A) Two parameter, pseudo-colour
plots identifying nuclei and non-nuclear particles (indicated) in cells based on the FSC and RedDot1 fluorescence
signals (left: unstained, right: stained with RedDot1). (B) Non-nuclear particles were then analysed for the presence
of inclusions based on the FSC versus EGFP fluorescence signals in cells transiently transfected to express EGFP
(left) or FlucDM-EGFP (right). Fluc inclusions (indicated) are identified based on increased EGFP fluorescence. (C)
The number of inclusions measured in HEK293 cells transiently transfected to express FlucWT-EGFP or FlucDMEGFP. Data in (C) are presented as the mean ± S.E.M (n=3). Significant differences between group means were
determined using a two-tailed unpaired Student’s t-test (** = P < 0.01).
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Next, to establish whether FlucDM expressed in cells is enzymatically active, a luciferase assay
was performed to quantify the luminescence-based activity of FlucDM compared to the wild-type
protein. Cells were transfected (or not) to express increasing amounts (0.1, 0.2 or 0.3 µg) of
FlucWT-EGFP or FlucDM-EGFP and were incubated for 48 h prior to being lysed and analysed for
luciferase activity using a luminometer. The luciferase activity of untransfected cells, which was
very low (~500 relative light units; RLUs) compared to the other samples, was subtracted from all
other treatment groups. The absolute RLUs was significantly higher for cells expressing FlucWT
compared to those expressing FlucDM at each amount of DNA tested (Figure 3.4A). At 0.1, 0.2
and 0.3 µg of DNA, cells expressing FlucDM exhibited 11.6, 9.4 and 14.6% respectively of the
luciferase activity of cells expressing FlucWT (Figure 3.4B). This is in accordance with previous
work which indicated that FlucDM retained ~20% of the luciferase activity compared to FlucWT
(Gupta et al., 2011). Nevertheless, this work shows that FlucDM has measurable luciferase activity
and therefore is a suitable client protein to screen for Hsps that modulate unfolding and/or
inclusion formation of aggregation-prone proteins in the cell.

Figure 3.4. FlucDM retains measureable luciferase activity. Flp-In T-REx HEK293 cells were transfected to express
increasing amounts of FlucWT-EGFP or FlucDM-EGFP by using 0.1, 0.2 or 0.3 µg of plasmid DNA and incubated for
48 h prior to analysis for luciferase activity. Luciferase activity is presented in (A) as the mean ± S.E.M (of 3 technical
replicates) (relative light units; RLUs). Data in (B) are presented as the mean ± S.E.M (of 3 technical replicates) of
FlucDM luciferase activity as a percentage of the FlucWT control at the same concentration. Significant differences
between group means were determined using a one-way ANOVA (P < 0.05) followed by a Tukey’s post-hoc test.
Group means determined to be statistically different from each other are indicated (***P < 0.001).
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3.3.2

The effect of sHsps on FlucDM inclusion formation

Following the validation of FlucDM as a model system to monitor inclusion formation by
aggregation-prone proteins in cells, a comprehensive overexpression screen of the major human
Hsps was conducted using quantitative flow cytometry in order to identify those molecular
chaperones that modulate the aggregation of FlucDM. This experimental approach can elicit
positive results of those chaperones which i) work singly or ii) are bottle-necks, whereby their
amount is limiting for all the other chaperones in the network. In addition, cells co-expressing
mRFP were used as a negative control throughout this work as mRFP is a protein with no intrinsic
chaperone activity and is expressed from the same vector backbone as the other constructs
screened from the V5-tagged Hsp library.

The sHsps (HspBs) have been previously identified as highly dynamic species which play a
primary role in minimising disease-related protein aggregation in cells (Outeiro et al., 2006, Vos
et al., 2010, Carra et al., 2013, Minoia et al., 2014b, Cox and Ecroyd, 2017). To compare the
relative efficacies of the HspB family to inhibit FlucDM inclusion formation, all ten members
(HspB1 - HspB10) were individually co-expressed with FlucDM in Flp-In T-REx HEK293 cells.
PulSA was used to determine the proportion of cells with FlucDM inclusions. HspB2 and HspB3
significantly increased the percentage of cells with inclusions compared to the mRFP control
(Figure 3.5A), whilst the remaining HspBs had no significant effect on the proportion of cells with
FlucDM inclusions.

As an alternate and complementary approach, FloIT was used to assess the number of inclusions
formed in the transfected cell population. As determined by FloIT, and when compared to cells
expressing mRFP, HspB2, HspB3 and HspB10 increased the number of FlucDM inclusions per 100
cells (Figure 3.5B), whereas HspB4, HspB6, HspB7 and HspB9 significantly inhibited the number
of FlucDM inclusions per 100 cells. HspB1, HspB5 and HspB8 had no significant effect on the
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number of FlucDM inclusions per 100 cells. Interestingly, HspB10 has no significant effect on the
percentage of cells with inclusions as assessed by PulSA; however, when the cells were lysed, the
FloIT assay demonstrated that HspB10 significantly increased the number of inclusions per 100
cells. This most likely reflects an increased sensitivity of the FloIT technique compared to PulSA
to detect inclusions in cells or that expression of HspB10 increases the number of inclusions
formed in a cell, but not the proportion of cells with inclusions.

Figure 3.5. The effect of sHsp (HspB) family members on intracellular inclusion formation by FlucDM is
variable. Flp-In T-REx HEK293 cells were co-transfected with V5-tagged HspBs (or mRFP as a negative control)
and FlucDM-EGFP. Expression of HspBs was induced by addition of tetracycline and cells were analysed by (A)
PulSA or (B) FloIT 48 h post-transfection. Data in (A) are presented as the mean ± S.E.M (n=3) of the percentage of
cells containing inclusions and data in (B) are presented as the mean ± S.E.M (n=3) of the number of inclusions per
100 cells. Significant differences between group means in the data were determined using a one-way ANOVA (P <
0.05) followed by a Dunnett’s post-hoc test, comparing group means to the mRFP control. Group means determined
to be statistically different to the mRFP control are indicated (*P < 0.05, **P < 0.01 and ***P < 0.001).

3.3.3

Investigating the role of nucleotide exchange factors (NEFs) on intracellular FlucDM

aggregation
Previous studies have suggested that co-chaperones, such as NEFs, play a central role in
determining the fate of Hsp-loaded substrates (Takayama et al., 1997, Gamerdinger et al., 2011,
Winkler et al., 2012, Serlidaki et al., 2020). To identify whether NEFs are capable of modulating
the intracellular aggregation of FlucDM into inclusions, members of the Bag family (Bag1-5) and
two HspH (Hsp110) family members (HspH1 and HspH3) were tested in the overexpression
screen. None of these NEFs were capable of significantly inhibiting inclusion formation by
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FlucDM, as determined by either PulSA (Figure 3.6A) or FloIT (Figure 3.6B). Whilst there were
trends towards Bag1, Bag4 and Bag5 increasing FlucDM inclusion formation compared to the
mRFP-expressing control, these were not statistically significant.

Figure 3.6. Overexpression of individual NEFs has no effect on intracellular inclusion formation by FlucDM.
Flp-In T-REx HEK293 cells were co-transfected with NEFs (or mRFP as a negative control) and FlucDM-EGFP.
Expression of V5-tagged NEFs were induced by addition of tetracycline and cells were analysed by (A) PulSA or (B)
FloIT 48 h post-transfection. Data in (A) are presented as the mean ± S.E.M (n=3) of the percentage of cells containing
inclusions and data in (B) are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells.
Significant differences between group means were tested using a one-way ANOVA (P > 0.05).

3.3.4

Assessing the chaperone activity of the Hsp70 family on FlucDM inclusion formation

Various members of the Hsp70 (HspA) family have previously been identified as suppressors of
protein aggregation (Kampinga and Craig, 2010, Hageman et al., 2011, Serlidaki et al., 2020) and
were therefore screened for their capacity to modulate the aggregation of FlucDM into inclusions.
Of the 13 members of the Hsp70 family, the major nuclear/cytosolic Hsp70s were chosen for
testing, including HspA1A (stress-inducible Hsp70), HspA1L (Hsp70-like), HspA2, HspA6,
HspA8 (constitutive Hsp70; Hsc70), HspA9 (also present in mitochondria) and HspA14. Only
HspA1A and HspA2 significantly inhibited inclusion formation by FlucDM compared to the
mRFP-expressing control, as assessed by both PulSA (Figure 3.7A) and FloIT (Figure 3.7B). The
remaining Hsp70 members tested had no significant effect on inclusion formation by FlucDM.
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Figure 3.7. Hsp70 members have diverse effects on intracellular FlucDM aggregation. Flp-In T-REx HEK293
cells were co-transfected with V5-tagged Hsp70s (or mRFP as a negative control) and FlucDM-EGFP. Expression of
Hsp70s was induced by addition of tetracycline and cells were analysed by (A) PulSA or (B) FloIT 48 h posttransfection. Data in (A) are presented as the mean ± S.E.M (n=3) of the percentage of cells containing inclusions and
data in (B) are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells. Significant differences
between group means in the data were determined using a one-way ANOVA (P < 0.05) followed by a Dunnett’s posthoc test, comparing group means to the mRFP control. Group means determined to be statistically different compared
to the mRFP control are indicated (***P < 0.001).

Strikingly, despite sharing 89% sequence identity, HspA1A was capable of significantly
suppressing the aggregation of FlucDM, whilst HspA1L was ineffective under these experimental
conditions. To investigate this further, the two protein sequences were aligned: the majority of the
amino acid variations occur in the C-terminal domain, whilst the nucleotide binding domain and
the substrate binding domain share 91% and 97% sequence identity, respectively (Figure 3.8A).
However, previous studies have reported that the nucleotide binding domain is responsible for the
observed functional differences between members of the Hsp70 family (James et al., 1997,
Hageman et al., 2011, Serlidaki et al., 2020). An alignment of the nucleotide binding domains of
HspA1A and HspA1L using previously published crystal structures (Wisniewska et al., 2010)
revealed that the non-conserved regions are found throughout the entire domain and display
slightly different degrees of surface exposure (Figure 3.8B), with the exception of the ATP/ADPbinding pocket (located in the middle of the nucleotide binding domain), which is fully conserved
between HspA1A and HspA1L (Figure 3.8B). Thus, these slight differences in surface-exposed
residues between the nucleotide binding domains may account for the differences in the abilities
of HspA1A and HspA1L to inhibit FlucDM inclusion formation. This finding is consistent with
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work that suggests that differences in the nucleotide binding domain of Hsp70s may be important
for recognition by specific co-chaperones and NEFs (Serlidaki et al., 2020).

Figure 3.8. The nucleotide binding domain appears to be responsible for opposing chaperone effects of HspA1A
and HspA1L, despite being 91% homologous. (A) Pairwise sequence alignment of human HspA1A and HspA1L.
Identical residues are highlighted in grey and are denoted by (*), chemically similar amino acids are represented by
(:), amino acids denoted by (.) share weak chemical similarity and mismatches or gaps are marked by a space. The
nucleotide binding domain (blue), substrate binding domain (red), C-terminal domain (black) and flexible linker
(green) region are indicated by different coloured text. Alignment was created using the Clustal Omega (EMBL-EBI)
Needle (EMBOSS) pairwise sequence alignment tool and the Needleman-Wunsch algorithm. (B) Non-conserved
regions between the nucleotide binding domains of HspA1A and HspA1L. Ribbon structure of HspA1A (blue; PDB
ID: 3JXU) in complex with ADP (pink). Residues that are not conserved with HspA1L (PDB ID: 3GDQ) are
highlighted with main chain spheres (red). Subdomains (IA/B and IIA/B) are indicated for orientation purposes.
Structure of the HspA1A nucleotide binding domain was built in PyMOL.
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To further investigate these apparent differences in the capacity of HspA1A and HspA1L to inhibit
inclusion formation by FlucDM in cells, Flp-In T-REx HEK293 cells were transiently cotransfected with a selection of the V5-tagged HspAs (HspA1A, HspA1L, HspA2 and HspA6) and
EGFP-tagged FlucDM and an NP-40 fractionation of cell lysates was performed. Overall, the data
obtained using this approach mirrored the results of the flow cytometry-based screen. Thus, upon
lysis with NP-40 most of the FlucDM was found in the insoluble (pellet) fraction (Figure 3.9A).
Co-expression of HspA1A decreased FlucDM aggregation, as measured by a substantial decrease
in the amount of FlucDM in the insoluble fraction and a corresponding increase in the amount in
the soluble fraction. The decrease in the total amount of FlucDM in the lysate of cells co-transfected
with FlucDM and HspA1A may be due to HspA1A promoting the degradation of this aggregationprone protein. Interestingly, co-expression of FlucDM with HspA2 reduced FlucDM in the total and
soluble fractions of the cell lysate, but had little effect on the amount in the insoluble fraction. In
addition, HspA1L and HspA6 did not reduce the amount of FlucDM in the total or insoluble
fractions of the cell lysate. These data confirm that HspA1A and HspA1L, despite sharing nearly
90% sequence identity, differ in their capacity to inhibit inclusion formation by FlucDM. The
expression of V5-tagged HspAs did differ slightly among treatment groups, which may be due to
differences in the capacity of HspA members to inhibit inclusions formed by FlucDM. However,
quantification of the levels of the V5-tagged HspAs was not performed in this work.

The mechanism by which HspA1A suppresses FlucDM aggregation was investigated by measuring
the luciferase activity (in RLUs) in cell lysates from Flp-In T-REx HEK293 cells co-transfected
to express FlucDM and one of the aforementioned HspAs (Figure 3.9B). To account for potential
differences in the levels of FlucDM expression between treatment groups, the EGFP geometric
mean of live, transfected cells was assessed using flow cytometry. There was no significant
difference between the amount of FlucDM-EGFP expressed in transfected cells from each treatment
(Figure 3.9C). When the luciferase activity was normalised to the corresponding level of FlucDM80
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EGFP expressed in the cells it was determined that luciferase activity was significantly reduced in
cells expressing the Hsp70 isoforms compared to those expressing mRFP (Figure 3.9D). Coexpression of HspA1A or HspA2 reduced the luminescence-based activity of FlucDM to 40% and
33%, respectively compared to the mRFP (non-chaperone) control, whilst cells co-expressing
either HspA1L or HspA6 retained 87% of the luciferase activity relative to the mRFP control.
Together with the immunoblotting data, these results show that co-expression of HspA1A or
HspA2 with FlucDM reduces luciferase activity and the overall amount of FlucDM in the total
protein fraction. Moreover, HspA2 decreases the amount of FlucDM found in the soluble fraction
and its luciferase activity, but has little impact on the amount of protein found in the insoluble
pellet. This suggests that whilst co-expression of either HspA1A or HspA2 results in a decrease
in the amount of FlucDM in cells, these chaperones play different roles in the processing of this
destabilised protein. Given that expression of HspA1A, but not HspA1L, leads to a reduction in
the aggregation of FlucDM as well as the amount of FlucDM in both the total and insoluble fractions
of the cell lysate, this suggests that HspA1A mediates the degradation of FlucDM in these cells.
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Figure 3.9. HspA1A, but not HspA1L, reduces FlucDM aggregation by facilitating its degradation. Flp-In T-Rex
HEK293 cells were co-transfected with V5-tagged HspA1A, HspA1L, HspA2, HspA6 or mRFP (as a negative
control) and FlucDM-EGFP and analysed 48 h post-transfection by (A) NP-40 fractionation and subsequent
immunoblotting or (B – D) luciferase activity assay. In (A) an anti-GFP antibody was used to detect FlucDM in the
total (T), insoluble pellet (P) and soluble (S) fractions. In the total protein fraction, the expression of HspAs were
detected with an anti-V5 antibody and GAPDH was used as a loading control. The blots shown are representative of
two experiments. Data in (B) are presented as mean ± S.E.M (of 3 technical replicates) RLUs of FlucDM luciferase
activity following co-expression of HspA members. Data in (C) are the mean S.E.M (n=3) EGFP geometric mean
(arbitrary fluorescence units; AFU) of live, transfected cells co-expressing FlucDM-EGFP and an HspA member (or
mRFP as a negative control), measured by flow cytometry. Data in (D) are the mean ± S.E.M (of 3 technical replicates)
FlucDM luciferase activity in cells co-expressing a member of the HspA family, normalised for the levels of FlucDMEGFP expression. Significant differences between group means in the data were determined using a one-way ANOVA
(P < 0.01) followed by a Tukey’s post-hoc test. Group means determined to be statistically different are indicated (**
P < 0.01 and ***P < 0.001).
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3.3.5

Comparing the ability of DNAJB family members to suppress FlucDM aggregation

The Hsp70 chaperone system is a highly complex integrative machine which often requires cofactors to mediate its functions. Ongoing evidence has suggested that the DNAJs (J proteins;
Hsp40s) are the drivers of the Hsp70 chaperone cycle and govern Hsp70-client interaction
(Kampinga and Craig, 2010). Of the DNAJs, the DNAJB proteins are the most extensively studied
due to some of them (namely DNAJB6b and DNAJB8) being previously identified as potent
suppressors of amyloid aggregation associated with many disease-related proteins, including
polyQ-expanded proteins (Hageman et al., 2010). To test the ability of DNAJBs to engage
destabilised proteins at risk of forming amorphous aggregates in cells, V5-tagged DNAJBs were
transiently co-expressed with FlucDM in Flp-In T-REx HEK293 cells. The PulSA (Figure 3.10A)
and FloIT (Figure 3.10B) assays demonstrated that FlucDM inclusion formation was significantly
reduced by all the DNAJB isoforms tested, with DNAJB1, DNAJB5, DNAJB6b and DNAJB8
being the most potent suppressors.

Figure 3.10. DNAJBs prevent the intracellular aggregation of FlucDM into inclusions. Flp-In T-REx HEK293
cells were co-transfected with V5-tagged DNAJBs (or mRFP as a negative control) and FlucDM-EGFP. Expression of
DNAJBs was induced by addition of tetracycline and cells were analysed by (A) PulSA or (B) FloIT 48 h posttransfection. Data in (A) are presented as the mean ± S.E.M (n=3) of the percentage of cells containing inclusions and
data in (B) are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells. Significant differences
between group means were determined using a one-way ANOVA (P < 0.05) followed by a Dunnett’s post-hoc test,
comparing group means to the mRFP control. Group means determined to be statistically different to the mRFP
control are indicated (***P < 0.001).
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The EGFP geometric mean of live, transfected cells was assessed using flow cytometry to
determine whether there were any differences in FlucDM expression across the Hsp overexpression
screen. There were no significant differences in the amount of FlucDM-EGFP expressed following
co-transfection with members of the HspB (Figure 8.1A), NEF (Figure 8.1B), HspA (Figure 8.1C)
or DNAJB (Figure 8.1D) families compared to the corresponding mRFP control (Appendix I).
Some small inter-assay variability was observed for the mean number of inclusions formed in cells
expressing the mRFP control between the Hsp families screened. The R188Q and R261Q
mutations in the N-terminus of Fluc influences its thermostability and hence, aggregation
propensity. As such, the levels of inclusions formed by FlucDM are influenced by temperature (San
Gil et al., 2017). Therefore, the observed inter-assay variability is likely an effect of fluctuations
in ambient temperature across replicates.
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3.4

Discussion

In this work, FlucDM was used as a model aggregation-prone protein to screen for the generic
capacity of the major human Hsps to suppress intracellular inclusion formation by a destabilised
protein. The work outlined in this chapter represents the first use of quantitative flow cytometry
to conduct an Hsp overexpression screen for modifiers of inclusion formation in cells. Expression
of the destabilised aggregation-prone FlucDM protein in HEK293 cells results in the formation of
intracellular inclusions, a process which is able to be quantified by PulSA and FloIT. In addition,
FlucDM-EGFP retains measurable enzyme activity and thus its levels in the cell, as well as its
folded (native) and aggregation states can be assessed. This makes it an ideal model to screen for
Hsps that modulate the folding, unfolding and/or processing of aggregation-prone proteins in cells.
The major findings of the Hsp overexpression screen conducted as part of this work are as follows:
(i) of the sHsps, HspB4 HspB6, HspB7 and HspB9, reduce the aggregation of FlucDM in cells; (ii)
the major NEFs, including members of the Bag and Hsp110 families, do not modulate FlucDM
aggregation; (iii) of the Hsp70 family members tested, HspA1A and HspA2 significantly reduce
inclusion formation by FlucDM. Following further investigation into the mechanism by which
Hsp70 members reduce protein aggregation, it was identified that HspA1A, and not HspA1L
(despite sharing 89% sequence identity at the amino acid level), likely facilitates the degradation
of FlucDM in these cells; and (iv) all of the DNAJBs tested were effective at reducing the
aggregation of FlucDM into inclusions in cells.

3.4.1

sHsps have variable effects on FlucDM inclusion formation

The sHsps are some of the first and most upregulated molecular chaperones in response to
conditions of cellular stress (Haslbeck et al., 2005, Garrido et al., 2012, Hilton et al., 2013), which
makes them interesting potential therapeutic targets for disease intervention. This study examined
the effect of overexpression of the ten mammalian sHsps on the intracellular aggregation of FlucDM
in order to assess their relative capacity to inhibit FlucDM from forming intracellular inclusions.
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Hsp27 (HspB1) and αB-crystallin (HspB5) are the most widely-studied sHsps, in part because
they have been found to co-localise with astrocytic inclusions in patients with familial ALS (Kato
et al., 1997). In addition, both Hsp27 and αB-crystallin have been previously reported to prevent
the aggregation of a range of model client proteins (Ito et al., 2001, Lee et al., 2006, Outeiro et al.,
2006, Ecroyd et al., 2007, Vos et al., 2009, Kulig and Ecroyd, 2012, Cox and Ecroyd, 2017).
HspB8 (Hsp22) is another well-characterised sHsp that plays a key role in recognising misfolded
clients and, in doing so, forms a complex with Bag3 in order to shuttle the aggregation-prone client
protein for degradation via macroautophagy (Carra et al., 2008b, Fuchs et al., 2010). Furthermore,
when overexpressed in cells, HspB8 can reduce the aggregation of many disease-related clients,
including proteins containing a polyQ-expanded tract (Carra et al., 2008a), amyloid-β (Wilhelmus
et al., 2006), TDP-43 (Carra et al., 2013) and SOD1 (Crippa et al., 2010). However, in this current
work none of these three sHsps (i.e. neither Hsp27, αB-crystallin nor HspB8) had a significant
impact on the formation of Fluc-based inclusions. These results could be attributed to FlucDM
forming insoluble inclusions too rapidly to facilitate the interaction of these chaperones with the
protein.

Previous work has shown that the rate of aggregation is a significant factor in determining how
effectively the sHsps can prevent protein aggregation. For example, the sHsp αB-crystallin
prevents amorphous aggregation by forming stable high molecular mass complexes with the client
protein, but inhibits ordered fibril formation via weak and transient interactions (Kulig and Ecroyd,
2012). This suggests that the conformation of the aggregation-prone intermediate dictates the
mechanism by which αB-crystallin prevents the aggregation of client proteins (Kulig and Ecroyd,
2012). Cox et al. (2016) identified that the rate of α-synuclein aggregation has a significant effect
on the chaperone efficacy of αB-crystallin and Hsp27, whereby an increase in the rate of αsynuclein aggregation resulted in a reduced capacity of these sHsps to prevent protein aggregation.
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Thus, the chaperone capacity of Hsp27, αB-crystallin and HspB8 may be overwhelmed in the
context of FlucDM aggregating to form inclusions.

3.4.1.1 sHsps have distinct client protein specificities and mechanisms of action
An analysis of purified recombinant Drosophila melanogaster sHsps demonstrated that HspB8
and Hsp27 can inhibit the heat-induced aggregation of Fluc at a 1:1 molar ratio (Morrow et al.,
2006); however, this is the first work undertaken to assess the capacity of the human sHsps to
prevent the aggregation of Fluc into inclusions within the highly dynamic intracellular
environment. An alternate explanation as to why these sHsps do not prevent inclusion formation
by FlucDM is that Hsp27, αB-crystallin and HspB8 simply do not interact with FlucDM within the
cellular environment. Previous research has demonstrated that the sHsps do have some specificity
with regard to their interactions with client proteins. Overexpression of Hsp27 significantly
reduced the intracellular aggregation of α-synuclein (Outeiro et al., 2006, Cox and Ecroyd, 2017)
and a Parkinson’s disease-associated mutant form of Parkin (Minoia et al., 2014b), but did not
inhibit the intracellular oligomerisation of the amyloid-β peptide (Ojha et al., 2011) or inclusion
formation by polyQ-expanded proteins, including mutant huntingtin exon 1 or a fragment of
ataxin-3 (associated with spinocerebellar ataxia type 3) (Wyttenbach et al., 2002, Vos et al., 2010).

A comparative analysis of the capacity of the eight major human sHsps (HspB1-HspB8) to inhibit
the in vitro aggregation of various model proteins revealed that the sHsps do display distinct client
specificities (Mymrikov et al., 2017). It was discovered that the canonical sHsps, which form large
polydisperse oligomers (e.g. Hsp27, αA-crystallin, and αB-crystallin), are fairly promiscuous,
whereas the chaperone activity of the remaining sHsps is more client-dependent (Mymrikov et al.,
2017). For example, Hsp27, αA-crystallin, and αB-crystallin could prevent malate dehydrogenase
aggregation, whereas HspB6 (Hsp20) and HspB3 had no effect, and HspB2, HspB7, and HspB8
increased malate dehydrogenase aggregation. A similar result was observed in this work, whereby
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overexpression of HspB2 or HspB3 resulted in a significant increase in the number of FlucDM
inclusions, which could be due to these sHsps co-aggregating with the client protein. In addition
to displaying varying degrees of client specificity with regard to their chaperone action, the
mechanism by which members of the sHsp family interact with clients can also differ substantially.
For example, unlike HspB7, Hsp27 and αB-crystallin form high-molecular mass oligomers with
client proteins in cells, thereby preventing their aggregation by holding them in a foldingcompetent state for Hsp70-assisted refolding (Vos et al., 2009, Vos et al., 2010). Furthermore,
unlike HspB9, the anti-aggregation activity of HspB7 against polyQ-expanded proteins is not
dependent upon degradation via the proteasome (Carra et al., 2013). In contrast to HspB8, HspB7
does not stimulate autophaghic clearance, but does require an active autophagy pathway for antiaggregation activity (Vos et al., 2010, Minoia et al., 2014b). HspB7 is instead thought to prevent
the primary nucleation of fibrillar intermediates prior to them forming mature (toxic) fibrils,
mediating their clearance via autophagy (Vos et al., 2010). Moreover, HspB8 and its co-chaperone
Bag3, traffic misfolded client proteins for degradation via a specific arm of macroautophagy,
called CASA, an action that is mediated only by HspB8 (Carra et al., 2008a, Carra et al., 2008b,
Behl, 2011).

This work identified HspB4, HspB6, HspB7 and HspB9 as potent inhibitors of FlucDM inclusion
formation. These results are consistent with previous studies that have examined the capacity of
one or more of these sHsps to inhibit the aggregation of client proteins. For example, HspB9 can
efficiently inhibit the aggregation of polyQ-containing proteins by lowering the level of soluble
protein present in the cell and keeping clients in a degradation-competent state, thereby facilitating
their disposal via the proteasome before they form large, insoluble species (Carra et al., 2013).
αA-crystallin (HspB4) has been previously identified as a proteasome-dependent inhibitor of
inclusion formation by a mutant isoform of Parkin (Minoia et al., 2014b); however, it is not
capable of inhibiting the aggregation of proteins containing polyQ-expansions (Vos et al., 2010).
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Of the ten sHsps members, HspB6 and HspB7 were found to be the most potent inhibitors of
FlucDM inclusion formation in this work. Overexpression of HspB6 and HspB7 significantly
decreases the intracellular inclusion formation of polyQ-expanded proteins (Vos et al., 2010), with
HspB7 being the most potent inhibitor. Overexpression of HspB6 or HspB7 in cardiomyocytes
protects against cytoskeletal injury during stress to prevent tachycardia remodelling (Ke et al.,
2011). However, whilst overexpression of HspB7 can suppress the formation of intracellular
inclusions by misfolded Parkin, HspB6 is ineffective at doing so (Minoia et al., 2014b). This again
highlights that whilst there is some degree of overlap with regard to client protein specificity of
some sHsps, this needs to be empirically tested since the mechanisms that drive client specificity
remain to be established.

Co-expression of HspB10 did not affect the proportion of cells containing FlucDM inclusions (as
assessed by PulSA), however, it did result in a significant increase in the number of inclusions
formed by FlucDM (as determined via FloIT). HspB10 is the largest and most structurally diverse
sHsp (in terms of its amino acid sequence and in comparison to the other nine sHsp members) and
has been hypothesised to participate in cytoskeletal stabilisation (Fontaine et al., 2003, Kappé et
al., 2003). There is little currently known about the capacity of HspB10 to act as a molecular
chaperone. Based on the data obtained in this study, overexpression of HspB10 may result in an
imbalance within the cell, such that the ability of other chaperones to facilitate the degradation of
inclusions formed by FlucDM becomes limited. Hence, this results in more inclusions being formed
in the cell but does not change the number of cells containing inclusions. In any case, since
HspB10 expression is localised only to the testis, HspB10 upregulation as a means of treating
neurodegenerative diseases is not likely to be a viable approach. However, these results do
highlight the differences between the two flow cytometry methods used to assess inclusion
formation in this work. The inability of PulSA to identify cells with small inclusions is a
disadvantage of the technique (Whiten et al., 2016). FloIT is therefore advantageous as the
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technique can enumerate small inclusions and, since the cells are lysed, can facilitate the release
of multiple inclusions from the same cell for analysis. Thus, this work highlights that PulSA and
FloIT are highly complementary techniques to study intracellular inclusion formation in cells.

Overall, the data obtained in this study suggests that the human sHsps have distinct client protein
specificities (albeit with some overlap) as has been suggested by previous work (Vos et al., 2010,
Boncoraglio et al., 2012, Carra et al., 2013, Kakkar et al., 2014, Minoia et al., 2014b, Mymrikov
et al., 2017). Moreover, the sHsp members can hold clients in a refolding-competent state
following acute stress and facilitate degradation. Thus, upregulation of certain sHsps may offer a
novel therapeutic strategy to reduce the accumulation of misfolded proteins in cells that arise from
disease states or those which have been exposed to cellular stress, including aging.

3.4.2

NEFs do not inhibit FlucDM aggregation

The NEFs encompass families of co-chaperone proteins which have diverse roles in the cell. These
include participation in Hsp70-mediated folding by facilitating substrate binding and release, and
in the targeting of Hsp-loaded substrates for proteolytic degradation (Bukau et al., 2006). In this
study, two members of the human Hsp110 family and most of the Bag family members were
screened for their ability to inhibit inclusion formation by FlucDM in cells. None of the NEFs tested
had a significant effect on inclusion formation by FlucDM; however, there was a trend whereby
overexpression of Bag3 did reduce intracellular aggregation. Previous cell-based studies have
described the ability of Bag3 to clear aggregation-prone huntingtin (Fuchs et al., 2010) and SOD1
(Crippa et al., 2010). When cells age or become exposed to acute stress, misfolded and aggregated
proteins can accumulate such that they exceed the degradative capacity of the proteasome. It has
been shown that this leads to an increase in Bag3 expression, which subsequently switches the
degradation of polyubiquitinated Hsp70 client proteins and facilitates, along with HspB8, the
degradation of these misfolded proteins by trafficking them for degradation via macroautophagy
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(Behl, 2011). In this work, overexpression of Bag1, Bag4 and Bag5 resulted in a trend towards an
increase in the number of FlucDM inclusions present in cells. Given that this is an overexpression
system, these results are not unexpected as previous studies have reported that high stoichiometric
ratios of NEFs to Hsp70 can have inhibitory effects on Hsp70-mediated folding and regulation
(Nollen et al., 2000, Gässler et al., 2001, Rampelt et al., 2012, Rauch and Gestwicki, 2014,
Serlidaki et al., 2020).

Previous research has indicated that targeting of the Hsp110 members may be a viable therapeutic
approach to treat protein misfolding diseases. For example, overexpression of Hsp110s in a mutant
SOD1 mouse model of ALS has been reported to enhance overall survival (Nagy et al., 2016) and
also decrease inclusion formation in a SOD1 cell culture model of disease (Serlidaki et al., 2020).
However, in this current work, expression of the Hsp110s had no effect on intracellular
aggregation of FlucDM into inclusions. This is likely due to the chaperone action of Hsp110s
requiring interaction with HspA1A (the major stress-inducible Hsp70), which is likely not
sufficiently expressed under the conditions used in these cell-based assays. For example, the
interaction of Hsp110s with HspA1A is essential for the chaperone action of this disaggregation
machinery (Shorter, 2011, Rampelt et al., 2012). The identification of a role of Hsp110s in the
targeting of Hsp70-loaded substrates for degradation in yeast (Kandasamy and Andréasson, 2018)
further supports the claim that the Hsp110-Hsp70 interaction is crucial for the chaperone function
of Hsp110. Future studies investigating the function of NEFs in the context of protein aggregation
should therefore consider co-expressing relevant Hsp70s that are required for NEF chaperone
activity. Alternatively, the knockdown of specific NEFs to elucidate chaperone function could be
more advantageous than an overexpression-based screen, as this would eliminate the need to
increase the expression of other members of the Hsp machinery.
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3.4.3

FlucDM inclusion formation is significantly reduced by HspA1A, but not HspA1L,

despite it being 89% identical
The Hsp70 family of chaperones are among some of the most highly conserved proteins
throughout evolution (Gribaldo et al., 1999). The Hsp70 machinery plays a central role in many
branches of cellular protein quality control, including protein refolding, degradation,
disaggregation and suppression of aggregation. This work tested the capacity of seven major
cytosolic members of the Hsp70 family to inhibit FlucDM inclusion formation. HspA1A is the most
extensively studied and well-characterised Hsp70 member, however, there is currently little
known about HspA1L and its role in maintaining proteostasis. In this work, FlucDM inclusion
formation was significantly reduced by HspA1A, but not HspA1L. This result is in accord with
previous work that has reported a similar effect against the intracellular inclusion formation by
other amorphous clients, including SOD1 (Serlidaki et al., 2020), a Parkin mutant associated with
familial Parkinson’s disease (Kakkar et al., 2016a), and heat-denatured Fluc (Hageman et al.,
2011). Moreover, the overexpression of HspA1A resulted in an increase in the amount of soluble
FlucDM present in these cells and a reduction in the luciferase activity, pointing to a holdase-type
function of HspA1A. The majority of the amino acid differences between HspA1A and HspA1L
exist within the substrate binding (C-terminal) domains - the nucleotide binding domains share
high sequence identity. As such, this has prompted analysis into the C-terminal substrate binding
region in an attempt to identify residues in HspA1A that interact with amorphous clients (Serlidaki
et al., 2020). Surprisingly, this work showed (via co-immunoprecipitation) that both HspA1A and
HspA1L efficiently bind SOD1. In addition, the ATPase activities of HspA1A and HspA1L were
found not to be significantly different, which suggests that differences in ATP-dependent
(re)folding are not responsible for the opposing anti-aggregation effects (Serlidaki et al., 2020).

The alignment of the nucleotide binding domains of HspA1A and Hspa1L revealed that the nonconserved residues differ in terms of their surface exposure, suggesting that this may account for
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the capacity of HspA1A, but not HspA1L, to inhibit FlucDM inclusion formation. This finding is
consistent with previous studies using yeast (James et al., 1997) and cell culture models (Hageman
et al., 2011, Serlidaki et al., 2020), which have identified that the nucleotide binding domain is
responsible for conferring functional differences between Hsp70 members. More specifically, the
differential function of HspA1A compared to HspA1L in cells is thought to be due to the
interaction of HspA1A with the Hsp110 co-chaperone HspH2, which results in HspA1A-mediated
degradation of SOD1 via the proteasome (Serlidaki et al., 2020). Since HspA1A (i) suppressed
FlucDM inclusion formation, (ii) decreased the overall amount of FlucDM in the total protein and
insoluble fraction of the cell lysate, and (iii) reduced luciferase activity in the cell lysate, it is likely
that a mechanism of HspA1A-driven degradation following interaction with NEFs in exposed
regions of the nucleotide binding domain also mediates chaperone activity against FlucDM.

3.4.4

Conserved HspA members, HspA8, HspA6 and HspA2, have unique chaperone

activities
HspA8, otherwise known as the constitutively expressed Hsp70 (Hsc70), is ubiquitously
expressed at high basal levels in normal (non-stressed) cells and its expression is not heatinducible (Hageman et al., 2011). Analysis of the human chaperome revealed that the gene
encoding for HspA8 is significantly repressed in both Alzheimer’s disease and Huntingtin’s
disease (Brehme et al., 2014). In addition, targeted knockdown of HspA8 in cells leads to toxicity
and eventual cell death (Hageman et al., 2010, Vos et al., 2010). Whilst it is clear that functional
expression of HspA8 is vital for maintaining proteostasis, overexpression of HspA8 in this work
did not significantly reduce the intracellular aggregation of FlucDM into inclusions. This was
similar to the results obtained following the overexpression of HspA8 in cells models of polyQ
(Hageman et al., 2010, Hageman et al., 2011) and SOD1 (Serlidaki et al., 2020) aggregation,
whereby the levels of insoluble protein in cells was unaffected by increased levels of HspA8.
Previous studies have suggested that a complex of HspA8, Hsp110, and a DNAJ can solubilise
93

Chapter 3 – Hsp overexpression screen
fibrils resulting from polyQ-expanded protein fragments, suggesting that DNAJs (most notably
DNAJB1, DNAJB6b and DNAJB8) are the rate-limiting factor in reducing intracellular polyQ
aggregation (Scior et al., 2018). Thus, the overexpression of HspA8 alone may not have been
sufficient to suppress FlucDM inclusion formation. Despite this, it appears that when the
‘housekeeping’ function of HspA8 is reduced, as observed in patients with neurodegenerative
diseases (Brehme et al., 2014), the capacity of the cell to maintain proteostasis in response to
inclusion formation becomes compromised. As such, a decline in the expression of HspA8 could
be used as an early marker to help in identifying those most at risk of developing
neurodegenerative diseases in the future.

HspA6 is a heat-inducible member of the Hsp70 family, with 85% sequence similarity to the wellcharacterised HspA1A (Daugaard et al., 2007b); however, in this work HspA6 had no significant
effect on FlucDM inclusion formation. This result was similar to previous work which identified
that HspA6 is unable to assist in the refolding of heat-unfolded Fluc in cells or in solution in vitro,
nor can it prevent the in vitro aggregation of the model protein citrate synthase (Hageman et al.,
2011). Following mutational studies, it was concluded that HspA6 contains an irregular Nterminal ATPase domain (compared to related Hsp70 members) and this accounts for its inability
to interact with and refold heat-inactivated Fluc (Hageman et al., 2011). This same study
demonstrated that the basal ATPase activity of HspA6 is significantly higher than that of HspA1A,
supporting the notion that the functional differences between these two Hsp70s are intrinsic to the
ATPase domain and, subsequently, the nucleotide exchange cycle (Hageman et al., 2011). Thus,
it has been postulated that HspA6 has evolved a distinct functional role in the maintenance of cell
reproduction and viability under conditions of cellular stress (Noonan et al., 2007). Overall, the
inability of HspA6 to interact with Fluc in solution in vitro explains why HspA6 did not affect
intracellular FlucDM inclusion formation in this work.
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HspA2 is a constitutively expressed member of the Hsp70 family, ubiquitously expressed at low
levels in most tissues but highly expressed in the testis and brain (Bonnycastle et al., 1994, Son et
al., 2000). Interestingly, it was found in this work that overexpression of HspA2 potently reduces
inclusion formation by FlucDM as determined by flow cytometry and immunoblotting. Moreover,
there was a decrease in the amount of total and soluble FlucDM in cell lysates and a reduction in
luciferase activity in these cells, suggesting that HspA2 may inhibit FlucDM inclusion formation
by promoting its degradation. Previous work has shown that the aggregation of heat-denatured
Fluc (Hageman et al., 2011) and SOD1 (Serlidaki et al., 2020) are also significantly reduced
following overexpression of HspA2, however, the mechanism by which HspA2 prevents the
aggregation of these amorphous clients has not been defined. Given that low expression of HspA2
is associated with abnormal spermatogenesis (Son et al., 2000) and sterility (Dix et al., 1996),
HspA2 is gaining interest as a potentially useful clinical marker of sperm quality in fertility-related
conditions (Nixon et al., 2015). Overexpression of HspA14 had no anti-aggregation effect against
FlucDM; this was not unexpected as this member lacks the canonical substrate binding domain and
instead participates in protein translation (Kampinga and Craig, 2010). Similarly, the role of
HspA9 in the cell (along with select DNAJs and NEFs) involves translocating polypeptides from
the cytosol into the inner mitochondrial matrix (Chacinska et al., 2009) and this likely accounts
for why its overexpression has no effect on inclusion formation in this study.

3.4.5

DNAJB family members are potent suppressors of FlucDM inclusion formation

The Hsp70 chaperone activities require the regulatory and substrate targeting function of various
DNAJs (Bukau et al., 2006, Kampinga and Craig, 2010, Rosenzweig et al., 2019). In this work,
FlucDM inclusion formation was significantly reduced by all DNAJBs tested, with DNAJB1,
DNAJB5, DNAJB6b and DNAJB8 being the most potent suppressors. The finding that all of the
DNAJBs tested significantly suppressed FlucDM inclusion formation contrasts to the ability of only
a few specific DNAJB isoforms, namely DNAJB2a, DNAJB6 and DNAJB8, to strongly inhibit
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polyQ aggregation, with DNAJB1 having an intermediate effect (Hageman et al., 2010). However,
unlike what was observed for suppression of inclusion formation by FlucDM, DNAJB4, DNAJB5,
DNAJB9 were significantly less active against polyQ aggregation, with DNAJB2b having no
effect at all (Hageman et al., 2010). This suggests that the mechanism by which DNAJBs act to
suppress the amorphous aggregation of FlucDM is not the same as that used to suppress the fibrillar
aggregation of proteins.

The mechanistic interaction of DNAJBs with aggregation-prone proteins that form amyloid, such
as polyQ and the amyloid-β peptide, have been investigated previously (and will be discussed in
the next chapter) (Månsson et al., 2014a, Kakkar et al., 2016b), however, whether DNAJBs handle
amorphously aggregated clients, such as disordered Fluc, via the same or a distinct route remains
unclear. Since DNAJB1 (weak polyQ aggregation inhibitor), DNAJB6b (herein referred to as
DNAJB6) and DNAJB8 (strong polyQ aggregation inhibitors) were among the most effective
DNAJBs at suppressing FlucDM aggregation, these isoforms formed the basis of the work in the
following chapter of this thesis aimed at further interrogating the mechanism by which DNAJBs
and Hsp70 together act to suppress inclusion formation by FlucDM in cells.

3.4.6

Summary

In summary, the results of this work demonstrate that not all Hsps are equal in their capacity to
suppress the intracellular inclusion formation of the model destabilised aggregation-prone protein
FlucDM. This study is unique in that it used FlucDM as a model protein to provide insights into the
Hsps that are important for suppressing amorphous inclusion formation by destabilised client
proteins in cells. The results of the Hsp overexpression screen performed in this study confirm that
sHsps possess unique specificities for substrates, some of which overlap with other chaperones.
This work identified that the handling of FlucDM by HspA1A is likely mediated by NEFs which,
in turn, hold amorphous client proteins in a soluble state for their subsequent degradation by the
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proteolytic machinery. Significantly, DNAJBs are potent suppressors of destabilised protein
aggregation in cells, however, the mechanism by which DNAJBs act to suppress the amorphous
aggregation of FlucDM is distinct from that used to suppress the fibrillar aggregation of proteins.
This screening approach has prompted further investigation into the exact mechanism by which
specific DNAJBs prevent inclusion formation by destabilised client proteins in cells. Overall, this
work highlights that chaperones are viable targets for the development of drugs aimed at reducing
proteinopathies that are associated with neurodegenerative conditions; however, it will be essential
to consider chaperone specificity in such work.
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The majority of this chapter has been previously published in the following work:
McMahon, S., Bergink, S., Kampinga, H. H. and Ecroyd, H. (2021). DNAJB chaperones suppress
destabilised protein aggregation via a region distinct from that used to inhibit amyloidogenesis.
Journal of Cell Science.134, jcs255596.
Author contributions: S.M., H.E., S.B. and H.H.K conceptualised the project and the experimental
approach. S.M. performed the experiments, analysed the data, constructed the figures and wrote
the initial manuscript. All authors edited the manuscript for submission.
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4.1

Introduction

The DNAJs are a diverse class of multifunctional molecular chaperones that act as cofactors for
the Hsp70 chaperone machine. Ongoing research into the chaperone action of the DNAJB family
has identified that they are extremely potent suppressors of disease-related protein aggregation.
For example, previous work has shown that DNAJB2a and the closely related members DNAJB6
and DNAJB8 potently suppress the aggregation of a polyQ-expanded protein in a cell culture
model of disease (Howarth et al., 2007, Hageman et al., 2010, Gillis et al., 2013). Increasing the
expression of DNAJB2a or DNAJB6 in a mouse model of Huntington’s disease delays polyQ
aggregation, alleviates symptoms and prolongs lifespan (Labbadia et al., 2012, Kakkar et al.,
2016b). Moreover, DNAJB6, both in vitro and in cells, prevents the nucleation of the amyloid-β
peptides into mature fibrils (Månsson et al., 2014a). More recently, mutant SOD1 aggregation was
reported to be significantly suppressed by DNAJB1, DNAJB2b and DNAJB7, whilst other
DNAJBs were found to have little or no effect (Serlidaki et al., 2020).

Broadly, DNAJB proteins contain the highly conserved N-terminal J-domain shared by all DNAJ
proteins, as well as an internal G/F-rich linker region and a C-terminal domain (Figure 4.1A, B)
(Cheetham and Caplan, 1998) The J-domain contains the conserved HPD motif for interaction
with the Hsp70 machinery, whilst the C-terminal region is thought to bind substrates (Kampinga
and Craig, 2010). Specialised members of the DNAJB6-like family (DNAJB6 and DNAJB8)
contain a serine/threonine (S/T)-rich motif in between the G/F-rich region and C-terminal domain.
The hydroxyl groups within the side chains of this S/T-rich region participate in intramolecular
hydrogen bonding with β-hairpin structures in amyloid-β and polyQ peptides to prevent their
primary nucleation into mature (disease causing) toxic amyloid fibres (Hageman et al., 2010,
Månsson et al., 2014a, Kakkar et al., 2016b). The role of the G/F-rich region is currently not well
understood; however, mutations in this region have been linked to a reduced capacity to bind
substrates (Perales-Calvo et al., 2010) and have been implicated in inheritable forms of limb-girdle
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muscular dystrophy (Harms et al., 2012, Sarparanta et al., 2012). It has therefore been
hypothesised that the G/F-rich region may also be directly involved in substrate binding, as well
as participate as a flexible linker region for inter-domain stabilisation.

Figure 4.1. The structure of DNAJB6-like proteins and proposed substrate binding regions. (A) Schematic
representation of DNAJB6b. The conserved N-terminal J-domain of DNAJB6b is depicted in red and contains the
HPD motif; the site for interaction with Hsp70. The G/F-rich linker region is indicated in dark blue and is proposed
to participate in substrate binding and inter-domain stabilisation. The C-terminal substrate binding domain contains
the S/T-rich region (shown in light blue), which is known to prevent the nucleation of amyloid precursors into mature
fibrils. The capacity of the remaining substrate binding domain (highlighted in grey) to bind client proteins is currently
unknown. (B) Ribbon structure of a DNJAB6b monomer (PDB ID: 6U3R) with regions colour-coded as outlined in
(A). The HPD motif in the J-domain is highlighted in yellow using the side chain stick representation. The surface
exposed S/T residues within the β-sheet-containing C-terminal domain are indicated with side chain sticks. The
structure of the DNAJB6b monomer was built in PyMOL using previously published structural data (Karamanos et
al., 2019).

Based on the Hsp overexpression screen conducted as part of the work described in Chapter 3 of
this thesis, it was found that all DNAJBs tested significantly supressed FlucDM inclusion
formation, a result that contrasts to what has been reported previously regarding the capacity of
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DNAJBs to inhibit amyloidogenesis (Hageman et al., 2010). This suggests that the mechanism by
which DNAJBs suppress the nucleation of amyloid precursors into toxic fibrils is different to that
required for the suppression of amorphous aggregation by destabilised client proteins. Thus, the
intrinsic properties of an aggregation-prone client may dictate the mechanism by which these
specialised DNAJBs interact with client proteins Whilst the mechanism for how specific DNAJBs
inhibit amyloidogenesis has been investigated previously (Hageman et al., 2010, Månsson et al.,
2014b, Kakkar et al., 2016b), their interaction with client proteins that aggregate in a disordered
manner remains to be elucidated. This work aimed to exploit the aggregation propensity of FlucDM
to first investigate whether an interaction with Hsp70 is required for the DNAJB-mediated
suppression of FlucDM inclusion formation. This work then went on to assess whether the antiaggregation activity by DNAJBs is dependent upon the activity of the ubiquitin-proteasome
system or autophagy. The role of the S/T-rich domain in DNAJB6 and DNAJB8, which is essential
for inhibiting nucleation of polyQ amyloid fibrils (Hageman et al., 2010, Kakkar et al., 2016b),
was also investigated with regard to its role in the suppression of FlucDM aggregation. Finally, the
role of the C-terminal of DNAJB6 and DNAJB8, a region not required for the suppression of
polyQ aggregation (Hageman et al., 2010), was analysed for its anti-aggregation activity against
FlucDM.
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4.2

Methods

4.2.1

Plasmid constructs

Plasmids expressing mutations in DNAJBs in which a histidine residue is replaced with a
glutamine (H/Q) within the J-domain and C-terminal deletions in DNAJB8 (ΔSSF-SST and
ΔTTK-LKS) are outlined in Hageman et al. (2010). Plasmids encoding mutations in the S/T-rich
region of DNAJB6 have previously been described by Kakkar et al. (2016b) and similarly referred
to herein as M1–4. Constructs expressing disease-related missense mutations (F93L and P96R) in
the G/F-rich region have previously been described by Thiruvalluvan et al. (2020). The plasmid
encoding deletion of the TTK-LKS region in DNAJB6 was cloned by Dr Jurre Hageman (Hanze
University of Applied Sciences, Groningen, The Netherlands).

4.2.2

Cell culture, transient transfections and treatment

HEK293 and Flp-In T-Rex HEK293 cells were cultured, plated and transfected as per section
3.2.2. For co-transfections, 0.2 µg of plasmid encoding for FlucDM and 0.8 µg of plasmid DNA
encoding for either mRFP (as a negative control) or a DNAJB isoform (wild-type or mutational
variant) was used. For inhibition of the proteasome, 10 µM MG132 was added to cells 24 h posttransfection and cells were incubated for a further 18 or 24 h. Autophagy was inhibited 24 h posttransfection using a combination of 1 µM bafilomycin A1 and 5 mM 3-methyladenine and then
the cells were incubated for a further 24 h. Since MG132, bafilomycin A1 and 3-methyladenine
were dissolved in dimethyl sulfoxide, an equivalent volume of DMSO was added to control
samples. In some experiments, HEK293 cells were grown as above and at 48 h post-plating were
heat-shocked at 42°C for 1 h, before being allowed to recover at 37°C for 2 h prior to harvesting.
The concentrations of MG132 (Tanaka et al., 2004), bafilomycin A1 (Yoshimori et al., 1991) and
3-methyladenine (Li et al., 2010) used in these experiments were chosen based on previous work.
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4.2.3

Cellular protein extraction, quantification and fractionation

Cells were fractionated and protein was extracted and quantified as outlined in section 2.7.2.
Subsequent SDS-PAGE and immunoblotting was undertaken as described in sections 2.7.3 and
2.7.4, respectively.
4.2.4

Antibodies

See Table 2.1 in section 2.2 for antibodies and dilutions used for immunoblotting.
4.2.5

Flow cytometry assay to assess inclusion formation

See sections 2.6 and 2.6.2 for methods pertaining to standard flow cytometry and FloIT analyses
of cells, respectively.
4.2.6

Immunocytochemistry and confocal microscopy

Immunocytochemistry and confocal microscopy was performed to detect the co-expression of
FlucDM-EGFP and V5-tagged DNAJBs or mutational variants (or mRFP). HEK293 cells were
grown to 60-70% confluency in 8-well chamber µ-slides and transfected as above (section 4.2.2).
Immunocytochemistry and confocal microscopy were then performed as outlined previously
(section 2.5) with the following modifications. Cells were incubated with an anti-V5 antibody
(1:200; 46-0705, Thermo Fisher Scientific) diluted in blocking buffer for 1 h at 37°C and then
washed 3 times (each for 10 min) with gentle rocking in 0.1% (v/v) Triton X-100 in PBS. Cells
were then incubated with the goat anti-mouse IgG H&L Dylight® 550 secondary antibody (1:250;
ab96872, Abcam) diluted in blocking buffer for 30 min at 37°C in the dark. Cells were then
washed, stained with the Hoechst 33342 nucleic acid stain and imaged using a SP8 TCS confocal
microscope and the 63× objective lens and the 4× zoom function in the LAS-X Version 3 software
as described in section 2.5.
4.2.7

Statistics

Statistical tests were performed as described in section 3.2.10.
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4.3

Results

4.3.1

DNAJBs promote the degradation of FlucDM, primarily via the proteasome

We first sought to determine whether the inhibition of FlucDM aggregation into inclusions by
DNAJBs requires the degradative activity of the proteasome or autophagy. To do so, HEK293
cells were co-transfected to express FlucDM and DNAJB1 or DNAJB6 (or mRFP as a control) and,
24 h post-transfection, were treated with proteasome (MG132) or autophagy (3-methyladenine +
bafilomycin A1) inhibitors and analysed at 48 h. Treatment of cells with inhibitors of autophagy
had no significant effect on the level of inclusion formation and little effect on the insolubility of
FlucDM in cells co-expressing a DNAJB (Figure 4.2A, B). Inhibition of autophagy was confirmed
in cells treated with 3-methyladenine + bafilomycin A1 by the increased levels of SQSTM1/p62
(a commonly used marker of autophagy). An increase in SQSTM1/p62 was also observed in cells
treated with MG132, an effect which has been reported previously whereby inhibition of the
proteasome leads to upregulation of p62 transcription (Myeku and Figueiredo-Pereira, 2011),
suggesting a crosstalk between these two pathways (Liu et al., 2016). As there was no substantial
increase in the level of insoluble FlucDM in cells treated with the autophagy inhibitors, these data
suggest that FlucDM is primarily degraded by the proteasome.

Upon treatment with MG132, the number of FlucDM inclusions as assessed by FloIT significantly
increased in cells co-expressing the mRFP non-chaperone control (Figure 4.2A) and this
corresponded to an increase in the proportion of FlucDM found in the NP-40 insoluble fraction
(Figure 4.2B). Inhibition of the proteasome following treatment with MG132 was evidenced by
large smears of polyubiquitinated protein in these samples. Proteasome inhibition also led to a
significant increase in inclusion formation in cells overexpressing DNAJBs compared to DMSOtreated cells, such that the capacity of the co-expressed DNAJBs to reduce the amount of insoluble
FlucDM was significantly reduced when cells were treated with MG132. Additionally, the amount
of soluble FlucDM also decreased in cells expressing DNAJBs that were treated with MG132
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compared to the DMSO-treated controls. This was despite aggregation still being significantly
reduced in MG132-treated cells that overexpressed a DNAJB compared to those expressing
mRFP. Furthermore, treatment with MG132 also likely impairs the capacity of endogenous
DNAJBs (primarily DNAJB1 and DNAJB6) to process FlucDM for degradation via the
proteasome, hence why we observed a significant increase in inclusions formed by cells
expressing the mRFP control. These data suggest that DNAJBs can keep destabilised FlucDM in a
non-aggregated soluble form (proteasome independent) such that, with time, the proteasome can
facilitate its degradation. Furthermore, FlucDM aggregation is dependent upon proteasomal
degradation and the inhibition of FlucDM aggregation into inclusions by DNAJBs requires the
activity of the proteasome.
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Figure 4.2. DNAJBs require an active proteasome to facilitate the degradation of FlucDM. HEK293 cells were
co-transfected to express FlucDM-EGFP and mRFP (as a negative control), DNAJB1 or DNAJB6 and 24 h posttransfection, cells were treated with the proteasome inhibitor MG132 (10 µM) or autophagy inhibitors 3methyladenine (3-MA; 5 mM) and bafilomycin A1 (Baf A1; 1 µM), or a DMSO-treated control. Cells were incubated
for a further 24 h and then analysed by (A) quantitative flow cytometry or (B) NP-40 fractionation and subsequent
immunoblotting. Data in (A) are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells.
Significant differences between group means were determined using a one-way ANOVA (P < 0.05) followed by a
Tukey’s post-hoc test. Group means determined to be statistically different from each other are indicated (*P < 0.05
and ***P < 0.001). In (B) an anti-GFP antibody was used to detect FlucDM in the insoluble pellet (P) and soluble (S)
fractions. In the total protein fraction, the expression of DNAJBs were detected with an anti-V5 antibody, an antiubiquitin antibody was used to detect ubiquitinated proteins and an anti-SQSTM1/p62 antibody was used to assess
autophagy inhibition. Total protein was used as a loading control. The blots shown are from a single experiment.
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4.3.2

The J-domain is crucial for DNAJBs to protect against FlucDM aggregation

We next examined whether DNAJBs require an interaction with Hsp70 in order to suppress the
aggregation of FlucDM into inclusions. To do so, we employed mutant forms of the DNAJBs in
which a histidine residue is replaced with a glutamine (H/Q) within the highly conserved HPD
motif of the J-domain (Hageman et al., 2010) (Figure 4.3A). The HPD motif plays a critical role
in the regulation of Hsp70 activity; the H/Q mutation in this motif blocks the ability of the DNAJB
to interact with Hsp70 (Cheetham and Caplan, 1998), thereby abrogating its ability to stimulate
Hsp70 ATPase activity (Tsai and Douglas, 1996) and recruit Hsp70 to clients. The H/Q mutation
abolished the capacity of each of the three DNAJBs to inhibit the aggregation of FlucDM, as
evidenced by FloIT and assessment of the aggregation of FlucDM by NP-40 cell fractionation
(Figure 4.3B, C). Thus, co-expression of the wild-type DNAJBs reduced the amount of insoluble
protein whereas cells expressing the H/Q mutant isoforms contained an equivalent or increased
amount of insoluble FlucDM compared to the mRFP control. The amount of soluble FlucDM in cells
expressing a wild-type DNAJB decreased compared to cells expressing the mRFP control. This
effect is likely due to there being less total FlucDM in cells expressing wild-type DNAJBs due to
them promoting its degradation. The expression of the DNAJB H/Q variants were slightly higher
than the corresponding wild-type protein and this could be due to the mutant becoming trapped
with their substrates within inclusions, such that their own normal turnover is delayed. Strikingly,
the relative loss in activity of the H/Q variants was highest for DNAJB1 (i.e. largest increase in
insoluble protein compared to wild-type variant) and the ratio of insoluble to soluble FlucDM was
different to that of cells expressing DNAJB6 H/Q or DNAJB8 H/Q. This effect could be, at least
in part, due to an increased dependence of DNAJB1 upon interaction with Hsp70 for chaperone
activity compared to DNAJB6 and DNAJB8. DNAJB1 may require more immediate interaction
with Hsp70 in order to suppress inclusion formation by FlucDM, whereas DNAJB6 and DNAJB8
may be more capable of acting in an ATP-independent manner to hold this destabilised client
protein, before requiring interaction with Hsp70 for subsequent proteasomal degradation.
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We next investigated whether increased activation of HSF1 activity may account for the observed
effect whereby DNAJB overexpression led to decreased FlucDM inclusion formation, for example
by increasing levels of Hsp70. Thus, the expression of Hsp70 was also assessed following
overexpression of these DNAJB isoforms, because levels of some Hsp70s increase when HSF1 is
activated (Lindquist, 1986, Lindquist and Craig, 1988). As expected, there was an increase in the
expression of Hsp70 in heat-shocked cells as a result of HSF1 activation (~2 fold); however, the
expression of Hsp70 was not increased in cells overexpressing DNAJBs compared to cells
expressing mRFP as a control (Figure 4.3C). Thus, these data indicate that increased activity of
HSF1 does not account for the decrease in FlucDM inclusion formation in cells overexpressing
DNAJBs. Moreover, given the expression of Hsp70 was not affected by DNAJB overexpression,
these data imply that whilst DNAJBs prevent the aggregation of FlucDM by interacting with Hsp70,
their mode of action and relative dependence on Hsp70 may be dissimilar.
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Figure 4.3. Interaction with Hsp70 is required for DNAJBs to suppress FlucDM aggregation. Schematic overview
of DNAJB proteins identifying location of mutation within the J-domain, in which the histidine residue has been
substituted for a glutamine (termed H/Q) at amino acid position 31 within the HPD (Hsp70-interacting) motif.
HEK293 cells were co-transfected to express FlucDM-EGFP and mRFP (as a negative control), DNAJB1, DNAJB6,
DNAJB8 or their H/Q variants. Cells were analysed 48 h post-transfection by (B) quantitative flow cytometry or (C)
NP-40 cell fractionation followed by immunoblotting. Data in (B) are presented as the mean ± S.E.M (n=3) of the
number of inclusions per 100 cells. Significant differences between group means were determined using a one-way
ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means determined to be statistically different from
each other are indicated (*P < 0.05, **P < 0.01 and ***P < 0.001). In (C) an anti-GFP antibody was used to detect
FlucDM in the insoluble pellet (P) and soluble (S) fractions. In the total protein fraction the expression of DNAJBs was
detected with an anti-V5 antibody and an anti-Hsp70 antibody was used to detect endogenous Hsp70 or expression
of Hsp70 following a 1 h heat shock (HEK293 HS) at 42°C with 2 h recovery at 37°C. Total protein was used as a
loading control. The blots shown are from a single experiment.

4.3.3

DNAJBs facilitate interaction with Hsp70 and FlucDM for proteasomal degradation

In order to examine whether DNAJBs mediate FlucDM degradation by the proteasome via
interaction with Hsp70, we co-expressed FlucDM and the DNAJB H/Q variants in cells and then
treated with MG132. We surmised that if Hsp70 was the driver of proteasomal degradation of
FlucDM, the H/Q variants, which are unable to interact with Hsp70, should not further increase the
levels of inclusions formed in MG132-treated cells. Inhibition of the proteasome in these
experiments was again confirmed by an increase in polyubiquitinated species, observed as large,
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high molecular weight smears by immunoblotting with an anti-ubiquitin antibody. As before, there
was a significant increase in the number of inclusions in cells expressing either the DNAJB1 H/Q
or DNAJB8 H/Q variant compared to the mRFP expressing control (Figure 4.4A). However,
inclusion formation did not further increase in cells expressing an H/Q variant and treated with
MG132. Again, the result was different for DNAJB1 compared to DNAJB6 and DNAJB8,
whereby treatment of cells expressing DNAJB1 with MG132 lead to a decline in the number of
inclusions compared to the DMSO-treated control. Since MG132 is a substrate analogue (Lee and
Goldberg, 1998), this effect could be attributed to the drug interfering with FlucDM-DNAJB1 H/Q
complex formation. The C-terminus of DNAJB1, which is thought to be responsible for substrate
binding, is structurally diverse from DNAJB6 and DNAJB8 (Kampinga and Craig, 2010) and this
may explain why the effect is specific for DNAJB1 H/Q. There was no difference in the amount
of insoluble protein detected between cells expressing the H/Q variants treated with MG132
compared to DMSO-treated controls (Figure 4.4B). We did note some inter-assay variability for
cells expressing mRFP treated with MG132 compared to previous experiments (Figure 4.2A); we
attribute this to differences in the time cells were treated with MG132 (i.e. cells were treated with
MG132 for 24 h in the experiments presented in Figure 4.2 and 18 h in the experiments presented
in Figure 4.4). Taken together, these data provide further evidence that DNAJBs antagonise
FlucDM aggregation by keeping it competent for proteasomal degradation, which requires
interaction with Hsp70 to be effective.
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Figure 4.4. DNAJBs rely upon interaction with Hsp70 to deliver FlucDM for the degradation via the proteasome.
HEK293 cells co-transfected with FlucDM-EGFP and mRFP (as a negative control), DNAJB1, DNAJB6 or DNAJB8
H/Q variants. Cells were treated with a proteasome inhibitor MG132 (10 µM) or a DMSO-treated control 24 h posttransfection. Cells were incubated for a further 18 h and analysed 42 h post-transfection by (A) quantitative flow
cytometry or (B) NP-40 fractionation and subsequent immunoblotting. Data in (A) are presented as the mean ± S.E.M
(n=3) of the number of inclusions per 100 cells. Significant differences between group means were determined using
a one-way ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means that are significantly different from
one another are indicated (ns represent non-significant groups, *P < 0.05 and ***P < 0.001). In (B) an anti-GFP
antibody was used to detect FlucDM in the insoluble pellet (P) and soluble (S) fractions. In the total protein fraction,
expression of DNAJBs was detected with an anti-V5 antibody and an anti-ubiquitin antibody was used to observe
inhibition of the proteasome. Total protein was used as a loading control. The blots shown are from a single
experiment.
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4.3.4

Disease-related mutations in the G/F-rich region of DNAJB6 do not impact the

capacity to prevent the aggregation of FlucDM into inclusions
To probe for other regions within DNAJBs that are required to suppress FlucDM aggregation, the
impact of two disease-related missense mutations within the G/F-rich region of DNAJB6 (F93L
and P96R) were assessed (Figure 4.5A). The F93L and P96R mutations have been associated with
limb-girdle muscular dystrophy and it has been suggested that these mutations lead to disruption
of the J to G/F-inter-domain interaction and minor loss of function in their capacity to suppress
polyQ aggregation (Sarparanta et al., 2012, Thiruvalluvan et al., 2020). However, we found that
both the F93L and P96R mutational variants of DNAJB6 fully retained the ability to inhibit the
aggregation of destabilised FlucDM into inclusions (Figure 4.5B, C).

Figure 4.5. Disease-related mutations in the G/F-rich domain of DNAJB6 do not affect its capacity to inhibit
FlucDM inclusions formation. (A) Schematic overview of DNAJB6 disease-related missense mutations at amino acid
positions 93 and 96 in the G/F-rich region. HEK293 cells were co-transfected with FlucDM-EGFP and mRFP (as a
negative control) or DNAJB6 wild-type or G/F-domain disease-related mutational variants. Cells were analysed 48 h
post-transfection by (B) quantitative flow cytometry or (C) NP-40 fractionation and immunoblotting. Data in (B) are
presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells. Significant differences between group
means were determined using a one-way ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means
determined to be statistically different from each other are indicated (***P < 0.001). In (C) an anti-GFP antibody was
used to detect FlucDM in the insoluble pellet (P) and soluble (S) fractions. The expression of DNAJBs was detected
with an anti-V5 antibody in the total protein fraction. Total protein was used as a loading control. The blots shown
are from a single experiment.

112

Chapter 4 – Mechanism for DNAJB interaction with destabilised client proteins
4.3.5

The C-terminus, and not the serine-rich region of DNAJBs, is required for DNAJBs

to suppress FlucDM inclusion formation in cells
Previous work has suggested that the hydroxyl groups of S/T side chains in the C-terminal domain
of DNAJB6 participate in intramolecular hydrogen bonding with polyQ peptides and that this
likely mediates inhibition of amyloid formation. For example, increasing the number of S/T
residues substituted with alanine (A) residues (from 6, to 13 and to 18 substitutions; variants
referred to as M1, M2 or M3, respectively: Figure 4.6A), leads to a progressive loss in the ability
of DNAJB6 to inhibit polyQ or amyloid-β aggregation, with the M3 variant being functionally
inactive in these assays (Kakkar et al., 2016b, Månsson et al., 2018). Interestingly, we found that
the DNAJB6 M1, M2 and M3 variants fully retain their ability to suppress intracellular inclusion
formation by FlucDM (Figure 4.6B, C), indicating that the hydroxyl groups of the S/T-rich domain
of DNAJB6 are not required for interaction between DNAJB6 and FlucDM. Deletion of almost the
entire S/T-rich region of the C-terminus of DNAJB6 (M4) did result in abrogation of DNAJB6mediated suppression of FlucDM aggregation; however, this is likely due to the structural
destabilisation of this DNAJB6 mutant which results in it being readily degraded (Kakkar et al.,
2016b), as evidenced by its very low levels in the lysate from transfected cells (Figure 4.6C).
Together, these data imply that the residues in DNAJB6 responsible for the inhibition of the
amorphous aggregation of FlucDM into inclusions differ from those used to suppress amyloid fibriltype aggregation of proteins.

To further define the functional regions within the C-terminal domain responsible for the antiaggregation activity of DNAJBs, the DNAJB6 ΔTTK-LKS deletion construct was co-expressed
with FlucDM in cells (Figure 4.6A). Deletion of the short C-terminal TTK-LKS motif, which in
DNAJB8 is dispensable for inhibiting polyQ aggregation (Hageman et al., 2010), does abrogate
the capacity of DNAJB6 to inhibit FlucDM inclusion formation (Figure 4.6D, E). Consistent with
the data obtained for DNAJB6, deletion of the TTK-LKS motif in DNAJB8 also abrogated this
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activity (Figure 4.6F, G), further indicating different requirements for dealing with amorphous
FlucDM aggregation compared to polyQ aggregation. In line with the results following expression
of the M3 isoform of DNAJB6, deletion of the S/T-rich region (ΔSSF-SST) in DNAJB8 had no
effect on the ability to suppress the aggregation of FlucDM.
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Figure 4.6. The TTK-LKS region in the C-terminus of DNAJB6 and DNAJB8 is required to suppress the
aggregation of FlucDM into inclusions. (A) Schematic overview of DNAJB6 and DNAJB8 C-terminal mutational
variants used in this work. Regions identified between sets of arrows indicate deletion mutations. M1, M2 and M3
are mutations in the S/T-rich region of DNAJB6 in which underlined amino acids represent 6, 13 and 18 S/T-to-A
substitutions, respectively. HEK293 cells were co-transfected with FlucDM-EGFP and the indicated V5-tagged
DNAJB6 (B – E) or DNAJB8 (F, G) wild-type or C-terminal mutational variants (or mRFP as a negative control).
Cells were analysed 48 h post-transfection by quantitative flow cytometry (B, D and F) or NP-40 fractionation and
subsequent immunoblotting (C, E and G). Data in (B), (D) and (F) are presented as the mean ± S.E.M (n=3) of the
number of inclusions per 100 cells. Significant differences between group means were determined using a one-way
ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means determined to be statistically different from
each other are indicated (*P < 0.05, **P < 0.01 and ***P < 0.001). In (C), (E) and (G) an anti-GFP antibody was
used to detect FlucDM in the insoluble pellet (P) and soluble (S) fractions. The expression of DNAJBs was detected
with an anti-V5 antibody in the total protein fraction. Total protein was used as a loading control. The blots shown
are from a single experiment.
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Immunostaining and confocal microscopy was undertaken on HEK293 cells co-expressing FlucDM
and V5-tagged wild-type DNAJB6/8 or various mutational variants (or mRFP). Cells expressing
FlucDM together with the mRFP (non-chaperone) control contained many punctate FlucDM
inclusions located throughout the cytoplasm whilst mRFP remained diffuse and was expressed in
both the cytoplasm and nucleus (Figure 4.7). Overexpression of DNAJB6 or DNAJB8 resulted in
fewer cells with FlucDM inclusions. In those cells with FlucDM inclusions, the wild-type DNAJBs
were co-localised with the inclusions. More cells expressing the DNAJB6 H/Q variant contained
FlucDM inclusions and the H/Q variant also co-localised with the inclusions. As expected, fewer
cells that expressed the DNAJB6 M3 variant contained FlucDM inclusions and co-localisation of
FlucDM inclusions with DNAJB6 M3 was also observed. Conversely, deletion of the TTK-LKS
region in DNAJB8 resulted in increased FlucDM inclusion formation compared to cells expressing
wild-type DNAJB8 and DNAJB8 ΔTTK-LKS was not found to co-localise with FlucDM in
inclusions. Together these data suggest that DNAJB6 and DNAJB8 may have at least two regions
involved in substrate handling, one that is responsible for proteins that form β-hairpins during
amyloid formation (Kakkar et al., 2016b) and another that is required for the handling of
destabilised aggregation-prone proteins, such as those represented here by FlucDM.
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Figure 4.7. DNAJB6 and DNAJB8 co-localise with FlucDM inclusions and deletion of the TTK-LKS region in
the C-terminus abrogates this effect. HEK293 cells were co-transfected with FlucDM-EGFP and wild-type
DNAJB6/DNAJB8 or mutational variants (or mRFP as a negative control) and at 48 h post-transfection were fixed,
permeabilised and analysed following immunostaining by confocal microscopy. Expression of FlucDM-EGFP (green)
fluorescence was detected by excitation at 488 nm. Expression of the V5-tagged chaperones or mRFP (magenta) was
detected following excitation at 552 nm and nuclei stained with Hoechst 33482 (blue) were excited at 405 nm. All
images were taken using the Leica SP8 confocal microscope. Images on the left were taken at 63× magnification and
scale bars represent 50 µm. The right-hand panels represent the zoomed-in area indicated by dotted squares in the left
panel. Zoomed images were taken at 63× magnification with an additional 4× zoom and scale bars represent 10 μm.
Representative cells containing FlucDM-EGFP inclusions co-localised with V5-tagged wild-type DNAJBs or
mutational variants are denoted by the arrows. Images shown are representative of two experiments.
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4.4

Discussion

In this work, we demonstrate that the DNAJB molecular chaperones are potent suppressors of the
aggregation of FlucDM into inclusions in cells. This contrasts with what has been observed
previously, whereby only specific DNAJB isoforms suppress the aggregation of polyQ-expanded
proteins (Hageman et al., 2010). For DNAJB1, DNAJB6 and DNAJB8, we show that they inhibit
FlucDM aggregation in a manner that depends on their ability to interact with Hsp70 and is
associated with the cellular capacity to degrade FlucDM via the proteasome, thereby alleviating
protein aggregation. For DNAJB6 and DNAJB8, the suppression of FlucDM aggregation not only
appears mechanistically different from DNAJB1, but is also distinct from what has been reported
previously for the handling of amyloid-fibril forming proteins, such as polyQ-expanded proteins
and the amyloid-β peptide (Hageman et al., 2010, Kakkar et al., 2016b, Månsson et al., 2018).
Whilst the S/T-rich region and, to some extent, the G/F-rich region (Sarparanta et al., 2012,
Thiruvalluvan et al., 2020) in DNAJB6 and DNAJB8 are essential for amyloid suppression, these
regions are not required to inhibit FlucDM inclusion formation. Finally, we identified a short, 23
amino acid (TTK-LKS) sequence in the C-terminus of DNAJB6 and DNAJB8 that is required to
inhibit FlucDM inclusion formation: this region in these proteins is dispensable for suppression of
polyQ aggregation (Hageman et al., 2010). Thus, whilst DNAJB6 and DNAJB8 are both potent
inhibitors of polyQ and FlucDM aggregation, the mechanism by which they interact with these
aggregation-prone proteins is different. Our data suggests that DNAJB6-like proteins possess
distinct regions for interacting with clients and that this is likely dictated by the structure or
composition of the aggregation-prone protein.

The S/T-rich stretch in DNAJB6 (amino acids 155-195) and DNAJB8 (amino acids 149-186) is
highly conserved between these proteins. It has been proposed that interaction with hydroxyl
groups in side chains of these S/T residues inhibits primary nucleation by outcompeting for
hydrogen bonding essential for β-hairpin and mature amyloid fibril formation, thereby suppressing
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aggregation (Kakkar et al., 2016b). DNAJB2 also contains a partial serine-rich stretch and,
although it is not confirmed to be involved in polyQ handling, is also more effective than DNAJB1
and DNAJB5 (which lack this region) at suppressing polyQ aggregation (Hageman et al., 2010).
DNAJB5 shares close homology to DNAJB1 (Chen et al., 1999) and has been shown to interact
with Hsp70 (Hageman et al., 2011). Moreover, since DNAJB5 was also identified as a potent
suppressor of FlucDM inclusion formation, it is likely that DNAJB1 and DNAJB5 inhibit FlucDM
aggregation into inclusions via a similar mechanism. Mutation or deletion of the S/T-rich region
did not result in loss of the ability of DNAJB6 or DNAJB8 to suppress the aggregation of FlucDM
into inclusions, indicating that a different region of the protein is involved in this process.
Interestingly, DNAJB1 and the other DNAJBs we tested were all capable of suppressing FlucDM
aggregation. Whilst our data does not provide insight into the domains required by these other
DNAJBs to prevent FlucDM aggregation, our work has identified a short TTK-LKS
(TTKRIVENGQERVEVEEDGQLKS) fragment conserved between DNAJB6 (amino acids 204226) and DNAJB8 (amino acids 195-217) that is crucial for the handling of FlucDM. Since this
TTK-LKS domain in DNAJB8 is dispensable for its capacity to inhibit polyQ aggregation
(Hageman et al., 2010), our findings are the first to demonstrate that DNAJB6 and DNAJB8 have
two distinct regions for handling client proteins. Little is currently known regarding the functional
role of this conserved TTK-LKS motif in DNAJB6 and DNAJB8. However, based on our current
data, we hypothesise that it is either directly or indirectly involved in binding hydrophobic patches
in destabilised aggregation-prone proteins.

Recent structural homology modelling of the DNAJB6 dimer/oligomer revealed four β-strands
within the C-terminal domain of DNAJB6 (Söderberg et al., 2018). Dimerisation of each DNAJB6
monomer likely occurs via same-to-same-residue crosslinks at lysine residues K189 and K232
within the first and fourth β-strands, respectively. When cross-linked to form a dimer, the
symmetrically positioned β-strands within DNAJB6 monomers form a peptide-binding pocket that
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is surface exposed and lined with the S/T residues responsible for binding fibrillar proteins. Based
on these structural data, the TTK-LKS region (which lies downstream of the S/T-rich region) is
contained within the fourth β-strand of DNAJB6/8, which is surface-exposed in the monomeric
and dimeric form of DNAJB6. Thus, this region has the potential to be a second substrate binding
region in DNAJB6/8, responsible for binding hydrophobic aggregation-prone client proteins.

One possible reason why DNAJB6 and DNAJB8-like proteins possess distinct mechanisms to
interact with aggregation-prone client proteins is due to intrinsic structural differences in the
misfolded states of proteins that lead to the formation of amorphous aggregates as opposed to
amyloid fibrils. PolyQ-expanded proteins form large, tightly aggregated structures that are
extremely insoluble and typical of amyloidogenic deposits (Hageman et al., 2010, Kubota et al.,
2011). The R188Q and R261Q mutations in the N-terminus of Fluc used in this study
conformationally destabilises the protein (Gupta et al., 2011), thereby inducing protein misfolding
and increased regions of exposed hydrophobicity. This causes the protein to form aggregates that
are SDS-soluble and localise into diffuse cytosolic inclusions (Gupta et al., 2011), distinct from
the amyloid-like aggregates formed by polyQ-expanded proteins. Indeed, when both polyQexpanded huntingtin and FlucDM are expressed together in human cell lines, the two proteins
deposit into distinct aggregated structures (Gupta et al., 2011), reaffirming that they aggregate via
different mechanisms. Importantly, our data highlight that it may be possible to design therapeutics
that boost the ability of DNAJB6/8 to prevent amyloid fibril formation associated with disease,
whilst not impacting its capacity to interact with highly destabilised aggregation-prone proteins
destined for degradation by the proteasome.

A major finding of this work is that all of the DNAJBs tested significantly inhibited FlucDM
inclusion formation, a result which contrasts with previous observations regarding the suppression
of polyQ-expanded protein aggregation, whereby only a subset of DNAJB isoforms were effective
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(Hageman et al., 2010). Whilst we identified that the TTK-LKS motif in DNAJB6 and DNAJB8
is essential for these proteins to prevent the intracellular aggregation of destabilised client proteins,
such as FlucDM, this does not account for the capacity of other DNAJBs (that lack this region) to
suppress inclusion formation by FlucDM. Our data are nevertheless largely consistent with findings
on mutant Parkin in which the overexpression of most DNAJ proteins tested reduced its propensity
to form amorphous aggregates (Kakkar et al., 2016a). Also, in the case of an ALS-causing mutant
SOD1 protein, overexpression of multiple DNAJs (albeit not all) supressed its aggregation
(Serlidaki et al., 2020). In all these cases, including our current data, the effects coincided with a
reduction in steady state levels of the mutant protein. Whilst we cannot formally exclude effects
of quality control during co-translational folding, we favour the hypothesis that the various DNAJs
recognise and bind to these (partially) misfolded substrates post-translationally to support their
proteasomal degradation (Kakkar et al., 2016a; this report). This mechanism is distinct from that
seen for polyQ proteins which aggregate in a precise and ordered manner that can be chaperoned
by distinct binding regions present only in the DNAJB6-like proteins (i.e. DNAJB2, DNAJB6,
DNAJB7 and DNAJB8). The global unfolding of the other more structurally destabilised proteins
may expose many hydrophobic surfaces that can be recognised by the multiple different substrate
binding sites in DNAJB1-like proteins and by other regions of the DNAJB6-like chaperones.
Future studies to elucidate the specific region(s) within DNAJB1-like proteins that act to suppress
the aggregation of destabilised client proteins could utilise a similar approach to that undertaken
in this work, by encompassing a range of deletion mutations located throughout the C-terminal
substrate binding domain(s).

In conclusion, we have utilised the proteostasis sensor FlucDM to demonstrate that overexpression
of the DNAJB molecular chaperones acts to boost the protein quality control capacity of cells. We
demonstrate that the ability of DNAJBs to inhibit the aggregation of FlucDM into inclusions relies
on interaction with Hsp70 and this facilitates degradation of FlucDM by the proteasome.
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Significantly, we show that the TTK-LKS region in the C-terminal domain of DNAJB6 and
DNAJB8 is essential for engaging this destabilised client protein to prevent its aggregation.
Moreover, we show that the S/T-rich region of DNAJB6-like proteins that mediates interactions
with amyloid-forming client proteins is not involved in suppressing FlucDM aggregation. Overall,
our data emphasises the important role of DNAJB molecular chaperones in preventing all forms
of protein aggregation in cells and highlights the potential of targeting them for the amelioration
of diseases associated with protein aggregation.
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5.1

Introduction

The proteostasis capacity of a cell can be defined as the ability to prevent protein accumulation
and aggregation into intracellular inclusions. Thus, proteostasis capacity is highly dependent on
the protein quality control network. The ability to quantitatively measure the proteostasis capacity
of a cell is an important step towards deciphering why some cell types are more susceptible to the
formation of inclusions than others. This is especially true given that the proteostasis capacity of
a cell is known to influence the rate at which misfolded proteins accumulate (Gidalevitz et al.,
2006, Hutt et al., 2009, Powers et al., 2009, Gidalevitz et al., 2010). Thus, a decline in proteostasis
capacity is linked to an impaired ability of a cell to prevent protein aggregation, which can lead to
the onset and progression of toxicity associated with disease (Brehme et al., 2014, Hipp et al.,
2014). Work towards characterising the proteostasis capacity of cells is an important first step in
understanding why this varies between cell types.

The innate ability of a cell to prevent protein aggregation is known to vary significantly among
different cell types (Lim and Yue, 2015). For example, it has been proposed that neurons have a
reduced capacity to prevent the formation of inclusions (Saxena and Caroni, 2011), as neuronal
loss and neurodegeneration are often characterised by the accumulation of misfolded proteins into
inclusions (Soto and Pritzkow, 2018). However, it remains to be definitively established why
neurons in particular are so vulnerable to inclusion formation. Since neurons are long-lived cells,
it is likely a result of their post-mitotic inability to dilute toxic protein species through cell-division
and/or due to an age-related failure in the mechanisms that act to degrade and clear aggregationprone proteins (Balch et al., 2008, Powers et al., 2009, Liu et al., 2011, Proctor and Lorimer, 2011,
Taylor and Dillin, 2011). Neuron-specific degeneration in the context of disease occurs despite
many aggregation-prone proteins being ubiquitously expressed (sometimes at higher
concentrations) in other cells of the body. It has been hypothesised that the relative susceptibility
of some cells to inclusion formation is due to intrinsic differences in the cellular protein quality
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control systems that maintain proteostasis (Finkbeiner et al., 2006, Komatsu et al., 2006, Malhotra
and Kaufman, 2007, Rutkowski and Kaufman, 2007, Morimoto, 2008, Matus et al., 2011).

Few studies have used quantitative cell-based experiments to elucidate the precise roles each of
these protein quality control systems have on proteostasis. The protein quality control network
comprises the systems that act to prevent protein aggregation, for example, through proper
guidance of protein folding or assisting in protein degradation (Kampinga and Bergink, 2016).
These systems encompass all of the responses in the cell that are activated by proteotoxic stress
and include the ER-unfolded protein response, the HSF1-mediated heat-shock response and
proteolytic processing by the degradation machinery (i.e. autophagy or the ubiquitin-proteasome
system). Whilst many studies have utilised genetic or pharmacological approaches to probe the
molecular mechanisms involved in protein folding and misfolding in cells (Seglen and Gordon,
1982, Lee and Goldberg, 1998, Yamamoto et al., 1998, Taylor et al., 2007, Lee et al., 2010,
Oslowski and Urano, 2011, Hou et al., 2012, Wang et al., 2017), no work has been done to
systematically assess the impact that modulation of the protein quality control network has on the
capacity of neuronal-like cells to prevent the formation of inclusions by an aggregation-prone
protein.

In order to better understand the molecular mechanisms that underpin diseases associated with
protein aggregation, and to advance the development of therapeutic strategies, methods to
quantitatively measure the proteostasis capacity of a cell are essential. To address this,
aggregation-prone FlucDM was exploited to quantitatively compare the ability of two neuronal cells
lines (mouse neuroblastoma cells [Neuro-2a] cells and mouse neuroblastoma × motor neuron
hybrid [NSC-34] cells) to prevent the formation of inclusions. The impact of specific protein
quality control pathways on the capacity of each cell line to prevent the formation of inclusions
was also assessed. Previous work conducted to delineate differences in the proteomes of Neuro125
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2a and NSC-34 cells revealed that these cell types are highly similar with regard to their global
proteomes (Hornburg et al., 2014). However, the work presented in this chapter demonstrates that
FlucDM forms inclusions more readily in NSC-34 cells compared to Neuro-2a cells. The inclusions
formed by FlucDM in both Neuro-2a and NSC-34 cells were purified in order to identify differences
in the types of proteins that engage with aggregation-prone proteins in these cells. The impact that
protein quality control systems have on inclusion formation in these neuronal-like cells was also
investigated. Overall, the work presented in this chapter is a step towards using a model
aggregation-prone protein to quantitatively measure the proteostasis capacity of cells, and thus
understanding why some cells are vulnerable to proteome dysfunction, leading to the formation
of inclusions.

126

Chapter 5 – Method to measure the proteostasis capacity of cells
5.2

Methods

5.2.1

Plasmid constructs

The pcDNA3.1 constructs encoding wild-type HSF1 (HSF1WT), a constitutively active form of
HSF1 (HSF1+) that has a deletion of the sequence encoding amino acids 203-315 (i.e. Δ203-315)
of the regulatory domain, and an inactive variant of HSF1 (HSF1-) that has a deletion of amino
acids 453-523 (i.e. Δ453-523) located in the transcription activation domain, previously described
by Taylor et al. (2007), were generously donated by Professor Heather Durham (McGill
University, Canada). The Ub[9]-mRFP plasmid originally described by Salomons et al. (2009) was
gifted by Dr Luke McAlary and Professor Justin Yerbury (both of the University of Wollongong,
Australia).

5.2.2

Cell culture, transfection and treatment of Neuro-2a and NSC-34 cells

Neuro-2a and NSC-34 cells were cultured as described in section 2.4.1. Unless otherwise
specified, 1.3 × 105 cells/mL were seeded into 6-well or 12-well plates, or 8-well chamber µ-Slides
and cultured in DMEM/F-12 with L-glutamine and 10% (v/v) FCS by incubation overnight at
37°C. In a 6-well plate, cells were transiently transfected with 2 μg/well of plasmid DNA using
Lipofectamine® LTX/PLUS™ (6 μL/well of Lipofectamine® LTX and 2 μL/well PLUS™ reagent)
or Lipofectamine™ 3000 (3 μL/well of Lipofectamine™ 3000 and 4 μL/well P3000 reagent)
reagents, according to the manufacturer’s instructions. For experiments involving cotransfections, complexes at a ratio of 4:1 of FlucDM-EGFP to chaperone, Ub[9]-mRFP[1], HSF1 (or
one of its mutational variants) or mRFP plasmid DNA were mixed together prior to the addition
of the transfection reagent. DNA/reagent complexes were added in a dropwise manner to cells.
Untransfected controls received equivalent volumes of Lipofectamine® LTX/PLUS™ or
Lipofectamine™ 3000 reagents, but did not receive any plasmid DNA.
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In some experiments, Neuro-2a and NSC-34 cells expressing FlucDM-EGFP were treated with
various compounds known to modulate protein quality control pathways, namely the ER network,
autophagy and the ubiquitin-proteasome system. To modulate the ER network, 24 h posttransfection cells were treated with 3 µM thapsigargin (to induce ER stress) or 20 µM azoramide
(to upregulate ER resident chaperones for improved ER protein folding) and cells were incubated
for a further 16 h prior to analysis. To modulate autophagy, 32 h post-transfection cells were
treated with 1 µM bafilomycin A1 (inhibits late-stage autophagy) or rapamycin (binds mTOR to
upregulate autophagy) and were incubated for a further 16 h before analysis. To inhibit the
proteasome, 42 h post-transfection cells were treated with 10 µM MG132 and incubated for an
additional 6 h. In each of these experiments an equivalent volume of DMSO was added to control
samples. The concentrations of thapsigargin (Oslowski and Urano, 2011, Cox and Ecroyd, 2017),
azoramide (Fu et al., 2015), bafilomycin A1 (Yoshimori et al., 1991), rapamycin (Ravikumar et
al., 2004) and MG132 (Tanaka et al., 2004, Li et al., 2010) used in these experiments were chosen
based on previous work.

5.2.3

Confocal microscopy to assess inclusion formation

Neuro-2a and NSC-34 cells were plated and transfected as above (section 5.2.2) and inclusions
formed following expression of FlucWT-EGFP, FlucDM-EGFP or EGFP (as a control) were
analysed directly in 8-well chamber µ-Slides. Cells were incubated for 37°C for 48 h prior to being
analysed by confocal microscopy. Live cells were analysed using a Leica TCS SP5 confocal
microscope and the 63× oil-immersion objective lens (Leica Microsystems), controlled by the
LAS-AF Version 3 software. EGFP fluorescence was detected by excitation at 488 nm.

5.2.4

Flow cytometry assays to assess inclusion formation

Standard flow cytometry, including PulSA and FloIT analyses of cells, was conducted as per
sections 2.6, 2.6.1 and 2.6.2, with slight modifications. To account for differences in protein
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expression between the Neuro-2a and NSC-34 cell lines, PulSA analysis was only conducted on
an equivalent subset of EGFP-positive events expressed by both cell types.

5.2.5

Flow cytometry to measure the relative proteostasis capacity of Neuro-2a and NSC-

34 cells
Neuro-2a and NSC-34 cells were plated as described above in a 6-well plate and incubated at 37°C
for 24 h. Both cell lines were then transfected (or not) to express EGFP, FlucWT-EGFP or FlucDMEGFP using 2 μg of plasmid DNA/well. Following a 48 h incubation, cells were trypsinised,
harvested and washed before being analysed by flow cytometry (section 2.6). In order to compare
the relative propensity of Fluc to form aggregates in Neuro-2a and NSC-34 cells (and hence the
capacity of cells to prevent aggregation), three different strategies were employed. Two of these
strategies involved the use of PulSA. First, live, EGFP-positive cells were identified and selected
(using the untransfected cells as a negative control), and the geometric mean of the EGFP
fluorescence in EGFP-positive cells was determined (indicating the level of Fluc expression in the
cell). The percentage of cells identified to contain inclusions, as assessed by PulSA, along with
the EGFP geometric mean (of cells expressing FlucWT-EGFP or FlucDM-EGFP) were used to
generate a PulSA aggregation index (PulSAAI):
PulSA𝐴𝐴𝐴𝐴 =

Cells with inclusions (%)
× 100
EGFP Geometric mean

(Equation 5.1)

A second approach using PulSA was employed to determine the proportion of cells with inclusions
as the levels of Fluc increased in the cells. To do so, EGFP-positive cells were identified and
binned into groups based on their levels of EGFP fluorescence: On a log10-based scale, 16 gates
(bins) of equal size were used to subdivide the EGFP-positive cells. PulSA was then performed
on cells within each of these bins to determine the proportion of cells with inclusions in each bin
(only bins with >100 cells were analysed). Data are presented as a plot of the bin number versus
the proportion of cells with inclusions in that bin.
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The third approach used to ascertain the relative propensity of Fluc to form inclusions in Neuro2a and NSC-34 cells involved the use of FloIT analysis on these same cells. The number of
inclusions/100 cells was determined using the gating strategies specified above (section 5.2.4) and
equation 2.1. An aggregation-index based on FloIT analysis (FloITAI) was calculated using the
following equation:
FloIT𝐴𝐴𝐴𝐴 =

5.2.6

Inclusions/100 cells
× 100
EGFP Geometric mean

(Equation 5.2)

Time-resolved fluorescent imaging and image analysis to track inclusion formation

Fluorescence imaging of live cells was conducted on Neuro-2a and NSC-34 cells to assess the
effects of inclusion formation by FlucWT or FlucDM (or EGFP as a control) on cell survival in realtime, using the IncuCyte® automated fluorescence microscope (Essen BioScience, Ann Arbor, MI,
USA). Immediately following transfection (see section 5.2.2), cells were placed into the
microscope. At least 4 images were acquired per well at 3 h time points over 192 h using the 10×
objective in the phase (bright field) and green channel. A standard exposure time of 400
milliseconds was chosen to capture fluorescence in the green channel. The processing definition
generated to analyse images acquired in the phase channel utilised segmentation adjustment (0.5
towards background) and clean-up (hole fill = 0 µm2, pixel size = - 2). The processing definition
produced to quantify fluorescence in the green channel used Top-Hat subtraction (radius = 25 µm,
threshold = 0.8 GCU), edge split (edge sensitivity = 4) and clean-up (hole fill = 0 µm2, pixel size
= - 1).
The following equations used for analysis and data presentation were performed as described by
McAlary et al. (2016) with modifications. The number of green objects (i.e. EGFP+ve cells) at each
time point (EGFPtx), was normalised to the value determined in the first scan immediately after
plating (EGFPt0):
Normalised EGFPtx =
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The number of EGFPtx of cells was then normalised to the total number of cells (phase object
count) at the corresponding time point:
EGFP+𝑣𝑣𝑣𝑣 cells relative to total number of cells =

Normalised sample EGFPtx
Sample phase object count

(Equation 5.4)

The normalised values at each time point taken from equation 5.4 (EGFP+ve cells relative to total
number of cells) were divided by the normalised EGFP data at the same time point to determine
the proportion of EGFP-positive cells for each transfection, relative to those cells expressing
EGFP alone.

5.2.7

Purification of FlucDM inclusions from SDS-PAGE

In order to purify FlucDM-EGFP inclusions from Neuro-2a and NSC-24 cells to identify proteins
contained within these inclusions, cells were harvested, fractionated and the insoluble protein was
extracted and quantified for loading onto SDS-PAGE gels as outlined in section 2.7.2. SDS-PAGE
was undertaken as per section 2.7.3, with the following modifications. Native loading buffer
without reducing agents (final concentrations: 200 mM Tris-HCl, 40% (v/v) glycerol, 0.01%
(w/v), pH 8.6), was added to insoluble cell lysates and the samples were heated at 45°C for 5 min
prior to loading onto SDS-PAGE gels, which were then run as previously described (section 2.7.3).
Gels were placed into Milli-Q water and immediately imaged using the ChemiDoc™ Imaging
System and the Pro-Q Emerald 488 exposure setting (exposure time ~ 5 sec) to visualise EGFP
fluorescence from FlucDM-EGFP. Proteins were then fixed in Coomassie Blue staining solution
and de-stained using de-staining solution as previously described (section 2.7.3). Regions of the
stacking gel identified to contain aggregated FlucDM-EGFP (based on the in-gel fluorescence) were
cut out using a clean razor blade and fixed in 10% (v/v) acetic acid for proteomic mass
spectrometry. Untransfected Neuro-2a and NSC-34 cells were used as controls and treated as
above in order to identify endogenous proteins or protein complexes that are found in the same
region of the stacking gel. The subsequent in-gel trypsin digest and proteomic mass spectrometry
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of the FlucDM inclusions were performed by Dr Albert Lee and Ms Flora Cheng (Macquarie
University, Sydney, Australia) as described below.

5.2.8

In-gel trypsin digestion

Excised protein gel bands were further de-stained in 50% (v/v) acetonitrile (ACN) and 50 mM
ammonium bicarbonate (pH 8.0) and dehydrated in 100% ACN. The gel pieces were dried by
vacuum centrifugation, reduced with 10 mM dithiothreitol at 55°C for 30 min and alkylated with
20 mM iodoacetamide at room temperature for 30 min. The gel pieces were then rehydrated with
trypsin (12.5 ng/µL; Promega) and resuspended in 50 mM ammonium bicarbonate (pH 8.0), where
the proteins were then digested overnight at 37°C. The digestion was inactivated by the addition
of 2 μL of formic acid. Tryptic peptides were extracted twice with 50% (v/v) ACN and 2% (v/v)
formic acid and dried under vacuum centrifugation. The peptides were resuspended in 0.1% (v/v)
formic acid and desalted on a pre-equilibrated C18 Omix Tip (Agilent, Santa Clara, CA, USA) and
eluted in 50 % (v/v) ACN, 0.1% (v/v) formic acid, and dried under vacuum centrifugation.

5.2.9

Reverse phase C18 liquid chromatography mass spectrometry (RP-LC-MS/MS)

Lyophilised peptides were resuspended in 0.1% (v/v) formic acid and sonicated for 20 min in a
sonication bath (Branson Ultrasonics). The resuspended peptides were then centrifuged at 14,000
× g for 15 min to remove any insoluble debris, and the clarified peptides were analysed by LCMS/MS. The peptides were separated on an UltiMate™ 3000 RSLCnano system (Thermo Fisher
Scientific) fitted with an Acclaim PepMap RSLC column (Thermo Fisher Scientific), making use
of a 60 min gradient (2-95% (v/v) ACN, 0.1% (v/v) formic acid) running at a flow rate of 300
nL/min. Peptides eluted from the nano-LC column were subsequently ionised into the Q
Exactive™ Plus Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Fisher Scientific).
The electrospray source was fitted with a 10 μm emitter tip (New Objective, Woburn, MA, USA)
and maintained at 1.6 kV electrospray voltage. The temperature of the capillary was set to 250°C.
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Precursor ions were selected for MS/MS fragmentation using a data-dependent “Top 10” method
operating in Fourier transform (FT) acquisition mode with Higher C-trap Dissociation (HCD)
fragmentation. FT-MS analysis on the Q Exactive™ Plus was carried out at 70,000 resolution and
an automatic gain control (AGC) target of 1×106 ions in full MS. MS/MS scans were carried out
at 17,500 resolution with an AGC target of 2×104 ions. Maximum injection times were set to 30
and 50 milliseconds, respectively. The ion selection threshold for triggering MS/MS
fragmentation was set to 25,000 counts and an isolation width of 2.0 Da was used to perform HCD
fragmentation with normalised collision energy of 27.

Raw spectra files were processed using the Proteome Discoverer software 2.4 (Thermo Fisher
Scientific) incorporating the Sequest search algorithm. Peptide identifications were determined
using a 20 ppm precursor ion tolerance and a 0.1 Da MS/MS fragment ion tolerance for FT-MS
and HCD fragmentation. Carbamidomethylation modification of cysteines was considered a static
modification while oxidation of methionine, deamidation of asparagine and glutamine, and acetyl
modification on N-terminal residues were set as variable modifications allowing for a maximum
of two missed cleavages. The data were processed through Percolator for estimation of false
discovery rates. Protein identifications were validated employing a q-value of 0.01. The relative
abundance of proteins within each sample was calculated by the Proteome Discoverer 2.4 software
using the cumulative intensities of unique peptides. Only proteins identified with an abundance ≥
2-fold higher than in the untransfected control, and which appeared in all three biological
replicates of each sample were considered for further analyses.

5.2.10 Functional pathway enrichment analysis of proteins identified within FlucDM
inclusions
Venn diagrams constructed to show the overlap of proteins identified in FlucDM inclusions in
Neuro-2a and NSC-34 cells were produced using the Ven de Peer lab’s Bioinformatics and
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Evolutionary Genomics online tool (http://bioinformatics.psb.ugent.be/webtools/Venn). The
functional enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG)
biological pathways represented by proteins identified to co-interact with FlucDM inclusions in
Neuro-2a and NSC-34 cells was conducted using g:Profiler (Raudvere et al., 2019) with the
following parameters: organism: Mus Musculus, statistical domain scope: only annotated genes,
multiple testing significance threshold: g:Profiler tailor made g:SCS, user threshold: P ≤ 0.05 and
data sources: biological pathways – KEGG. To identify the classes of proteins enriched in these
samples, Protein Annotation through Evolutionary Relationship (PANTHER) analysis was
conducted using the following settings: organism: Mus Musculus, analysis: functional
classification viewed as pie chart, ontology: protein class. Pie charts were constructed whereby
the number of genes was expressed as a percentage of the total number of protein class hits. Dr
Albert Lee performed the STRING analysis (Szklarczyk et al., 2017) of overlapping proteins
identified with FlucDM inclusions in both Neuro-2a and NSC-34 cells using Cytoscape (Shannon
et al., 2003) and data are presented to show how the proteins identified were clustered based on
protein class using the Reactome database (Croft et al., 2014).

5.2.11 Cellular protein fractionation and subsequent immunoblotting
Cells were fractionated and protein was extracted and quantified as outlined in sections 2.7.1 and
2.7.2. Subsequent SDS-PAGE and immunoblotting was undertaken as described in sections 2.7.3
and 2.7.4.

5.2.12 Antibodies
Refer to Table 2.1 in section 2.2 for antibodies and dilutions used for immunoblotting.
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5.2.13 Immunocytochemistry, tUi staining and confocal microscopy
Free ubiquitin levels were measured in Neuro-2a and NSC-34 cells co-expressing FlucDM-EGFP
and Ub[9]-mRFP (or mRFP) using the high-affinity free ubiquitin sensor tUi-HA, described
previously by Choi et al. (2019), and expressed and purified as outlined by Farrawell et al. (2020).
Neuro-2a and NSC-34 cells were grown and transfected in 8-well chamber µ-slides as above
(section 5.2.2). Immunocytochemistry and confocal microscopy were then performed as outlined
in section 2.5, with the following modifications. Briefly, following blocking overnight, cells were
incubated with the tUi-HA probe, diluted to a final concentration of 7.5 µg/mL in blocking buffer,
for 30 min at room temperature followed by 3 washes with rocking (each for 10 min) in 0.1% (v/v)
Triton X-100 in PBS. Cells were incubated with an anti-HA antibody (1:1000; ab9110, Abcam)
diluted in blocking buffer for 1 h at room temperature and then washed 3 times (each for 10 min)
with gentle rocking in 0.1% (v/v) Triton X-100 in PBS. Cells were incubated with the Alexa Fluor
647-conjugated anti-rabbit-IgG secondary antibody (1:1000; ab150079, Abcam) diluted in
blocking buffer for 1 h at room temperature in the dark. Cells were then washed, stained with the
Hoechst 33342 nucleic acid stain and imaged using the SP8 TCS confocal microscope and 20×
objective lens as described in section 2.5.

5.2.14 Epifluorescence microscopy
Inclusions formed in Neuro-2a and NSC-34 cells following the co-expression of FlucDM-EGFP
and either HSF1WT, HSF1+ or HSF1- were analysed directly in 6-well plates 48 h post-transfection
by epifluorescence microscopy. Fluorescence from EGFP was detected following excitation at
488 nm. All images were taken at 20× magnification using a Leica DMi8 fluorescence microscope.
Images were prepared with the LAS-AF Version 3 software.

5.2.15 Statistics
Statistical analyses were performed as described in section 5.2.15.
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5.3

Results

5.3.1

Measuring the relative capacity of Neuro-2a and NSC-34 cells to prevent the

aggregation of FlucDM into inclusions
The aggregation propensity of FlucDM was exploited in order to measure and compare the relative
capacities of Neuro-2a and NSC-34 cells to prevent inclusion formation by aggregation-prone
proteins. First, the presence and localisation of Fluc-based inclusions formed in Neuro-2a (top)
and NSC-34 (bottom) cells was analysed 48 h post-transfection by confocal microscopy (Figure
5.1). Neuro-2a and NSC-34 cells expressing EGFP (left) exhibited soluble and diffuse green
fluorescence throughout the cytoplasm and the nucleus. Punctate inclusions formed by FlucWTEGFP (centre) were occasionally observed in transfected Neuro-2a and NSC-34 cells (< 3% of
transfected cells). Both Neuro-2a and NSC-34 cells expressing FlucDM-EGFP (right) had a greater
population of transfected cells containing inclusions (~ 15%) compared to cells expressing EGFP
or FlucWT-EGFP. Overall, it was concluded that FlucDM-EGFP forms inclusion in both Neuro-2a
and NSC-34 cells under these experimental conditions.

Figure 5.1. Characterisation of the formation of inclusions by Fluc in Neuro-2a and NSC-34 cells, as assessed
by confocal microscopy. Neuro-2a and NSC-34 cells were transiently transfected to express EGFP, FlucWT-EGFP or
FlucDM-EGFP and live cells were analysed 48 h post-transfection by confocal microscopy to examine the formation
of inclusions. Images are representative of three experiments and show confocal micrographs of Neuro-2a (top) and
NSC-34 (bottom) cells transfected with EGFP (left), FlucWT-EGFP (centre) or FlucDM-EGFP (right). EGFP
fluorescence was detected by excitation at 488 nm. Arrowheads indicate cells with inclusions. All images were taken
using a Leica SP5 confocal microscope and the 63× oil-immersion objective lens. Scale bar represents 50 µm.
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Next, to determine the relative capacity of Neuro-2a and NSC-34 cells to maintain FlucDM-EGFP
in a non-aggregated state, cells were transiently transfected with EGFP, FlucWT-EGFP or FlucDMEGFP for 48 h and then analysed via the flow cytometric method PulSA. In Neuro-2a cells
expressing FlucWT-EGFP or FlucDM-EGFP, the proportion of cells with inclusions was identified
to be 2.0 ± 0.4% and 3.7 ± 0.2% respectively, whilst for NSC-34 cells the proportion of cells
containing inclusions was 2.1 ± 0.6% and 8.3 ± 0.8% (Figure 5.2A). To further assess and compare
the capacity of Neuro-2a and NSC-34 cells to prevent aggregation of Fluc, an aggregation index
(AI) was calculated based upon the data obtained from PulSA (PulSAAI). This aggregation index
provides a first step towards establishing a quantitative evaluation of the susceptibility of a
particular cell type to the formation of inclusions by Fluc. In order to take into account the amount
of Fluc expressed in the different cell populations, the geometric mean of the EGFP-positive cells
was determined (Figure 5.2B). There was no difference in the amount of FlucWT or FlucDM
expressed between cell types. The PulSAAI was calculated as the ratio of the percentage of cells
identified to contain inclusions (as determined by PulSA) to the EGFP geometric mean of
transfected cells. Based on these analyses, NSC-34 cells expressing FlucDM have a significantly
higher PulSAAI than Neuro-2a cells expressing FlucDM suggesting that NSC-34 cells have less
capacity to prevent the aggregation of FlucDM into inclusions (Figure 5.2C).
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Figure 5.2. The formation of inclusions by Fluc in Neuro-2a and NSC-34 cells, as assessed by PulSA. Neuro-2a
and NSC-34 cells were transiently transfected to express EGFP, FlucWT-EGFP or FlucDM-EGFP and were analysed
by PulSA 48 h post-transfection. (A) The proportion of Neuro-2a and NSC-34 cells expressing FlucWT-EGFP or
FlucDM-EGFP with inclusions. Data are presented as the mean ± S.E.M (n=3) of the percentage of cells containing
inclusions. (B) The EGFP geometric mean, which corresponds to the average amount of Fluc expressed in transfected
cells within each cell population. Data are presented as the EGFP geometric mean (arbitrary fluorescence units; AFU)
of live, transfected cells. (C) PulSA aggregation index (PulSAAI) calculated for Neuro-2a and NSC-34 cells
transfected with Fluc constructs. The PulSAAI was calculated as the ratio of the percentage of cells identified to contain
inclusions, divided by the EGFP geometric mean of EGFP-positive cells. Data in (A), (B) and (C) are presented as
the mean ± S.E.M. (n=3). Significant differences between group means were determined using an unpaired two-tailed
Student’s t-test (** = P < 0.01).

As an alternative approach to compare the relative capacity of Neuro-2a and NSC-34 cells to
maintain FlucDM-EGFP in a non-aggregated state, how the proportion of cells with inclusions
change as the amount of Fluc in the cell increases was investigated. To do so, cells with equivalent
levels of EGFP fluorescence were identified from the flow cytometry data and binned based upon
the EGFP fluorescence intensity. Overall, 16 bins of equal size (based on a log scale) were used
to subdivide the EGFP-positive cells (Figure 5.3A). The proportion of cells with inclusions was
then determined by PulSA for cells in each of these bins (i.e. with increasing amounts of Fluc). In
all samples, cells in bins 1–10 did not contain inclusions. From bin 11 onwards, there was a clear
trend whereby as the amount of Fluc expressed in cells increased, there was an increase in the
proportion of cells with inclusions (Figure 5.3B). Neuro-2a cells expressing FlucDM-EGFP were
found to be less susceptible to inclusion formation by FlucDM than NSC-34 cells. This is observed
as a significant shift to the right when bin number (e.g. bins 12 and 13) is plotted against the
proportion of cells with inclusions for Neuro-2a cells compared to NSC-34 cells. There was little
difference in the proportion of cells containing inclusions in both cell lines when they expressed
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FlucWT, which remained below 40% even in cells expressing high amounts of FlucWT-EGFP (i.e.
bins 14 – 16).

Figure 5.3. The relative susceptibility of Neuro-2a and NSC-34 cells to the formation of Fluc-based inclusions.
Neuro-2a and NSC-34 cells were transiently transfected to express FlucWT-EGFP or FlucDM-EGFP and analysed by
PulSA 48 h post-transfection. (A) Gating strategy used to determine the fraction of live cells with inclusions as a
function of Fluc-EGFP expression. Overlay histograms of untransfected (grey) and FlucDM-EGFP (blue) transfected
cells were generated to identify transfected cells for subsequent analyses. The frequency histogram of EGFP
fluorescence was then subdivided into 16 bins of equal size (based on a log scale), whereby bin 1 represents the
lowest, and bin 16 the highest level of Fluc-EGFP expression (indicated). PulSA was then applied to obtain (B) the
proportion of Neuro-2a and NSC-34 cells with Fluc-based inclusions with increasing amounts of Fluc. Data are
presented as the bin number plotted against the mean ± S.E.M. (n=3) percentage of cells containing inclusions.
Significant differences between group means were determined using a two-way ANOVA (P < 0.05) followed by a
Bonferroni's post-hoc test. Sample group means determined to be statistically different from each other within the
same bin number are indicated (***P < 0.001).

As a third approach to measure the relative capacities of NSC-34 and Neuro-2a cells to maintain
aggregation-prone Fluc in a soluble state, FloIT was performed as previously described (Whiten
et al., 2016). In Neuro-2a cells expressing FlucWT-EGFP or FlucDM-EGFP, the number of
inclusions/100 cells was 5 ± 1 and 9 ± 1, respectively (Figure 5.4A). In NSC-34 cells transfected
to express FlucWT-EGFP or FlucDM-EGFP, the number of inclusions/100 cells was 4 ± 1 and 15 ±
2, respectively. The FloIT-derived aggregation-index (FloITAI) again indicated that NSC-34 cells
are more susceptible to inclusion formation by FlucDM since these cells were found to have a
FloITAI that was significantly higher than Neuro-2a cells (Figure 5.4B).
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Figure 5.4. The formation of inclusions by Fluc in Neuro-2a and NSC-34 cells, as assessed by FloIT. Neuro-2a
and NSC-34 cells were transiently transfected to express EGFP, FlucWT-EGFP or FlucDM-EGFP and were analysed
by FloIT 48 h post-transfection. (A) The number of inclusions measured in Neuro-2a and NSC-34 cells transiently
transfected to express FlucWT-EGFP or FlucDM-EGFP. (B) FloITAI calculated for Neuro-2a and NSC-34 cells
transfected with Fluc constructs. The FloITAI was calculated as the ratio of the number of inclusions per 100 cells,
divided by the EGFP geometric mean of EGFP-positive cells. Data in (A) and (B) are presented as the mean ± S.E.M
(n=3). Significant differences between group means were determined using an unpaired two-tailed Student’s t-test
(*P < 0.05 and ** = P < 0.01).

5.3.2

The relative toxicity of FlucDM inclusion formation in Neuro-2a and NSC-34 cells

The localisation of misfolded proteins into inclusions in cells is associated with cytotoxicity
(Lang-Rollin et al., 2003). To assess whether there were cell-type dependent differences in the
toxicity associated with inclusion formation by an aggregation-prone protein, the cytotoxicity of
Fluc expression in Neuro-2a and NSC-34 cells was also assessed using real-time imaging, as
described previously (McAlary et al., 2016). Interestingly, Neuro-2a cells expressing FlucWT had
increased survival compared to cells expressing EGFP alone at most points throughout the
incubation; however, NSC-34 cells transfected to express FlucWT had lower overall survival
relative to those expressing EGFP alone (Figure 5.5A). After 192 h, NSC-34 cells expressing
FlucWT had significantly reduced survival compared to Neuro-2a cells expressing the same protein.
For both cell lines, the survival of cells transfected with FlucDM was lower, relative to those cells
expressing EGFP alone (Figure 5.5B). Moreover, the survival of NSC-34 cells expressing FlucDM
was markedly lower than that of Neuro-2a cells expressing this same protein. Thus, this data
demonstrates that aggregation-prone Fluc is more cytotoxic to NSC-34 cells than Neuro-2a cells.
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Figure 5.5. The relative toxicity of Fluc-EGFP expression compared to EGFP expression alone over time.
Neuro-2a and NSC-34 cells were transiently transfected to express EGFP, FlucWT-EGFP or FlucDM-EGFP and were
analysed over a 192 h time-course to examine the toxicity of cells expressing Fluc-EGFP constructs in real-time
relative to cells expressing EGFP alone, using the IncuCyte® automated fluorescence microscope. Neuro-2a or NSC34 cells expressing (A) FlucWT-EGFP or (B) FlucDM-EGFP. Data are presented as the mean ± S.E.M (n=3) of the fold
change in EGFP-positive cells/total number of cells, relative to cells expressing EGFP. Significant differences
between group means at the 192 h end-point were determined using a two-tailed Student’s t-test (*P < 0.05 and ** =
P < 0.01).

5.3.3

Identification of proteins associated with FlucDM inclusions in Neuro-2a and NSC-34

cells
The data presented above indicates that Fluc is more susceptible to protein aggregation into
inclusions when expressed in NSC-34 cells compared to Neuro-2a cells. To further investigate
potential reasons for this, the proteins that associate with FlucDM inclusions when they are formed
in these two cell lines was established. As a result of their large molecular mass, FlucDM inclusions
become trapped in the stacking gel during the migration of proteins as a result of SDS-PAGE
(Shevchenko et al., 2007). This was exploited in order to purify FlucDM inclusions and identify the
other proteins associated with them. Thus, Neuro-2a and NSC-34 cells expressing FlucDM-EGFP
were harvested, lysed and the insoluble proteins extracted for loading onto an SDS-PAGE gel.

Cell lysates from Neuro-2a and NSC-34 cells that were transfected to express FlucDM contained a
fluorescent band in the well of the stacking gel, indicative of EGFP-tagged FlucDM (Figure 5.6A).
The fluorescence detected in the wells of the Neuro-2a samples was higher than that of the NSC34 cells and is likely due to differences in transfection efficiency. Very low levels of fluorescence
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were also observed in the stacking gel of the untransfected Neuro-2a and NSC-34 cell lysates.
This likely arises due to autofluorescence from proteins such as collagen or elastin, cellular
organelles such as mitochondria or lysosomes, or cyclic ring containing molecules, including
NADPH or aromatic amino acids (Blomfield and Farrar, 1969, Fujimoto et al., 1977, Andersson
et al., 1998). There were no discernible differences between the samples with regard to the profile
of proteins that migrated within the resolving gel following SDS-PAGE (Figure 5.6B). Proteins
trapped in the stacking gel that contained FlucDM were isolated for proteomic mass spectrometry.
The corresponding region of the stacking gel from samples containing cell lysate from
untransfected cells was used as controls in the mass spectrometry analyses (regions indicated by
the arrow).

Figure 5.6. Isolation and purification of FlucDM-EGFP inclusions by SDS-PAGE. Neuro-2a and NSC-34 cells
were transfected (or not) to express FlucDM-EGFP and 48 h post-transfection were harvested, fractionated and the
insoluble protein from each sample was quantified and placed into native loading buffer (non-denaturing, nonreducing conditions) for loading prior to being subjected to electrophoretic separation by SDS-PAGE. (A) SDS-PAGE
gel imaged following exposure to 488 nm light to detect fluorescence from EGFP-tagged FlucDM. High molecular
mass proteins which are excited at 488 nm and are trapped in the stacking gel are indicated by the arrow. (B) SDSPAGE gel stained with Coomassie Blue showing total protein in the lysates from these cells. Biological triplicates of
cells transfected with FlucDM-EGFP are shown, along with insoluble protein from cell lysates of untransfected Neuro2a and NSC-34 cells (Unt). Molecular masses of the protein standards are shown to the left of the gel (in kDa).

Of the 676 proteins identified in the mass spectrometric analysis of proteins associated with
FlucDM inclusions, 259 (38.3%) were only detected in Neuro-2a cells and 176 (26%) were only
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detected in NSC-34 cells (Figure 5.7A) (see Table 8.1 in Appendix II for the full list of proteins
identified). Proteins implicated in neurodegenerative diseases, such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, spinocerebellar ataxia, ALS and prion-related diseases,
were found to be enriched within the FlucDM inclusions in both Neuro-2a and NSC-34 cells (Figure
5.7B). Other highly enriched KEGG pathways identified include those involved in cellular
functions such as transcription, translation, cell cycle control and cellular respiration and
metabolism. The remaining proteins identified corresponded to KEGG pathways that represent
major arms of the proteostasis network, including proteasomal degradation and protein processing
in the ER. In both Neuro-2a and NSC-34 cells, the most highly represented classes of proteins
identified associated with FlucDM inclusions by PANTHER analysis were metabolic enzymes,
RNA binding proteins (i.e. translational machinery), cytoskeletal proteins, proteins involved in
transport and chaperones (Figure 5.7C). Overall, the classes of proteins identified to be associated
with FlucDM inclusions and the relative distribution of these protein classes was nearly identical in
the two cell lines.
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Figure 5.7. Distribution and enrichment of the KEGG pathways and classes of proteins identified within FlucDM
inclusions by proteomic mass spectrometry. Proteins associated with FlucDM inclusions from Neuro-2a and NSC34 cells were identified by mass spectrometry. (A) The total number of proteins identified within FlucDM inclusions
from Neuro-2a (purple) and NSC-34 (blue) cells. (B) The functional enrichment of KEGG pathways represented by
proteins identified within FlucDM inclusions in Neuro-2a and NSC-34 cells. Only KEGG pathways that were
significantly enriched are shown (threshold set to P ≤ 0.05). Colours represent P-values, whereby the lowest values
(highest enrichment) are in black (P < 0.001), and the highest values (lowest enrichment) are in yellow (P ≤ 0.05) and
greyed-out boxes represent a pathway not enriched in that cell type. (C) PANTHER analysis of protein classes most
enriched within FlucDM inclusions in Neuro-2a (left) and NSC-34 (right) cells.

Finally, STRING analysis was conducted on the 241 proteins found within FlucDM inclusions in
both Neuro-2a and NSC-34 cells. The most highly represented protein classes were ribosomal
proteins, translational machinery, proteasome components and chaperone proteins (Figure 5.8).
These protein classes, all of which are components of the proteostasis network, act as interaction
hubs, linking all the proteins found to associate with FlucDM inclusions in both cell lines.
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Figure 5.8. STRING network analysis of proteins identified within FlucDM inclusions in both Neuro-2a and NSC-34 cells. The reactome network was constructed using the
STRING application in Cytoscape. Proteins within the most highly represented protein classes include ribosomal proteins (purple), proteins involved in translation (orange),
proteasomal machinery (teal) and chaperone proteins (red). Nodes denoted in grey represent proteins not clustered based on protein class. Grey lines connecting nodes represent
protein-protein associations.
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5.3.4

The effect of modulating key arms of the proteostasis network on FlucDM inclusion

formation in Neuro-2a and NSC-34 cells
5.3.4.1 The heat shock response
The relative susceptibility to inclusion formation between cell types may be dependent upon
intrinsic differences in the cellular pathways that act to maintain proteostasis. Thus, this work
sought to modulate key pathways involved in protein quality control, to identify those that are
most critical in preventing the formation of inclusions by aggregation-prone proteins in Neuro-2a
and NSC-34 cells. HSF1 is the master regulator of the heat shock response, a major arm of the
protein quality control network, which is activated under conditions of cellular stress (Vihervaara
and Sistonen, 2014). The activation of HSF1 leads to increased stress-induced gene transcription
leading to chaperone induction, refolding of protein aggregates, and the re-establishment of
proteostasis (Morimoto, 2011). Thus, to characterise the effect of increased HSF1 expression on
FlucDM inclusion formation, HSF1 variants were co-expressed with FlucDM-EGFP in Neuro-2a
and NSC-34 cells. These HSF1 isoforms have been previously described (Taylor et al., 2007) and
include wild-type HSF1 (HSF1WT), a constitutively active form of HSF1 (HSF1+) which has a
deletion of the sequence encoding amino acids (Δ203-315) of the regulatory domain, and an
inactive variant of HSF1 (HSF1-) that has a deletion of amino acids (453-523) located in the
transcription activation domain (Figure 5.9A). As assessed by FloIT, the number of FlucDM
inclusions was significantly reduced in both Neuro-2a and NSC-34 cells upon co-expression of
HSF1WT compared to cells co-expressing HSF1-, the transcriptionally inactive HSF1 isoform
(Figure 5.9B). In Neuro-2a cells, co-expression of the constitutively active HSF1+ isoform did not
significantly reduce inclusion formation by FlucDM; however, FlucDM inclusion formation was
significantly reduced by co-expression of HSF1+ in NSC-34 cells.

Whole cell fractionation by NP-40 detergent solubilisation followed by immunoblotting revealed
a similar trend to that observed by FloIT. Thus, the amount of FlucDM found in the insoluble
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fraction was reduced for both Neuro-2a and NSC-34 cells expressing HSF1WT or HSF1+ compared
to the HSF1- control (Figure 5.9C). In both cell lines, the amount of FlucDM observed in the soluble
fraction increased slightly upon co-expression of HSF1+ and was markedly higher in cells coexpressing HSF1WT. Immunoblotting with an anti-HSF1 antibody confirmed the overexpression
of the various HSF1 isoforms in these cells following transfection. To test whether overexpression
of HSF1 was consistent with activation of the heat shock response and subsequent upregulation
of common stress-inducible Hsps, cell lysates were probed for Hsp40, Hsc70 (constitutive Hsp70)
and Hsp90 expression. Heat-shocked HeLa cell lysate was used as a positive control for the
expression of these Hsps in this experiment (Figure 5.9D). Immunoblotting revealed that Hsp40,
Hsc70 and Hsp90 were endogenously expressed in Neuro-2a and NSC-34 cells. Furthermore, the
levels of Hsp40 and Hsp90 increased in Neuro-2a and NSC-34 cells transfected to express HSF1+
compared to cells expressing HSF1-, suggesting that expression of the constitutively active form
of HSF1 does result in the activation of stress-inducible chaperones. Interestingly, levels of these
Hsps were not substantially increased in cells expressing HSF1WT, which suggests that the ability
of HSF1WT to inhibit FlucDM inclusion formation may be independent of its transcriptional activity.
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Figure 5.9. The effect of HSF1 on inclusion formation by FlucDM in Neuro-2a and NSC-34 cells. (A) Schematic
overview of plasmids encoding HSF1WT and constitutively active HSF1 (HSF1+) or inactive HSF1 (HSF1-) mutational
variants. The DNA binding domain (DBD) was unaltered in all variants, whilst the regulatory domain (RD) (Δ203315) and the transactivation domain (TAD) (Δ453-523) were deleted in the active and inactive forms of HSF1,
respectively. Neuro-2a and NSC-34 cells were transiently co-transfected to express FlucDM-EGFP and HSF1WT,
HSF1+ or HSF1-. Cells were analysed 48 h post-transfection by (B) FloIT or (C and D) NP-40 fractionation and
subsequent immunoblotting. Data in (B) are presented as the mean ± S.E.M (n=3) of the number of inclusions per
100 cells. Significant differences between group means were determined using a one-way ANOVA (P < 0.05)
followed by a Tukey’s post-hoc test. Group means determined to be statistically different from each other are indicated
(*P < 0.05 and ***P < 0.001). In (C) an anti-GFP antibody was used to detect FlucDM in the insoluble pellet (P) and
soluble (S) fractions and expression of the HSF1 variants in the total protein fraction was detected with an anti-HSF1
antibody. For (D) in the total protein fraction, antibodies against Hsp40, Hsc70 and Hsp90 were used to detect
expression of the corresponding Hsps. Total protein was used as a loading control. A heat-shocked (HS; at 42°C for
1 h with 3 h recovery at 37°C) HeLa cell lysate was used as a positive control to probe for expression of Hsps. The
blots shown are representative of two experiments.

An interesting observation following the co-expression of the HSF1 variants with FlucDM was that
a decrease in the amount of insoluble protein directly correlated to an increase in the amount of
soluble FlucDM present in lysates from both Neuro-2a and NSC-34 cells (see Figure 5.9C). To
further investigate this, the formation of FlucDM inclusions in cells co-expressing the HSF1
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variants was assessed by epifluorescence microscopy. There was little difference in the appearance
of the FlucDM inclusions observed in Neuro-2a (top) or NSC-34 (bottom) cells expressing either
HSF1- (left) or HSF1+ (centre), albeit there appeared to be a slight reduction in the overall number
of inclusions in cells expressing HSF1+ (Figure 5.10). Thus, the Fluc inclusions formed in these
cells appeared as discrete, highly fluorescent puncta. In contrast, in cells expressing HSF1WT
(right), the majority of the green fluorescence appeared diffuse and was located throughout the
cytoplasm and the nucleus. In very few of these cells were punctate FlucDM inclusions observed.
Thus, these results support the findings of the fractionation and immunoblotting and indicate that
HSF1 reduces inclusion formation by FlucDM and maintains the protein in a soluble state.

Figure 5.10. The formation of inclusions by FlucDM in Neuro-2a and NSC-34 cells following overexpression of
HSF1, as assessed by epifluorescence microscopy. Neuro-2a and NSC-34 cells were transiently co-transfected to
express FlucDM-EGFP and either an inactive form of HSF1 (HSF1-), a constitutively active HSF1 (HSF1+) or HSF1WT
Live cells were analysed 48 h post-transfection by epifluorescence microscopy to examine the formation of inclusions.
Images are representative of three experiments and show epifluorescence micrographs of Neuro-2a (top) and NSC34 (bottom) cells co-transfected with FlucDM-EGFP and HSF1- (left), HSF1+ (centre) or HSF1WT (right). EGFP
fluorescence was detected by excitation at 488 nm. All images were taken using a Leica DMi8 fluorescence
microscope and the 20× objective lens. Scale bar represents 100 µm.
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5.3.4.2 Degradation by the ubiquitin-proteasome system
To ascertain whether the ubiquitin-proteasome system plays a critical role in preventing the
aggregation of FlucDM into inclusions in Neuro-2a and NSC-34 cells, the Ub[9]-mRFP plasmid was
co-transfected into cells for the overexpression of ubiquitin, with the aim of upregulating
proteasomal activity. Briefly, the translation of the Ub[9]-mRFP precursor results in the expression
of nine free ubiquitin monomers and one fluorescent mRFP protein (Figure 5.11A) (Salomons et
al., 2009). The drug MG132 was used as a proteasome inhibitor in these experiments. Treatment
of Neuro-2a and NSC-34 cells with MG132 significantly increased the number of FlucDM
inclusions compared to DMSO-treated cells or cells expressing Ub[9]-mRFP; however, for both
cell types, expression of Ub[9]-mRFP did not change the number of inclusions formed compared
to the DMSO-treated controls (Figure 5.11B).

In these cells, the distribution of FlucDM found in the insoluble fraction mirrored the results
obtained by FloIT, whereby increased insoluble FlucDM was observed in the lysates of cells treated
with MG132 (Figure 5.11C). There was a slight reduction (Neuro-2a) or increase (NSC-34) in the
amount of insoluble FlucDM observed following expression of Ub[9]-mRFP; however, the amount
of soluble FlucDM did not differ substantially between treatment groups. Inhibition of the
proteasome in these experiments was confirmed by an increase in polyubiquitinated species,
observed as large, high molecular mass smears by immunoblotting with an anti-ubiquitin antibody
in both the soluble and insoluble fractions (Figure 5.11D). However, the amount of free ubiquitin
did not appear to change substantially in cells transfected to express Ub[9]-mRFP compared to the
controls. The relatively small mass of the protein can make transfer onto the blotting membrane
difficult, given that smaller proteins need less time to transfer, which can lead to ‘over-transfer’
(Otter et al., 1987, Bolt and Mahoney, 1997, Kurien and Hal Scofield, 2015). Thus, levels of free
ubiquitin following expression of Ub[9]-mRFP were assessed by immunostaining with a ubiquitin
probe followed by confocal microscopy.
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Figure 5.11. The effect of proteasome modulation on inclusion formation by FlucDM in Neuro-2a and NSC-34
cells. (A) Schematic representation of the plasmid encoding Ub[9]-mRFP for the overexpression of ubiquitin. The
polyubiquitin precursor (UBC) gene, encoding nine ubiquitin monomers, is in frame with mRFP and downstream of
a CMV promoter for mammalian expression. Following transcription and translation, the ubiquitin precursors are
rapidly processed by ubiquitin C-terminal hydrolases and the chimeric Ub[9]-mRFP is converted into nine ubiquitin
monomers and one fluorescent mRFP protein. Neuro-2a and NSC-34 cells were co-transfected to express FlucDMEGFP and Ub[9]-mRFP or mRFP (as a control) and, 42 h post-transfection, cells co-expressing mRFP were treated
with the proteasome inhibitor MG132 (10 µM) or a DMSO as a control. Cells were incubated for a further 6 h and
then analysed by (B) FloIT or (C and D) NP-40 fractionation and subsequent immunoblotting. Data in (B) are
presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells. Significant differences between group
means were determined using a one-way ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means
determined to be statistically different from each other are indicated (**P < 0.01 and ***P < 0.001). In (C) an antiGFP antibody was used to detect FlucDM in the insoluble pellet (P) and soluble (S) fractions and total protein was used
as a loading control. In (D) an anti-ubiquitin antibody was used to detect high molecular mass, polyubiquitinated
proteins in the insoluble pellet (P) and soluble (S) fractions, and free ubiquitin monomers in the soluble fraction. The
blots shown are from a single experiment.
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In order to confirm that transfection with the Ub[9]-mRFP plasmid results in the overexpression of
ubiquitin, the probe tUi-HA, which has previously been shown to bind strongly and specifically
to free ubiquitin (Choi et al., 2019, Farrawell et al., 2020) was tested. Neuro-2a and NSC-34 cells
were transfected to express FlucDM-EGFP and either Ub[9]-mRFP or mRFP alone (as a negative
control) and, following immunostaining with the free ubiquitin probe tUi-HA, fixed cells were
imaged by confocal microscopy. Neuro-2a cells transfected to express the mRFP control exhibited
diffuse expression of the protein (Figure 5.12A; top). As expected, the tUi-HA probe for free
ubiquitin was detected in all cells at a relatively low level, with increased expression observed in
some cells. In the mRFP alone expressing control cells, increased expression of ubiquitin did not
correlate with higher levels of mRFP. In contrast, in Neuro-2a cells expressing Ub[9]-mRFP, the
fluorescence from the mRFP protein directly correlated with increased levels of immunostaining
with the tUi-HA probe (Figure 5.12A; bottom). Similarly, in NSC-34 cells, expression of mRFP
alone was not associated with increased amounts of free ubiquitin (Figure 5.12B; top), whereas
cells expressing Ub[9]-mRFP did contain high levels of immunostaining with the tUi-HA probe
(Figure 5.12B; bottom). Together, this confirms that expression of Ub[9]-mRFP is correlated with
increased expression of free ubiquitin in these cells.
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Figure 5.12. Free ubiquitin staining in Neuro-2a and NSC-34 cells overexpressing ubiquitin and FlucDM, as
assessed by confocal microscopy. (A) Neuro-2a and (B) NSC-34 cells were co-transfected to express FlucDM-EGFP
and mRFP (top) or Ub[9]-mRFP (bottom) and, 48 h post-transfection, were fixed, permeabilised and analysed
following immunostaining by confocal microscopy. Expression of mRFP (cyan) and FlucDM-EGFP (green) were
detected following excitation at 552 nm and 488 nm, respectively. Expression of the HA-tagged free ubiquitin tUi
probe (magenta) was excited with a 638 nm laser and nuclei stained with Hoechst 33482 (blue) were excited at 405
nm. Images are representative of three experiments and examples of cells containing high levels of ubiquitin
(following transfection with Ub[9]-mRFP) co-localised with HA-tagged tUi (free ubiquitin probe) are denoted by the
arrowheads. All images were taken at 20× magnification using a Leica SP8 confocal microscope. Scale bars represents
100 µm.
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5.3.4.3 Autophaghic degradation
To assess the impact of autophagy on the formation of inclusions by FlucDM, Neuro-2a and NSC34 cells were treated with either rapamycin, a previously identified inducer of autophagy
(Ravikumar et al., 2004) or the autophagy inhibitor, bafilomycin A1 (Yoshimori et al., 1991,
Yamamoto et al., 1998). As measured by FloIT, treatment of both Neuro-2a and NSC-34 cells
with bafilomycin A1 resulted in a significant increase in the number of FlucDM inclusions formed
in cells compared to the DMSO-treated cells (Figure 5.13A). Treatment with rapamycin had no
effect on inclusion formation by FlucDM in either Neuro-2a or NSC-34 cells. Similar results were
obtained following NP-40 cell fractionation and immunoblotting of lysates from these cells. Thus,
treatment with the autophagy inhibitor bafilomycin A1 increased the amount of FlucDM found in
the insoluble pellet fraction in both Neuro-2a and NSC-34 cells (Figure 5.13B). Interestingly,
treatment with rapamycin led to an apparent increase in the amount of insoluble FlucDM in Neuro2a cell lysates, but decreased it in NSC-34 cells. Furthermore, the amount of soluble FlucDM in
NSC-34 cells treated with rapamycin increased relative to the DMSO-treated cells. Inhibition of
autophagy by bafilomycin A1 was confirmed by the increased expression of SQSTM1/p62 and
microtubule-associated protein-light chain 3II (LC3II) (commonly used markers of autophagy).
Similarly, conversion of LC3I to LC3II, which is associated with mammalian autophagosome
formation (Kabeya et al., 2000), increased following treatment with rapamycin.
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Figure 5.13. The effect of autophagy regulation on inclusion formation by FlucDM in Neuro-2a and NSC-34
cells. Neuro-2a and NSC-34 cells were transfected to express FlucDM-EGFP and, 24 h post-transfection, cells were
treated with either bafilomycin A1 (1 µM), rapamycin (1 µM) or DMSO as a control. Cells were incubated for a
further 16 h and then analysed by (A) FloIT or (B) NP-40 fractionation and subsequent immunoblotting. Data in (A)
are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells. Significant differences between
group means were determined using a one-way ANOVA (P < 0.05) followed by a Tukey’s post-hoc test. Group means
determined to be statistically different from each other are indicated (**P < 0.01 and ***P < 0.001). In (B) an antiGFP antibody was used to detect FlucDM in the insoluble pellet (P) and soluble (S) fractions. In the total protein
fraction, the expression of SQSTM1/p62 and expression of LC3I/LC3II was detected with an anti-SQSTM1/p62
antibody and an anti-LC3B antibody, respectively. Total protein was used as a loading control. The blots shown are
from a single experiment.

5.3.4.4 The ER-stress response
To assess the impact of the ER stress pathway on the capacity of Neuro-2a and NSC-34 cells to
prevent inclusion formation by FlucDM, cells expressing FlucDM were treated with either
azoramide, which has been shown to upregulate ER-resident chaperones for improved ER protein
folding (Fu et al., 2015), or thapsigargin, a well-known inducer of ER stress in mammalian cells
(Oslowski and Urano, 2011). Following treatment with thapsigargin, the number of inclusions
formed by FlucDM increased in both Neuro-2a and NSC-34 cells compared to the respective
DMSO-treated controls, as assessed by FloIT (Figure 5.14A). Treatment with azoramide did not
reduce inclusion formation by FlucDM in either cell line; rather, there was a trend by which the
number of inclusions increased relative to the DMSO control, however, this did not reach
statistical significance. Similar results were obtained by NP-40 cell fractionation and subsequent
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immunoblotting of cell lysates from these samples. Thus, the amount of insoluble FlucDM
increased following treatment with either azoramide or thapsigargin in both Neuro-2a and NSC34 cells compared to the DMSO-treated control cells (Figure 5.14B). Interestingly, the amount of
soluble FlucDM increased in Neuro-2a cells treated with azoramide, and even more so in cells
treated with thapsigargin. Neither of these treatments led to a change in the amount of soluble
FlucDM in NSC-34 cells.

Expression of the major ER-resident chaperone GRP78/BiP (HspA5) confirmed that treatment
with thapsigargin induced ER stress. Treatment with azoramide increased the expression of
GRP78/BiP relative to the DMSO-treated control in both cells lines, a result which is consistent
with previous work (Figure 5.14B) (Fu et al., 2015). Whilst treatment with either azoramide or
thapsigargin both resulted in the increased expression of the ER-resident chaperone GRP78/BiP,
the mechanistic action of these drugs is distinct. Thapsigargin induces ER stress by inhibiting the
ER Ca2+/ATPase, resulting in perturbation of calcium homeostasis in the cell. As a result, unfolded
proteins accumulate in the ER and cause ER stress (Oslowski and Urano, 2011), which is often
distinguished by the increased expression of GRP78/BiP in response to ER stress. Azoramide
treatment is associated with an increase in ER Ca2+/ATPase levels, leading to enhanced proteinfolding in the ER and subsequently, increased expression of GRP78/BiP and other ER-resident
chaperone proteins, such as DNAJC3, DNAJC10 and HspH4 (Fu et al., 2015). The expression of
GRP78/BiP can therefore be used as marker to report on the functional status of the ER as it is
involved in both the general folding of proteins and in the maintenance of proteostasis following
ER stress.
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Figure 5.14. The effect of ER stress modulation on inclusion formation by FlucDM in Neuro-2a and NSC-34
cells. Neuro-2a and NSC-34 cells were transfected to express FlucDM-EGFP and, 24 h post-transfection, cells were
treated with either azoramide (20 µM), thapsigargin (3 µM) or, as a control, an equivalent volume of DMSO. Cells
were incubated for a further 16 h and then analysed by (A) FloIT or (B) NP-40 fractionation and subsequent
immunoblotting. Data in (A) are presented as the mean ± S.E.M (n=3) of the number of inclusions per 100 cells.
Significant differences between group means were determined using a one-way ANOVA (P < 0.05) followed by a
Tukey’s post-hoc test. Group means determined to be statistically different from each other are indicated (**P < 0.01
and ***P < 0.001). In (B) an anti-GFP antibody was used to detect FlucDM in the insoluble pellet (P) and soluble (S)
fractions. In the total protein fraction, the expression of the ER-resident chaperone GRP78/BiP was detected with an
anti-GRP78/BiP antibody and total protein was used as a loading control. The blots shown are from a single
experiment.
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5.4

Discussion

As the accumulation of aggregation-prone proteins into inclusions is a pathological hallmark of
many diseases, it is critical to understand the precise roles various proteostasis pathways have in
preventing this process. Moreover, quantitatively assessing the proteostasis capacity of a cell
remains one of the major challenges in the field. The proteostasis capacity defines its ability to
prevent protein accumulation and aggregation through the regulation of the protein quality control
network. The ability to quantitatively measure the proteostasis capacity of a cell is an important
step towards deciphering why some cell types are more susceptible to the formation of inclusions
(and cause disease) than others. Furthermore, the deterioration of proteostasis capacity with age is
believed to be related to an increase in toxic protein aggregation that is associated with disease
(Brehme et al., 2014, Hipp et al., 2014).

In this work, aggregation indices were derived from flow cytometric analyses of cells expressing
aggregation-prone protein FlucDM. This was done as a first step towards measuring the proteostasis
capacity of cells. Along with real-time fluorescence microscopy, the flow cytometry-derived
aggregation indices demonstrate that NSC-34 cells are more susceptible to inclusion formation by
FlucDM than Neuro-2a cells. Thus, the results demonstrate that lower amounts of FlucDM are
required before inclusions start to form in NSC-34 cells compared to Neuro-2a cells. The level of
expression of an aggregation-prone protein is known to impact the formation of inclusions, with
proteins forming inclusions more readily when expressed at high levels (Arrasate et al., 2004,
Ramdzan et al., 2012, Ormsby et al., 2013, Ramdzan et al., 2013, Ciryam et al., 2015). By taking
into account the level of FlucDM expressed in the cell population, the aggregation-indices derived
from this work enable comparison between different cell types. Moreover, both the PulSAAI and
FloITAI were in accord with each other and the results obtained when cells expressing similar
levels of Fluc were analysed by PulSA. It must be noted that PulSA has a limited capability to
detect cells that contain smaller, punctate inclusions, as is the case for many proteins whose
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aggregation is associated with disease (e.g. TDP-43 and SOD1 aggregation associated with ALS)
(Whiten et al., 2016). For this reason, and since FloIT can enumerate these smaller inclusions in
cell lysates, FloIT may be the preferred method to develop this work in the future as it is broadly
applicable to most (if not all) model systems of intracellular protein aggregation.

Whilst the results of this study highlight that flow cytometric methods can be used as a mediumto-high-throughput approach to measure the proteostasis capacity of cells, they only provide a
snapshot of a cell population at a single point in time. Experiments utilising live cell imaging
techniques can provide valuable temporal information on the rate of inclusion formation in cells
and whether cells die as a result of the toxicity associated with inclusion formation. In this work,
the EGFP-positive cells were tracked over time in order to determine the toxicity of expression of
the Fluc constructs as compared to EGFP alone, in a similar manner to that previously described
to deduce the cytotoxicity associated with SOD1 ALS-causing mutations in comparison to wildtype SOD1 (McAlary et al., 2016). The results demonstrate that whilst expression of FlucDM was
cytotoxic to both cell lines used in this work, it was most cytotoxic to NSC-34 cells. Moreover,
expression of FlucWT was only cytotoxic to NSC-34 cells: the viability of Neuro-2a cells
expressing FlucWT was similar to that of cells expressing EGFP alone. Taken together with the
aggregation-indices derived from the flow cytometry, these results strongly suggest that
aggregation-prone FlucDM more readily forms toxic inclusions in NSC-34 cells compared to
Neuro-2a cells.

One potential reason why NSC-34 cells are more susceptible to cytotoxic inclusion formation than
Neuro-2a cells is that they are less equipped to deal with protein aggregation as it arises. Previous
work has indicated that the global proteomes of Neuro-2a and NSC-34 cells are very similar
(Hornburg et al., 2014); however, the types of proteins that readily associate with aggregationprone proteins as they form inclusions in these cells had never been defined. Differences in the
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classes of proteins found within proteinaceous deposits may begin to explain why some cell types
can more readily prevent inclusion formation (Bergemalm et al., 2010). Mass spectrometry
analysis revealed that the classes of proteins trapped within FlucDM inclusions in Neuro-2a and
NSC-34 cells are near identical. These protein classes include important components of the
systems in place that maintain intracellular proteostasis, including chaperones and components of
the proteasome.

The most enriched classes of proteins identified in FlucDM inclusions in both NSC-34 and Neuro2a cells were those associated with the translational machinery. Indeed, previous work has
suggested that disruption of translation is associated with neurodegenerative disorders. For
example, Halliday et al. (2017) identified a link between the expression of misfolded forms of
prion and tau proteins, and translational repression in vivo. Translation-relevant terms were also
reported by Kamelgarn et al. (2018) in a gene ontology assessment of the proteins contained within
cytoplasmic inclusions formed by the ALS- and frontotemporal dementia-associated fused in
sarcoma (FUS) protein. Moreover, in a humanised mouse model of ALS/frontotemporal dementia,
the expression of mutant FUS inhibited protein synthesis and led to impaired neuronal synaptic
function (López-Erauskin et al., 2018). Furthermore, the unfolded protein response pathway,
which mediates the rate of protein synthesis in cells, is over-activated in the brains of patients with
neurodegenerative diseases (Jackson et al., 2015, Halliday et al., 2017, Bosco, 2018, LópezErauskin et al., 2018, Zhang et al., 2018) and therefore may be a promising target for
pharmacological intervention to alleviate translational repression in neurodegeneration. The
identification of translational machinery within FlucDM inclusions reinforces the notion that the
aggregation of proteins into inclusions disrupts protein translation and this is associated with
neurodegenerative disease pathogenesis.
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Another highly represented class of proteins found within FlucDM inclusions in both cell lines were
chaperones, including members of the Hsp40, Hsp70, Hsp90, Hsp110 families and the chaperonin
TriC/CCT. Previous work has demonstrated the presence of chaperone proteins localised within
proteinaceous deposits. For example, Hsp70 and Hsp40 were found to be associated with
inclusions formed by polyQ-expanded ataxin-1 (Cummings et al., 2001), ataxin-3 (Chai et al.,
1999) and huntingtin (Wyttenbach et al., 2000). Intracellular inclusions formed by mutant SOD1
contain αB-crystallin and Hsc70 (Bergemalm et al., 2010). Hsp70 has been identified in protein
aggregates extracted from the brains of ALS/frontotemporal dementia patients with TDP-43positive proteinopathies (Laferrière et al., 2019). Furthermore, Hsp27 and αB-crystallin were
detected within neurofibrillary tangles of patients with Alzheimer’s disease (Renkawek et al.,
1994). It remains to be determined why chaperone proteins are found within inclusions associated
with neurodegenerative diseases; however, it is likely due to their roles in maintaining the
solubility and function of aggregation-prone proteins. Thus, the presence of chaperones in
inclusions may be due to them having an important role in mitigating the toxicity of inclusions
(e.g. through disaggregation). Conversely, chaperones may localise to inclusions due to them
failing to rescue misfolded proteins from aggregation.

A variety of proteins that play a role in proteostasis were found to be associated with FlucDM
inclusions in both Neuro-2a and NSC-34 cells. These included proteasome components, proteins
related to processing in the ER, and chaperones. Thus, whilst there were few differences between
Neuro-2a and NSC-34 cells with regard to the classes of proteins that associate with FlucDM in
inclusions formed in these cells, these data highlight the important role that protein quality control
pathways of the proteostasis network play in attempting to mitigate cytotoxic protein aggregation.
Whilst the major classes of proteins found to be associated with FlucDM inclusions in Neuro-2a
and NSC-34 cells were similar, the exact proteins identified did differ between cell lines. This
does prompt the question whether the abundance of proteins and complexes may account for the
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differences in proteins identified between these neuronal cell lines. Given this, it is possible that
destabilised FlucDM “seeds” the formation of inclusions which causes other proteins to coaggregate through a nonselective process; however, this was not experimentally tested in this
work. Nonetheless, this prompted further investigation into the impact of the individual protein
quality control pathways in preventing FlucDM inclusion formation in NSC-34 and Neuro-2a cells.

The heat shock response is a stress-inducible pathway that protects cells from conditions that
promote protein misfolding. Since HSF1 is the master regulator of the heat shock response in cells
(Vihervaara and Sistonen, 2014, Gomez-Pastor et al., 2018), activation of HSF1 has been proposed
as a potential therapeutic for the amelioration of protein misfolding diseases (Kampinga and
Bergink, 2016). In this work, as assessed by FloIT, FlucDM inclusion formation was reduced (by
~50%) in Neuro-2a cells by overexpression of HSF1WT, and in NSC-34 cells by overexpression
of HSF1WT or HSF1+. There was a trend by which expression of HSF1+ reduced intracellular
inclusion formation by FlucDM in Neuro-2a cells when analysed by FloIT, however, this result was
not statistically significant. Immunoblotting revealed a marked reduction in insoluble FlucDM in
these Neuro-2a cells, suggesting that expression of HSF1+ does have some capacity to reduce
inclusion formation, but to a lesser extent than HSF1WT. These data are largely consistent with
previous work which demonstrated that inclusions formed by mutant TDP-43 are reduced
following overexpression of HSF1WT or HSF1+ (Chen et al., 2016, Wang et al., 2017). Expression
of HSF1+ reduces the intracellular inclusion formation of polyQ-expanded ataxin-1 (Rimoldi et
al., 2001) and atrophin-1 (Fujimoto et al., 2005). Furthermore, HSF1WT expression in a SOD1
mouse model of ALS delays disease progression (Lin et al., 2013) and decreases the accumulation
of polyQ-expanded androgen receptor in mice, thereby promoting neuronal survival (Kondo et al.,
2013).
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The HSF1+ isoform lacks the regulatory domain and therefore does not need to be released from
chaperone-HSF1 complexes to perform its function. It was hypothesised that expression of HSF1+
would result in the upregulation of downstream HSF1-target Hsps to a similar or greater extent
than HSF1WT expression. This was confirmed in this study; however, HSF1WT was more effective
than HSF1+ at inhibiting FlucDM inclusion formation. Roth et al. (2014) reported that a sustained
heat shock response can impair the protein folding capacity of cells. This may explain why HSF1+
is less effective at inhibiting FlucDM inclusion formation compared to HSF1WT in Neuro-2a and
NSC-34 cells. In addition, upregulation of downstream products of HSF1 activation may be
insufficient to prevent inclusion formation of some aggregation-prone proteins in cells (Bersuker
et al., 2013). This is supported by the results of this work since expression of HSF1+, but not
HSF1WT, resulted in the increased expression of Hsps such as Hsp40 and Hsp90, however
overexpression of HSF1WT was more effective at preventing the formation of inclusions by
FlucDM. This suggests that the anti-aggregation capacity of HSF1WT is not solely dependent upon
the upregulation of Hsps. Indeed, the increase in soluble FlucDM observed by immunoblotting and
epifluorescence microscopy indicates that HSF1WT expression may have downstream effects on
other arms of the proteostasis machinery. For example, HSF1 activation can induce the expression
of products known to be responsible for trafficking misfolded proteins for degradation via the
ubiquitin-proteasome system or by autophagy (Trinklein et al., 2004, Vihervaara and Sistonen,
2014). Moreover, heat shock can accelerate the rate of endogenous protein degradation by the
proteasome in mammalian cells, which is evidenced by an increase in the ubiquitination of cellular
proteins and a decrease in the levels of free ubiquitin (Parag et al., 1987). Thus, activation of HSF1
may upregulate downstream products of the heat shock response in Neuro-2a and NSC-34 cells,
which help to maintain FlucDM in a soluble state so that it can be acted upon by the degradation
machinery. Overall, the data presented here provide evidence that activation of HSF1 can bolster
the capacity of Neuro-2a and NSC-34 cells to prevent protein aggregation. Thus, HSF1 activation
may be a therapeutic approach for the treatment of neurodegenerative diseases (Neef et al., 2010,

163

Chapter 5 – Method to measure the proteostasis capacity of cells
Neef et al., 2011, Kampinga and Bergink, 2016, Dayalan Naidu and Dinkova-Kostova, 2017,
Gomez-Pastor et al., 2018). Future work should aim to elucidate the precise mechanisms by which
activation of HSF1 inhibits intracellular inclusion formation.

Previous studies have indicated that the ubiquitin-proteasome system degrades up to 90% of the
aberrant, short-lived, denatured, destabilised or damaged nuclear and cytosolic proteins within
eukaryotic cells (Rock et al., 1994, Hershko and Ciechanover, 1998, Glickman and Ciechanover,
2002, Luo and Le, 2010). It is also widely accepted that defects in the ability of the proteasome
to degrade misfolded or aggregated proteins are linked to various neurodegenerative disorders
(Mori et al., 1987, Manetto et al., 1988, Li et al., 2010). The results from this work indicate that
inhibition of proteasomal degradation in Neuro-2a or NSC-34 cells expressing FlucDM leads to a
significant increase in the formation of inclusions in these cells. Furthermore, overexpression of
free ubiquitin did not have a significant effect on FlucDM inclusion formation in these cells, at least
under the experimental conditions tested in this work. The increase in FlucDM aggregation in cells
following treatment with MG132 suggests that this aggregation-prone protein is degraded by the
proteasome, a result that is consistent with the results presented in Chapter 4 of this thesis. While
proteasome inhibitors are cheap and readily available, activators of the proteasome are less well
described. In this work, overexpression of ubiquitin was chosen as an activator of proteasomal
degradation since an increase in free ubiquitin correlates to the accelerated ubiquitination of
destabilised proteins for subsequent targeting for degradation by the proteasome (Salomons et al.,
2009). However, further work is required to confirm that overexpression of ubiquitin does increase
proteasome activity in these cells.

Previous studies have identified that small molecule proteasome activators can enhance
proteasomal degradation to inhibit disease-related protein aggregation in cells. For example, Lee
et al. (2010) utilised a small molecule inhibitor of ubiquitin-specific protease 14, a proteasome-
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associated deubiquitinating enzyme, to promote the degradation of misfolded proteins such as tau
and TDP-43 (Lee et al., 2010). Similarly, the overexpression of the cellular proteasome activator
28 was shown to improve cell viability in a polyQ-expanded huntingtin-expressing neuronal cell
line (Seo et al., 2007). To test whether enhanced proteasome activity (i.e. using small molecule
proteasome activators) can boost the ability of NSC-34 cells to prevent FlucDM inclusion
formation, further studies are required. Upregulation of the ubiquitin-proteasome system through
proteasomal activation may offer a novel therapeutic strategy to reduce the accumulation of
misfolded proteins in cells that have been exposed to cellular stress or during aging.

In some cases the proteasome is unable to the facilitate degradation of aggregated proteins (Lee
and Goldberg, 1998). Induced activation of autophagy via certain drugs (e.g. rapamycin) has been
shown to be effective in removing aggregates that are unable to be degraded by the proteasome
(Rubinsztein et al., 2012). Moreover, previous work has demonstrated that activation of autophagy
can alleviate protein aggregation and its associated toxicity in disease models of Parkinson’s
disease (Webb et al., 2003), Alzheimer’s disease (Haung Yu et al., 2005) and Huntington’s disease
(Ravikumar et al., 2004, Bjørkøy et al., 2005). These results highlight the important role of
autophagy in clearing aggregation-prone proteins, independent of the proteasome. To decipher
whether autophagy plays a significant role in the degradation of aggregation-prone FlucDM in
Neuro-2a and NSC-34 cells, cells expressing FlucDM were treated with the autophagy inhibitor
bafilomycin A1 or autophagy activator rapamycin. The results from these experiments show there
was no significant effect of rapamycin treatment on inclusion formation in either cell line.
However, upon treatment with bafilomycin A1, FlucDM inclusion formation increased
significantly, such that it reached similar levels to that measured following inhibition of the
proteasome. These result suggest that autophagy does play a key role in the clearance of
aggregation-prone FlucDM in these cells; however, since rapamycin treatment did not further
decrease FlucDM inclusion formation, this suggests that the autophagic pathway is already maximal
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in these cells and so is not able to be further boosted by rapamycin. This is further supported by
the results of the immunoblotting assay, which show that the conversion of LC3I to LC3II (i.e.
autophagosome formation) is only slightly increased following treatment with rapamycin.

The final protein quality control network investigated in this work was the effect of ER stress,
which triggers a dynamic signalling pathway known as the unfolded protein response (Hetz, 2012).
The ER is an important component of the cell that helps to ensure correct folding of many newly
synthesised secretory and transmembrane proteins. Perturbations in ER homeostasis can result in
an accumulation of unfolded proteins in the ER lumen, termed ER stress (Oslowski and Urano,
2011). Ongoing ER stress, owing to mutations in disease-related genes or malfunctions in the
secretory pathway, can lead to cell death and, in some cases, neurodegeneration (Ron and Walter,
2007, Hetz and Mollereau, 2014). In this study, treatment of Neuro-2a and NSC-34 cells
expressing FlucDM with thapsigargin significantly increased inclusion formation in cells, as
measured by FloIT, thus demonstrating that ER stress can induce cytosolic accumulation of
FlucDM inclusions. Similar to activators of the proteasome, molecules that promote ER protein
folding to reduce ER stress are limited. Azoramide is one known small-molecule modulator of the
unfolded protein response that has been reported to lead to an increase in the expression of ERresident chaperones (e.g. HspH4, GRP78/BiP/HspA5, DNAJC3) for improved protein folding in
the ER (Fu et al., 2015); however, its efficacy to prevent intracellular inclusion formation had not
been previously tested. Whilst treatment with azoramide was found to increase expression of
GRP78/BiP, it had no effect on inclusion formation by FlucDM in Neuro-2a or NSC-34 cells.
Although the working concentrations of azoramide used in this research were chosen based upon
a previous study (Fu et al., 2015), it may be that the concentrations used were too low or perhaps
a 16 h incubation was insufficient to elicit a significant effect on inclusion formation in these cells.
Future work should aim to repeat these experiments with a broader range of azoramide
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concentrations to determine whether increasing the expression of ER-resident chaperones can
decrease the formation of inclusions in the cytoplasm.

The increase in protein aggregation and accumulation of FlucDM into inclusions following
treatment with thapsigargin was much less than what was observed following treatment of cells
with MG132. Together these results support previous findings of a link between ER stress and the
functionality of the ubiquitin-proteasome system. Menéndez-Benito et al. (2005) proposed a
model whereby ER stress reduces the functionality of the ubiquitin-proteasome system, resulting
in some accumulation of misfolded proteins in the cell. However, this accumulation normally only
represents ~10% of what is observed when the ubiquitin-proteasome system is inhibited
(Menéndez-Benito et al., 2005), findings that are supported by the data obtained for Neuro-2a cells
in this study. This suggests that when the ER is faced with an excess of ER misfolded proteins,
resulting in ER stress, the degradative capacity of the ubiquitin-proteasome system is
compromised, leading to an increased imbalance of substrates in the cytosol. When comparing the
relative accumulation of misfolded FlucDM into inclusions following thapsigargin versus MG132
treatment, it is interesting to note that NSC-34 cells are much more sensitive to thapsigargin
treatment than Neuro-2a cells (50% of the NSC-34 cells were found to contain inclusions
following thapsigargin treatment, compared to 15% of Neuro-2a cells). Therefore, the
susceptibility of NSC-34 cells to protein aggregation may be related to the functional status of the
ER and the levels of ER client proteins (Tanaka and Matsuda, 2014).

Overall, this work successfully exploited the aggregation-prone nature of FlucDM to quantitatively
ascertain that NSC-34 cells are more susceptible to inclusion formation by destabilised proteins
than Neuro-2a cells. Moreover, the methods presented here mark a first step towards generating a
proteostasis capacity index that is broadly applicable to many cell types. Whilst the proteins
identified within FlucDM-containing proteinaceous deposits in Neuro-2a and NSC-34 cells were

167

Chapter 5 – Method to measure the proteostasis capacity of cells
near identical, the major classes included those belonging to the protein quality control network,
suggesting that these systems are important in maintaining the solubility of the protein in these
cells. Investigation into the major arms of the protein quality control network validated the use of
FlucDM as a biological tool that can be used to study the proteostasis pathways responsible for
regulating the aggregation of destabilised proteins into inclusions. By utilising pharmacological
and genetic approaches to modulate the proteostasis machinery, the results presented in this
chapter suggest that the ubiquitin-proteasome and autophagy pathways are both responsible for
the degradation of FlucDM in Neuro-2a and NSC-34 cells. Furthermore, the functional status of the
heat shock response and/or the ER appears to contribute to the increased susceptibility of NSC-34
cells to inclusion formation compared to Neuro-2a cells. Identification of the pathways important
in preventing protein aggregation, along with techniques that can be used to assess the
susceptibility of cell types to inclusion formation, provides a basis for the development of effective
therapies against neurodegenerative diseases.
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The maintenance of proteostasis is essential for cell and organism survival. Many
neurodegenerative conditions are associated with protein aggregation and their incidence increases
with age, suggestive of a failure in the ability of cells to effectively maintain proteostasis in
response to cellular aging (Carra et al., 2008b, Behl, 2011, Minoia et al., 2014a). Overwhelming
evidence demonstrates that molecular chaperones provide protective effects against protein
aggregation; that the levels of many molecular chaperones is dramatically up-regulated during
times of cellular stress highlights the important role they play in preventing the accumulation of
aggregation-prone proteins into inclusions and plaques in the body. More broadly, identification
of the proteostasis mechanisms that play key roles in preventing protein aggregation, as well as
techniques that can be used to assess the susceptibility of cells to inclusion formation, provides a
foundation for the development of effective therapies to treat neurodegenerative disorders. Thus,
the basis of the work presented in this thesis was to determine how proteostasis mechanisms, and
in particular Hsp molecular chaperones, prevent inclusion formation by aggregation-prone
proteins.

6.1

FloIT is a broadly applicable and quantitative method to assess inclusion formation

The previously described flow cytometric technique FloIT (Whiten et al., 2016) was utilised
extensively in the work presented in this thesis. In Chapters 3 and 4, FloIT was used to screen
various human Hsp isoforms to identify those most effective at suppressing inclusion formation
by the aggregation-prone protein FlucDM. Previous to this, Hsp overexpression screens to identify
inhibitors of protein aggregation – including the effects of Hsp activity following mutations in
crucial domains/residues – have typically relied on using traditional biochemical analyses, such
as filter trap assays or fluorescence microscopy to count cells with inclusions (Hageman et al.,
2010, Vos et al., 2010, Hageman et al., 2011, Minoia et al., 2014b, Kakkar et al., 2016a, Serlidaki
et al., 2020). Whilst the basic principle behind the filter trap assay and FloIT are the same (i.e.
analysis of insoluble protein in a cell lysate), FloIT offers several advantages over the filter trap
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assay. First, FloIT can be used in a medium-to-high-throughput capacity for rapid non-subjective
quantification of inclusions across samples that may differ in transfection efficiency and cell
number. Second, FloIT can identify (and enumerate) inclusions that differ in size, granularity and
even protein composition, making FloIT broadly applicable to most (if not all) model systems of
protein aggregation in cells (Whiten et al., 2016). The work in this thesis describes the first use of
FloIT as a quantitative method to screen for the ability of molecular chaperones (and their
mutational variants) to prevent protein aggregation in cells. Furthermore, when the results of the
FloIT assay were compared to detergent-based cellular fractionation followed by immunoblotting
or counts of cells with inclusions, the FloIT data revealed the same (or similar) trends regarding
the aggregation state of the protein, suggesting that FloIT can provide the same level of
information as these traditional biochemical assays. Future cell-based overexpression screens
conducted to assess the effects of Hsp activity on inclusion formation by other aggregation-prone
proteins should therefore consider using FloIT due to it being a quantitative and non-subjective
approach.

One disadvantage of FloIT is that the aggregation-prone protein under investigation needs to be
fluorescently tagged in order to enumerate inclusions within a cell lysate. In addition, since
members of the Hsp library screened as part of Chapter 3 were also not fluorescently tagged,
differences in the amount of chaperone being expressed between groups was not able to be
determined. It is therefore possible that an increase in the expression of individual Hsps could be
responsible for differences in the capacity for some Hsps to inhibit the formation of inclusions by
FlucDM more potently than others. As previously reported, the addition of bulky fluorescent tags
can significantly perturb the conformation and function of the target protein (Zacharias et al.,
2002). One possible way to alleviate this issue is through the use of self-labelling enzymes, such
as SNAP (Sun et al., 2011), CLIP (Gautier et al., 2008) or Halo (Los et al., 2008) tags, which are
fused in frame with the protein of interest to enable the covalent attachment of small fluorescent
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ligands. Ideally, a fluorescent tag to label proteins for cell-based experiments should be small in
size, specific, chemically stable and bright, and have minimal perturbation on the folding and
function of the target protein. However, it is not always possible to meet all of these criteria and
compromises are often made depending on the system under investigation. Overall, the
overexpression screen was conducted as part of an initial analysis of many Hsps for their capacity
to modulate FlucDM inclusion formation, with the aim to perform follow up analyses on those
found to be the most potent suppressors of FlucDM aggregation. As part of the work presented in
Chapter 4, use of immunoblotting confirmed that the expression of V5-tagged DNAJBs did not
differ substantially between groups. Based on these findings it was concluded that variances in the
capacity of Hsp family members to inhibit FlucDM would primarily be due to intrinsic differences
in their chaperone activity against this aggregation-prone client protein.

The work presented in Chapter 5 successfully developed FloIT as one method for the derivation
of an aggregation index to measure the proteostasis capacity of two neuronal cell lines. The
approach undertaken in this work extends upon the previously reported uses of FloIT (Whiten et
al., 2016, Zeineddine et al., 2017, San Gil et al., 2020) by taking into account the amount of
aggregation-prone protein that is expressed in the transfected cell population. Future experiments
should seek to incorporate other cell lines, such as cancer (e.g. HeLa and MCF-7 cells) and humanderived neuronal (e.g. SH-SY5Y cells) cell lines or primary neurons differentiated from human
stem cells, in this type of approach as this would help to validate that this method for determining
the susceptibility of cell types to inclusion formation is broadly applicable. The eventual
development of a system to score or rank the proteostasis capacity of cells based on the propensity
of an aggregation-prone protein to form inclusions would be a significant step towards delineating
why some cell types are more susceptible to inclusion formation than others. Overall, the different
uses of FloIT described in this thesis highlight the power and potential applications of this
technique to the field of proteostasis.
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6.2

FlucDM as an aggregation-prone protein to model inclusion formation in cells

Cell-based models are important biological tools that can be used to study protein aggregation in
response to cellular stress within the highly dynamic intracellular environment. This work
exploited FlucDM as a structurally destabilised aggregation-prone protein to study the amorphous
aggregation of proteins into inclusions in cells. One distinct advantage of using FlucDM for this
work is that it readily forms cytosolic inclusions without the need to apply an unfolding stress
(Gupta et al., 2011). It therefore acts as an intracellular proteostasis sensor by reporting on the
capacity of cells to maintain the protein in a soluble state. To-date, the majority of cell-based
studies conducted to reveal the interaction of Hsps with client proteins have investigated proteins
whose aggregation is disease related (Hageman et al., 2010, Hageman et al., 2011, Månsson et al.,
2014a, Kakkar et al., 2016a, Serlidaki et al., 2020). However, as these proteins are expressed
endogenously in cells, their misfolding and aggregation may be associated with disruptions to
functional interactions that normally take place in the cell. Thus, FlucDM was chosen for this work
since the overall aim was to identify generic proteostasis mechanisms in cells that engage with
aggregation-prone proteins to prevent their aggregation into inclusions, rather than those that may
be specific for certain proteins. The work presented in Chapters 3 and 4 successfully identified
generic modulators of protein aggregation that arises as a result the destabilisation of a client
protein, highlighting the suitability of FlucDM as a model protein. Furthermore, this work
confirmed that inclusion formation by FlucDM can be monitored in response to the expression of
wild-type or mutational DNAJB variants, thereby facilitating the discovery of key mechanistic
details pertaining to how DNAJBs engage with destabilised proteins in cells (Chapter 4). Another
advantage of using FlucDM in this work was that the protein retains residual luciferase activity, and
thus it was possible to not only assess the capacity of chaperones to prevent aggregation, but also
retain FlucDM in a folded (functional) state (Chapter 3).
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As part of the work described in Chapter 5 of this thesis, proteins that assembled with FlucDM in
inclusions in both Neuro-2a and NSC-34 cells were identified. Many of these proteins were
associated with major KEGG pathways related to neurodegenerative diseases, including
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinocerebellar ataxia, ALS and
prion-related diseases. This again highlights the suitability of FlucDM as an aggregation-prone
protein that can be used to model inclusion formation associated with these neurodegenerative
diseases. Furthermore, the results from this work demonstrate that FlucDM is an extremely effective
biosensor that can be used to detect changes in proteostasis capacity following genetic and
pharmacological modulation. Finally, this work confirmed that FlucDM is a suitable protein to
compare the proteostasis capacity of different cell types.

Based on the Hsp overexpression screen performed as part of Chapter 3, the capacity of the
chaperones tested to prevent FlucDM inclusion formation was found not to be equivalent. For
example, the overexpression of a subset of members of the sHsp family (HspB4 HspB6, HspB7
and HspB9) significantly reduced inclusion formation by FlucDM, whereas others had no effect
(HspB1, HspB5 and HspB8). The ability of specific sHsps to prevent aggregation appears to be
dependent upon the client protein (discussed in depth in Chapter 3). Despite this, the capacity of
a diverse range of sHsps to inhibit the formation of amorphous (Crippa et al., 2010, Carra et al.,
2013, Minoia et al., 2014b) and amyloidogenic (Outeiro et al., 2006, Vos et al., 2010, Cox and
Ecroyd, 2017) aggregates in cells suggests that methods aimed at increasing the expression or
activity of individual sHsps remains a valid option for the amelioration of protein folding diseases.
Further research into the interactions between sHsps and FlucDM would enhance our understanding
of the molecular mechanisms by which sHsps stabilise aggregation-prone proteins in the cell.

The capacity of HspB7 to inhibit the aggregation of polyQ-expanded proteins has prompted further
investigation into the mechanism by which it inhibits amyloidogenesis in cells (Vos et al., 2010).
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However, the process by which HspB7 inhibits inclusion formation by destabilised proteins has
not been clearly defined. As such, using HspB7 as an example, future work could express FlucDM
and V5-tagged HspB7 mutational variants in cells to elucidate whether the anti-aggregation
activity of HspB7 is dependent upon the N- and/or C-terminal region, or the serine-rich stretch in
the α-crystallin domain. A similar approach has been described previously in which expression of
mutational variants of HspB7 with polyQ-expanded huntingtin revealed that the anti-aggregation
activity of HspB7 was dependent upon an interaction with the N-terminal domain (Vos et al.,
2010) The canonical mechanism of sHsp chaperone activity is believed to involve large
polydisperse oligomeric complexes that, via dynamic subunit exchange, bind client proteins,
which are then transferred to the Hsp70 machinery for refolding (Basha et al., 2004, Bryantsev et
al., 2007). To test whether HspB7 inhibits FlucDM inclusion formation in cells by forming
oligomers, future work could express HspB7 or HspB5 (a canonical sHsp) and separate the cell
lysates on sucrose gradients to observe complex formation. To assess whether the capacity of
HspB7 to inhibit inclusion formation by FlucDM is dependent upon interaction with the Hsp70
chaperone machinery, FlucDM could be co-expressed with HspB7, with or without Bag1. Since
Bag1 needs to be in a precise stoichiometric ratio with Hsp70 proteins in order to adequately
accelerate the Hsp70 ATPase cycle (Nollen et al., 2000, Gässler et al., 2001, Kampinga and Craig,
2010), if Bag1 overexpression did not significantly affect the capacity of HspB7 to prevent FlucDM
inclusion formation, this would indicate that HspB7 does not require interaction with Hsp70.
Finally, co-expression of HspB7 with FlucDM, followed by treatment with proteasomal (e.g.
MG132 or bortezomib) or autophagy (e.g. bafilomycin A1 or 3-methyladenine) inhibitors could
elucidate whether the anti-aggregation activity of HspB7 is dependent upon proteolytic processing
by the degradation machinery.

In line with the findings of the sHsp screen, only certain members of the Hsp70 family (i.e.
HspA1A and HspA2) were effective at preventing inclusion formation by FlucDM, whilst
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overexpression of the NEFs tested in this study did not inhibit FlucDM inclusion formation. In
addition, all the DNAJBs tested were potent inhibitors of intracellular inclusion formation by
FlucDM. Overall, these data provide evidence that overexpression of specific Hsps may prevent
amorphous aggregates from forming in cells. However, this work also highlights that when
seeking to target Hsp molecular chaperone action for preventing aggregation associated with
disease, not all Hsps are equal and there is a need to identify the Hsps capable of preventing the
aggregation of the disease-related protein (Kakkar et al., 2014). The results presented in Chapters
3 and 4 of this thesis highlight those Hsps capable of preventing generic aspects of the amorphous
aggregation of proteins into inclusions in cells.

6.3

Proteostasis mechanisms employed by cells to prevent inclusion formation

6.3.1

The mechanism by which DNAJBs prevent the aggregation of FlucDM into inclusions

A primary aim of this work was to utilise FlucDM to identify proteostasis mechanisms within the
cell that are important in maintaining the solubility of destabilised proteins. In Chapter 3, the
DNAJB family of proteins were identified as potent suppressors of FlucDM inclusion formation.
Accordingly, in Chapter 4, the mechanism by which specific members of the DNAJB family,
namely DNAJB6 and DNAJB8, prevent the aggregation of FlucDM into inclusions was
investigated. Based on these findings a new model for the chaperone mechanism of these DNAJB
proteins is presented below. Previous research has identified that DNAJB6-like proteins inhibit
the primary nucleation of β-hairpin structures in amyloid-β and polyQ peptides to prevent mature
amyloid fibril formation by participating in intramolecular hydrogen bonding with hydroxyl
groups in side chains of S/T residues present in the substrate binding domain (Figure 6.1A)
(Hageman et al., 2010, Månsson et al., 2014a, Kakkar et al., 2016b). In contrast, this work
identified that DNAJB6 and DNAJB8 bind destabilised proteins, such as FlucDM, via the
conserved TTK-LKS motif in the C-terminal domain, in doing so holding the protein in a soluble,
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degradation-competent state. These DNAJBs then interact with Hsp70 to support Hsp70dependent degradation of the destabilised protein via the proteasome (Figure 6.1B).
The finding that DNAJB6 and DNAJB8 possess two distinct domains for binding substrates,
highlights the potential of specifically targeting DNAJB chaperone action in the context of protein
aggregation associated with disease. This work suggests that it may be possible to identify small
drug-like molecules that target a distinct substrate binding region of DNAJB6 or DNAJB8, thereby
modulating their capacity to bind to certain client proteins without perturbing their ability to inhibit
other forms of protein aggregation as it arises in the cell. For example, it may be possible to
develop molecules that boost the ability of these DNAJBs to prevent amyloid formation without
interfering with the capacity of these chaperones to bind to destabilised proteins, such as those that
arise as a result of an acute cellular stress.
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Figure 6.1. The proposed model by which DNAJBs interact with Hsp70 for the handling of destabilised
aggregation-prone client proteins in the cell. (A) The hydroxyl groups within the side chains of the S/T-rich region
in DNAJB6-like proteins participate in intramolecular hydrogen bonding with β-hairpin structures to prevent their
primary nucleation into mature amyloid fibrils. In contrast, DNAJB6-like proteins bind destabilised proteins via the
conserved TTK-LKS motif in the C-terminal domain to support Hsp70-dependent degradation via the proteasome.
(B) (1) Destabilised client proteins can aggregate via a disordered mechanism to form amorphous aggregates which
may be sequestered into distinct proteinaceous JUNQ inclusions, previously reported to be associated with
proteasomes. (2) Alternatively, DNAJBs can interact with destabilised client proteins to prevent their aggregation. (3)
Destabilised client proteins can be held by DNAJBs in a soluble form for delivery to Hsp70 for (4) degradation via
the proteasome.
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Whilst co-localisation of FlucDM and DNAJB8 within inclusions was observed as part of the work
described in Chapter 4, this technique is limited in its capacity to resolve physical protein-protein
interactions. Thus, future work should aim to demonstrate a direct physical interaction between
FlucDM and DNAJB6 or DNAJB8, and examine the effect on DNAJB-FlucDM binding following
mutation of the C-terminal substrate binding domain. A traditional method used to decipher the
formation of protein-protein interactions is co-immunoprecipitation; however, these types of
experiments are extremely challenging with the DNAJB proteins because the DNAJB-client
interactions are generally very weak and transient, and therefore lost during the standard lysis
conditions. Another technique for detecting protein-protein interactions that could be performed
to confirm interaction between DNAJBs and FlucDM is biotinylation-based proximity labelling
(BioID) in live mammalian cells (Roux et al., 2012). BioID utilises a promiscuous E.coli biotin
ligase fused to the protein of interest for the selective biotinylation of proteins in proximity to the
fusion protein. Following cell lysis and protein denaturation, the biotinylated proteins can be
captured by streptavidin affinity purification for subsequent analysis by mass spectrometry or
immunoblotting. Thus, by fusing the biotin ligase to DNAJB6 or DNAJB8, client proteins engaged
by these chaperones could be identified. Another potential area for future study would be to
validate the mechanism by which DNAJB6 or DNAJB8 inhibits FlucDM aggregation in vivo. This
could be achieved using a similar approach to that described previously by Hageman et al. (2010),
where FlucDM is expressed in a transgenic Xenopus laevis model under the control of a muscle
specific promoter. DNAJB6 or DNAJB8, along with variants containing mutations in the J-domain
or C-terminal domain, could then be expressed to assess the effects on FlucDM inclusion formation
(Hageman et al., 2010).
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6.3.2

Proteostasis mechanisms to prevent destabilised inclusion formation may differ

between cell types
Based on the results presented in Chapter 4, DNAJBs facilitate interaction of destabilised client
proteins with Hsp70 for their subsequent degradation via the proteasome: autophagy plays little
(if any) role in the processing of FlucDM in HEK293 cells. However, manipulation of the arms of
the protein quality control network in Chapter 5 indicated that, in Neuro-2a and NSC-34 cells, the
capacity of the proteasome or autophagy to degrade FlucDM was equal. These data suggest that
neurons may not utilise the same cellular pathways to maintain proteostasis in response to
inclusion formation by destabilised proteins. The neurodegenerative diseases associated with
failures in proteostasis are typically late onset (i.e. middle age or later), depending on whether the
disease occurs from sporadic or familial origins. Thus, neurons remain functional for decades;
however, in some neuronal cells, age-related declines in proteostasis mechanisms lead to
misfolding and aggregation (Balch et al., 2008, Douglas and Dillin, 2010). The ability of neurons
to maintain proteostasis throughout many decades of life has been attributed to the protective
nature of the chaperone machinery (Smith et al., 2015). Links between mutations in molecular
chaperones and familial cases of neurodegenerative disease further demonstrate the importance of
molecular chaperones in the maintenance of proteostasis in neurons (Hansen et al., 2002, Irobi et
al., 2004, De Mena et al., 2009, Selcen et al., 2009). It would therefore be interesting to determine
whether the mechanisms by which chaperones prevent FlucDM inclusion formation in Neuro-2a
and NSC-34 cells is the same as that reported here for HEK293 cells. In addressing this area, future
studies could utilise a similar approach to that undertaken in this work, i.e. by overexpressing
individual DNAJBs (or H/Q variants) in neuronal cells, combined with the inhibition of
degradation pathways. Continued work into assessing which components of the proteostasis
network are the most critical with regard to preventing protein aggregation in cells may enable
therapeutic targeting of key regulators of this process as a means of treating neurodegenerative
diseases.
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6.3.3

The effect of the heat shock response on intracellular inclusion formation

A major result of the work presented in this thesis was that overexpression of HSF1 reduced
inclusion formation by FlucDM in both Neuro-2a and NSC-34 cells (Chapter 5). Interestingly, it
was found that the mechanism by which HSF1WT overexpression leads to a decrease in inclusion
formation by FlucDM is not dependent upon the upregulation of Hsp levels in the cell. Previous
work has demonstrated that HSF1 activation can increase the rate of protein degradation by the
proteasome in mammalian cells (Parag et al., 1987, Vihervaara and Sistonen, 2014). Thus, HSF1
overexpression in this work may increase the presentation of destabilised proteins to the ubiquitinproteasome system for degradation. To test this, future work could utilise immunoblotting to
investigate whether FlucDM is ubiquitinated upon overexpression of HSF1, and therefore most
likely intended for proteasomal degradation. Changes in the level of expression of representative
proteasomal regulatory subunits (e.g. 20Sα, 20Sβ3, 19S and 11S) could also be detected by
immunoblotting. Alternatively, the chymotrypsin-, caspase-, or trypsin-like specific proteasome
activities could be measured in lysates from cells overexpressing HSF1 (or not), as described
previously (Taylor et al., 2005). Future work to elucidate the mechanism by which HSF1
overexpression inhibits destabilised protein aggregation in cells is important given that modulation
of the heat shock response for disease intervention is continuing to be explored as a potential
avenue for therapeutic intervention (Gomez-Pastor et al., 2018).

Previous research has established pathological hallmarks of neurodegenerative diseases (i.e.
protein aggregation and neuro-inflammation), are poor inducers of the heat shock response in
neuronal cells (Nishimura et al., 1991, Krueger et al., 1999, Pavlik and Aneja, 2007, Oza et al.,
2008, Yang et al., 2008, San Gil et al., 2020). This suggests that the cause of protein aggregation
associated with neurodegenerative diseases may be the inability of neurons to sense and respond
to protein destabilisation. It may therefore be beneficial to pharmacologically or genetically
upregulate the heat shock response in these vulnerable cell types. Future work could utilise a stable
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Neuro-2a cell line that harbours a fluorescent reporter of heat shock response activation, such as
that previously described (San Gil et al., 2020), that is co-transfected with FlucDM, to screen
compound libraries for the identification of heat shock response-inducing compounds. This
method would facilitate the screening of compounds which induce the heat shock response as well
as deciphering whether (or not) this is correlated with a decline in inclusion formation in cells.

6.4

Concluding remarks

The work presented in this thesis confirms FlucDM as a “proteostasis sensor” and model protein
that can be used to investigate the ability of the protein quality control network to engage with,
and process, destabilised client proteins in cells. Through the use of FloIT, the work in this thesis
provides a basis for developing this flow cytometric technique as a standard approach for assessing
inclusion formation in cells, measuring the proteostasis capacity of cells, or as a screening tool to
identify proteins and compounds capable of preventing protein aggregation associated with a
variety of neurodegenerative diseases. For the first time, this work identified that DNAJBs possess
at least two distinct substrate binding regions for interacting with client proteins, one involved in
the interactions with amyloid-forming proteins and the other involved in binding to destabilised
proteins in danger of amorphously aggregating. Thus, this work significantly contributes to our
understanding of how DNAJBs interact with client proteins in the cell to prevent their aggregation
into inclusions. Overall, this knowledge highlights the potential of targeting molecular chaperones
and arms of the protein quality control network for the amelioration of debilitating
neurodegenerative diseases associated with protein aggregation.
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Appendix I

Figure 8.1. The amount of FlucDM-EGFP expressed in cells following co-transfection with a Hsp in the
overexpression screen. Flp-In T-Rex HEK293 cells were co-transfected with V5-tagged members of the (A) HspB,
(B) nucleotide exchange factor (NEF), (C) HspA or (D) DNAJB family or mRFP (as a negative control) and FlucDMEGFP and analysed 48 h post-transfection by quantitative flow cytometry. Data are the mean ± S.E.M (n=3) of the
EGFP geometric mean (arbitrary fluorescence units; AFU) of live, transfected cells co-expressing FlucDM-EGFP and
a HspB, NEF, HspA or DNAJB member (or mRFP as a negative control), as measured by flow cytometry. Significant
differences between group means were tested using a one-way ANOVA but no statistically significant differences
were found (P > 0.05 in all cases).
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Appendix II
Table 8.1. Proteins found in FlucDM inclusions in Neuro-2a and NSC-34 cells following proteomic mass
spectrometry. The lists of proteins identified in Neuro-2a and NSC-34 cells represent only those with an abundance
≥ 2-fold higher than proteins identified in the corresponding untransfected control, and which appeared in all three
biological replicates of each sample. Proteins are sorted by name in alphabetical order and corresponding UniProt
accession numbers are provided.

Neuro-2a
UniProt
accession #
Q9CQV8-1

NSC-34
UniProt
accession #
P62259

Description
14-3-3 protein beta/alpha

P62259

14-3-3 protein epsilon

P68254-1

P61982

14-3-3 protein gamma

P63101

P63101

14-3-3 protein zeta/delta

Q8VDM4

P62334

2'-5'-oligoadenylate synthase-like
protein 1
26S proteasome non-ATPase
regulatory subunit 13
26S proteasome non-ATPase
regulatory subunit 2
26S proteasome non-ATPase
regulatory subunit 3
26S proteasome regulatory subunit 10B

P62192

Description
14-3-3 protein epsilon
14-3-3 protein theta
14-3-3 protein zeta/delta
26S proteasome non-ATPase
regulatory subunit 2

P62334

26S proteasome regulatory subunit 10B

P62192

26S proteasome regulatory subunit 4

O88685

26S proteasome regulatory subunit 6A

P54775

26S proteasome regulatory subunit 6B

P46471

26S proteasome regulatory subunit 7

26S proteasome regulatory subunit 4

P62196

O88685

26S proteasome regulatory subunit 6A

Q8VE22

P54775

26S proteasome regulatory subunit 6B

Q99N87

P46471

26S proteasome regulatory subunit 7

Q80X85

P62196

26S proteasome regulatory subunit 8

Q9D7N3

26S proteasome regulatory subunit 8
28S ribosomal protein S23,
mitochondrial
28S ribosomal protein S5,
mitochondrial
28S ribosomal protein S7,
mitochondrial
28S ribosomal protein S9,
mitochondrial
39S ribosomal protein L11,
mitochondrial
39S ribosomal protein L15,
mitochondrial
39S ribosomal protein L3,
mitochondrial
39S ribosomal protein L38,
mitochondrial
39S ribosomal protein L40,
mitochondrial
39S ribosomal protein L41,
mitochondrial
39S ribosomal protein L46,
mitochondrial
39S ribosomal protein L47,
mitochondrial
39S ribosomal protein L53,
mitochondrial

Q8VI94
Q9WVJ2
Q8VDM4
P14685

Q9CQE3
Q8VE22
Q80ZS3
Q9ER88-1
Q80X85
Q9D7N3
Q9CPR5
Q9CQL5
Q9D1N9
Q9D1B9
Q921S7
Q9Z2Q5

28S ribosomal protein S17,
mitochondrial
28S ribosomal protein S23,
mitochondrial
28S ribosomal protein S26,
mitochondrial
28S ribosomal protein S29,
mitochondrial
28S ribosomal protein S7,
mitochondrial
28S ribosomal protein S9,
mitochondrial
39S ribosomal protein L15,
mitochondrial
39S ribosomal protein L18,
mitochondrial
39S ribosomal protein L21,
mitochondrial
39S ribosomal protein L28,
mitochondrial
39S ribosomal protein L37,
mitochondrial
39S ribosomal protein L40,
mitochondrial

Q9CQF0
Q9CPR5
Q99N95
Q8K2M0
Q9Z2Q5
Q9CQN7
Q9EQI8
Q8K2Y7
Q9D1H8
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40S ribosomal protein S10

P62301

40S ribosomal protein S13

P62843

40S ribosomal protein S15
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P63325

39S ribosomal protein L41,
mitochondrial
39S ribosomal protein L47,
mitochondrial
40S ribosomal protein S10

P62301

P63276

40S ribosomal protein S17

P62270

40S ribosomal protein S18

Q9CZX8

40S ribosomal protein S19

40S ribosomal protein S13

P62849-1

40S ribosomal protein S24

P62843

40S ribosomal protein S15

P62858

40S ribosomal protein S28

P63276

40S ribosomal protein S17

P62862

40S ribosomal protein S30

Q9CZX8

40S ribosomal protein S19

P62082

40S ribosomal protein S7

Q9CQN7
Q8K2Y7

P62267

40S ribosomal protein S23

P14206

40S ribosomal protein SA

P62849-1

40S ribosomal protein S24

P10852

P62852

40S ribosomal protein S25

Q5EG47

P62858

40S ribosomal protein S28

P47955

4F2 cell-surface antigen heavy chain
5'-AMP-activated protein kinase
catalytic subunit alpha-1
60S acidic ribosomal protein P1

P62862

40S ribosomal protein S30

P35979

60S ribosomal protein L12

P62242

40S ribosomal protein S8

P67984

60S ribosomal protein L22

Q6ZWN5

40S ribosomal protein S9

P62751

60S ribosomal protein l23a

P14206

40S ribosomal protein SA

P61255

60S ribosomal protein L26

P10852

P61358

60S ribosomal protein L27

P62900

60S ribosomal protein L31

Q6ZWV7

60S ribosomal protein L35

Q9CR57

4F2 cell-surface antigen heavy chain
4-trimethylaminobutyraldehyde
dehydrogenase
5'-AMP-activated protein kinase
catalytic subunit alpha-1
60S ribosomal protein L14

P47964

60S ribosomal protein L36

P62717

60S ribosomal protein l18a

P47962

60S ribosomal protein L5

P62751

60S ribosomal protein l23a

P12970

60S ribosomal protein l7a

P61358

60S ribosomal protein L27

Q9CQ60

P14115

60S ribosomal protein l27a

Q8QZT1

P62889

60S ribosomal protein L30

Q9EST5-1

P62911

60S ribosomal protein L32

Q99KI0

6-phosphogluconolactonase
Acetyl-CoA acetyltransferase,
mitochondrial
Acidic leucine-rich nuclear
phosphoprotein 32 family member B
Aconitate hydratase, mitochondrial

P47964

60S ribosomal protein L36

P60710

P47962

60S ribosomal protein L5

Q9JM76

P12970

60S ribosomal protein l7a

Q9D8Z1

Q9JLJ2
Q5EG47

Q9DCD0
Q9CQ60
Q8QZT1
Q9EST5-1
Q99KI0
Q9Z2N8
Q9WV32
Q9CVB6
P59999
Q8BK64

6-phosphogluconate dehydrogenase,
decarboxylating
6-phosphogluconolactonase
Acetyl-CoA acetyltransferase,
mitochondrial
Acidic leucine-rich nuclear
phosphoprotein 32 family member B
Aconitate hydratase, mitochondrial
Actin-like protein 6A
Actin-related protein 2/3 complex
subunit 1B
Actin-related protein 2/3 complex
subunit 2
Actin-related protein 2/3 complex
subunit 4
Activator of 90 kDa heat shock protein
ATPase homolog 1
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Actin, cytoplasmic 1
Actin-related protein 2/3 complex
subunit 3
Activating signal cointegrator 1
complex subunit 1

P08030

Adenine phosphoribosyltransferase

P50247

Adenosylhomocysteinase

P54822

Adenylosuccinate lyase

P46664

Adenylosuccinate synthetase isozyme 2

P61205

ADP-ribosylation factor 3

Q9JKX6

ADP-sugar pyrophosphatase
A-kinase anchor protein 1,
mitochondrial

O08715
Q8BGQ7
P47738
Q8C0I1

Alanine-tRNA ligase, cytoplasmic
Aldehyde dehydrogenase,
mitochondrial
Alkyldihydroxyacetonephosphate
synthase, peroxisomal
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Q8C6B9

Active regulator of SIRT1

P17182

Alpha-enolase

P08030

Adenine phosphoribosyltransferase

Q6PAM1

Alpha-taxilin

P50247

Adenosylhomocysteinase

Q91X58

AN1-type zinc finger protein 2B

Adenylate kinase isoenzyme 1

Q8K298

Anillin

P54822

Adenylosuccinate lyase

P07356

P46664

Adenylosuccinate synthetase isozyme 2

Q9Z0X1

P48962

ADP/ATP translocase 1

Q80WC7-1

P51881

ADP/ATP translocase 2

Q9QWY8

P61205

ADP-ribosylation factor 3
ADP-ribosylation factor-like protein
8B
Aldehyde dehydrogenase X,
mitochondrial
Aldehyde dehydrogenase,
mitochondrial
Alkyldihydroxyacetonephosphate
synthase, peroxisomal

Q91YI0

Annexin A2
Apoptosis-inducing factor 1,
mitochondrial
Arf-GAP domain and FG repeatcontaining protein 2
Arf-GAP with SH3 domain, ANK
repeat and PH domain-containing
protein 1
Argininosuccinate lyase

Q8BP47

Asparagine-tRNA ligase, cytoplasmic

Q9R0Y5-1

Q9CQW2
Q9CZS1
P47738
Q8C0I1

Q03265
P56480
Q9DB20

P61164

Alpha-centractin

Q8K268

P17182

Alpha-enolase

Q8BH59

Q8R010
Q9JKC8

Aminoacyl tRNA synthase complexinteracting multifunctional protein 2
Ap-3 complex subunit mu-1

ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
ATP synthase subunit O, mitochondrial
ATP-binding cassette sub-family F
member 3
Calcium-binding mitochondrial carrier
protein Aralar1

Q8BK63-1

Casein kinase I isoform alpha

P67871

Casein kinase II subunit beta

P30999-1

Q9D0I9

Apoptosis inhibitor 5
Apoptosis-inducing factor 1,
mitochondrial
Arf-GAP domain and FG repeatcontaining protein 2
Arginine-tRNA ligase, cytoplasmic

Q9Z1Q5

Catenin delta-1
Cell division control protein 42
homolog
Cell growth-regulating nucleolar
protein
Chloride intracellular channel protein 1

Q9Z2A5

Arginyl-tRNA-protein transferase 1

Q9QYB1

Chloride intracellular channel protein 4

Q8BP47

Asparagine-tRNA ligase, cytoplasmic

Q9CY57

Q922B2

Aspartate-tRNA ligase, cytoplasmic

Q6NVF9

Q9Z2W0

Aspartyl aminopeptidase

Q8BTV2

Chromatin target of PRMT1 protein
Cleavage and polyadenylation
specificity factor subunit 6
Cleavage and polyadenylation
specificity factor subunit 7

O35841
Q9Z0X1
Q80WC7-1

P56135

ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
ATP synthase subunit f, mitochondrial

Q9CPQ8
Q9DB20

Q03265
P56480

P61222
Q8K268
Q91V92
Q9CZ42-1
P12382

P60766-2
Q08288

P11440

Cyclin-dependent kinase 1

P30285

Cyclin-dependent kinase 4

Q03147

Cyclin-dependent kinase 7

ATP synthase subunit g, mitochondrial

P97315

Cysteine and glycine-rich protein 1

ATP synthase subunit O, mitochondrial
ATP-binding cassette sub-family E
member 1
ATP-binding cassette sub-family F
member 3
ATP-citrate synthase
ATP-dependent (S)-NAD(P)H-hydrate
dehydratase
ATP-dependent 6phosphofructokinase, liver type

Q9DCT8

Cysteine-rich protein 2
Cytochrome b-c1 complex subunit 1,
mitochondrial
Cytochrome b-c1 complex subunit 2,
mitochondrial
Cytochrome c oxidase subunit 2
Cytochrome c oxidase subunit 5B,
mitochondrial
Cytochrome c1, heme protein,
mitochondrial
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Q61655
O88967
Q9Z2H5-1
P18155

ATP-dependent RNA helicase
DDX19A
ATP-dependent zinc metalloprotease
YME1L1
Band 4.1-like protein 1
Bifunctional methylenetetrahydrofolate
dehydrogenase/cyclohydrolase,
mitochondrial
Bifunctional purine biosynthesis
protein PurH

Q61753

D-3-phosphoglycerate dehydrogenase

Q9JII5

DAZ-associated protein 1

Q80XN0

D-beta-hydroxybutyrate
dehydrogenase, mitochondrial

Q99L04

Dehydrogenase/reductase SDR family
member 1

Borealin

Q9Z110-1

Calcyclin-binding protein

Q8BHC4

Q60865

Caprin-1

O54908

P67871

Casein kinase II subunit beta

O08749

P60766-2

Cell division control protein 42
homolog

Q8BMF4

Q9QYB1

Chloride intracellular channel protein 4

Q9CY57

Chromatin target of PRMT1 protein

O08553

Dehydrogenase/reductase SDR family
member 7B
Delta-1-pyrroline-5-carboxylate
synthase
Dephospho-CoA kinase domaincontaining protein
Dickkopf-related protein 1
Dihydrolipoyl dehydrogenase,
mitochondrial
Dihydrolipoyllysine-residue
acetyltransferase component of
pyruvate dehydrogenase complex,
mitochondrial
Dihydrolipoyllysine-residue
succinyltransferase component of 2oxoglutarate dehydrogenase complex,
mitochondrial
Dihydropyrimidinase-related protein 2

P23198

Chromobox protein homolog 3

Q9EQF6

Dihydropyrimidinase-related protein 5

Q8BWT5

Disco-interacting protein 2 homolog A

Q99LC2

Clathrin interactor 1
Cleavage and polyadenylation
specificity factor subunit 4
Cleavage and polyadenylation
specificity factor subunit 6
Cleavage stimulation factor subunit 1

O89079

Q9CWJ9
Q8BHX3-1
Q9CXW3

Q99KN9-1

Q99J47

Q9D2G2-1

P37913

DNA ligase 1

Q9EQ28

DNA polymerase delta subunit 3

P97310

DNA replication licensing factor mcm2

Coatomer subunit epsilon

P25206

P11440

Cyclin-dependent kinase 1

P49717

P97315

Cysteine and glycine-rich protein 1

Q61881

P63254

Cysteine-rich protein 1

P52432

Q9DCT8

Cysteine-rich protein 2
Cytochrome b-c1 complex subunit 1,
mitochondrial
Cytochrome b-c1 complex subunit 2,
mitochondrial
Cytochrome c oxidase subunit 2
Cytochrome c oxidase subunit
NDUFA4
Cytoplasmic tRNA 2-thiolation protein
2
Cytosolic Fe-S cluster assembly factor
nubp1

P63037

DNA replication licensing factor mcm3
DNA replication licensing factor
MCM4
DNA replication licensing factor
MCM7
DNA-directed RNA polymerases I and
III subunit RPAC1
DnaJ homolog subfamily A member 1

Q9QYJ0

DnaJ homolog subfamily A member 2

Q8BQZ5-1
Q6NVF9

Q9CZ13
Q9DB77
P00405
Q62425
Q3U308
Q9R060
Q9JII5
Q80XN0
Q99J47

DAZ-associated protein 1
D-beta-hydroxybutyrate
dehydrogenase, mitochondrial
Dehydrogenase/reductase SDR family
member 7B

Q99KV1

DnaJ homolog subfamily A member 3,
mitochondrial
DnaJ homolog subfamily B member 11

Q9QYI4

DnaJ homolog subfamily B member 12

O54946-1

DnaJ homolog subfamily B member 6

Q5U458

DnaJ homolog subfamily C member 11

Q99M87-1

O70152
Q91YQ5
Q9QXS6
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Q9QXB9
O08749
Q9D2G2-1

Developmentally-regulated GTPbinding protein 2
Dihydrolipoyl dehydrogenase,
mitochondrial
Dihydrolipoyllysine-residue
succinyltransferase component of 2oxoglutarate dehydrogenase complex,
mitochondrial

Q62418

Drebrin-like protein

P63168

Dynein light chain 1, cytoplasmic

Q8VDF2

E3 ubiquitin-protein ligase UHRF1

O08553

Dihydropyrimidinase-related protein 2

Q99LC5

Q62188

Dihydropyrimidinase-related protein 3

P10126

Electron transfer flavoprotein subunit
alpha, mitochondrial
Elongation factor 1-alpha 1

P25206

P62631

Elongation factor 1-alpha 2

P58252

Elongation factor 2

Q8K0D5

Elongation factor G, mitochondrial

O08579

Emerin

P84089

Q99KV1

DNA replication licensing factor mcm3
DNA replication licensing factor
MCM7
DNA-directed RNA polymerase I
subunit RPA34
DNA-directed RNA polymerases I, II,
and III subunit RPABC1
DnaJ homolog subfamily A member 1
DnaJ homolog subfamily A member 3,
mitochondrial
DnaJ homolog subfamily B member 11

Q91WN1

DnaJ homolog subfamily C member 9

Enhancer of rudimentary homolog
Enoyl-CoA delta isomerase 1,
mitochondrial
Epoxide hydrolase 1
ER membrane protein complex subunit
8

Q61881
Q76KJ5
Q80UW8
P63037
Q99M87-1

P42125
Q9D379
O70378
Q91X78

Erlin-1

Q9QXS6

Dolichol-phosphate
mannosyltransferase subunit 1
Drebrin

Q8BFZ9

Erlin-2

Q62418

Drebrin-like protein

P60843

Eukaryotic initiation factor 4A-I

Q9D7X3

Dual specificity protein phosphatase 3

Q91VC3

Dynamin-1-like protein

Q8BWY3

P63168

Dynein light chain 1, cytoplasmic

Q8JZQ9

Q6ZPJ3

E2 ubiquitin-conjugating enzyme
UBE2O

O70194

Q3U319

E3 ubiquitin-protein ligase BRE1B

Q9DCH4

Q3UIR3-1

E3 ubiquitin-protein ligase DTX3L

Q91WK2

P46935

E3 ubiquitin-protein ligase NEDD4

Q9QZD9

Eukaryotic initiation factor 4A-III
Eukaryotic peptide chain release factor
subunit 1
Eukaryotic translation initiation factor
3 subunit B
Eukaryotic translation initiation factor
3 subunit D
Eukaryotic translation initiation factor
3 subunit F
Eukaryotic translation initiation factor
3 subunit H
Eukaryotic translation initiation factor
3 subunit I
Eukaryotic translation initiation factor
4E

O70152

Q8K1M6-1

Q61701-1

ELAV-like protein 4

P10126

Electron transfer flavoprotein subunit
alpha, mitochondrial
Electron transfer flavoprotein subunit
beta
Elongation factor 1-alpha 1

P62631

P63073
Q8BIW1

Exopolyphosphatase PRUNE1

Q921I9

Exosome complex component Rrp41

Q3U7R1

Extended synaptotagmin-1

Elongation factor 1-alpha 2

P47754

F-actin-capping protein subunit alpha-2

Q9D8N0

Elongation factor 1-gamma

P47757-1

Q99LC5
Q9DCW4

F-actin-capping protein subunit beta

P58252

Elongation factor 2

Q920E5

Farnesyl pyrophosphate synthase

Q8K0D5

Elongation factor G, mitochondrial

P49945

Ferritin light chain 2

P84089

Enhancer of rudimentary homolog
Enoyl-CoA delta isomerase 1,
mitochondrial
ER membrane protein complex subunit
1

Q80X90

Filamin-B

P42128

Forkhead box protein K1

P42125
Q8C7X2
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Q8VBV3

ER membrane protein complex subunit
8
Eukaryotic initiation factor 4A-I
Eukaryotic peptide chain release factor
GTP-binding subunit ERF3A
Eukaryotic peptide chain release factor
subunit 1
Eukaryotic translation initiation factor
2A
Eukaryotic translation initiation factor
3 subunit B
Eukaryotic translation initiation factor
3 subunit F
Eukaryotic translation initiation factor
3 subunit G
Eukaryotic translation initiation factor
3 subunit I
Eukaryotic translation initiation factor
4 gamma 1
Exosome complex component Rrp4

Q921I9

Exosome complex component Rrp41

O70310

P56960

Exosome component 10

Q3THK7

Glycogen synthase kinase-3 beta
Glycylpeptide Ntetradecanoyltransferase 1
GMP synthase [glutamine-hydrolyzing]

P47754

F-actin-capping protein subunit alpha-2

Q61543

Golgi apparatus protein 1

P47757-1

F-actin-capping protein subunit beta

P62827

GTP-binding nuclear protein RAN

O70378
P60843
Q8R050
Q8BWY3
Q8BJW6-1
Q8JZQ9
Q9DCH4
Q9Z1D1
Q9QZD9
Q6NZJ6

P05064

Fructose-bisphosphate aldolase A

P97807-1

Fumarate hydratase, mitochondrial

P25322

G1/S-specific cyclin-D1

P16045

Galectin-1

Q9D0D5
Q00612
O09172

General transcription factor IIE subunit
1
Glucose-6-phosphate 1-dehydrogenase
X
Glutamate-cysteine ligase regulatory
subunit

P19157

Glutathione S-transferase P 1

P16858

Glyceraldehyde-3-phosphate
dehydrogenase

Q9CZD3

Glycine-tRNA ligase

Q9WV60

Q91WJ8

Far upstream element-binding protein 1

O08582

GTP-binding protein 1

Q3U0V1

Far upstream element-binding protein 2

Q921J2

Q61553

Fascin

P62880

P05064

Fructose-bisphosphate aldolase A

P27601

P97807-1

Fumarate hydratase, mitochondrial

Q9CQS2

Q9R0N0

Galactokinase

GTP-binding protein Rheb
Guanine nucleotide-binding protein
G(I)/G(S)/G(T) subunit beta-2
Guanine nucleotide-binding protein
subunit alpha-13
H/ACA ribonucleoprotein complex
subunit 3
Heat shock 70 kDa protein 14

P16045

Galectin-1

Q61316

Heat shock 70 kDa protein 4

P58854

Gamma-tubulin complex component 3

P07901

Heat shock protein HSP 90-alpha

Q9Z1Z0-1

General vesicular transport factor p115
Glucose-6-phosphate 1-dehydrogenase
X
Glutamate-cysteine ligase regulatory
subunit

P11499

Heat shock protein HSP 90-beta
Heterogeneous nuclear
ribonucleoprotein A/B
Heterogeneous nuclear
ribonucleoprotein A0
Heterogeneous nuclear
ribonucleoprotein A1
Heterogeneous nuclear
ribonucleoprotein A3
Heterogeneous nuclear
ribonucleoprotein D-like
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein K
Heterogeneous nuclear
ribonucleoproteins A2/B1
Hexokinase-1
Histidine triad nucleotide-binding
protein 1

Q00612
O09172

Q99M31-1

Q99020
Q9CX86

P19157

Glutathione S-transferase P 1

P49312-1

P16858

Glyceraldehyde-3-phosphate
dehydrogenase

Q8BG05

Q9CZD3

Glycine-tRNA ligase

Q9Z130

Q9WV60

Glycogen synthase kinase-3 beta

P70333

Q8C5Q4

G-rich sequence factor 1

P61979

P62827

GTP-binding nuclear protein RAN

O88569

Q921J2

GTP-binding protein Rheb

Q9CQC9

P17710-1

GTP-binding protein SAR1b

P70349
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Guanine nucleotide-binding protein
G(s) subunit alpha isoforms short
H/ACA ribonucleoprotein complex
subunit 1
H/ACA ribonucleoprotein complex
subunit 3
H-2 class I histocompatibility antigen,
D-D alpha chain
Heat shock 70 kDa protein 14

Q61316
Q61699

P63094
Q9CY66-1
Q9CQS2
P01900
Q99M31-1

Q9CQN1
P07901

P10922

Histone H1.0

P43277

Histone H1.3

P43274

Histone H1.4

P43276

Histone H1.5

Q64523

Histone H2A type 2-C

Heat shock 70 kDa protein 4

Q8BFU2

Histone H2A type 3

Heat shock protein 105 kDa
Heat shock protein 75 kDa,
mitochondrial
Heat shock protein HSP 90-alpha

Q3THW5

Histone H2A.V

Q64475

Histone H2B type 1-B

Q64524

Histone H2B type 2-E

P62806

Histone H4

Q61081

Hsp90 co-chaperone Cdc37

Q8JZK9

Hydroxymethylglutaryl-CoA synthase,
cytoplasmic

Q9JLZ6

Hypermethylated in cancer 2 protein

Q9JKR6

Hypoxia up-regulated protein 1

Q9D819

Inorganic pyrophosphatase

Q9CXY6

Interleukin enhancer-binding factor 2

P10922

Heat shock protein HSP 90-beta
Hepatocyte growth factor-regulated
tyrosine kinase substrate
Heterogeneous nuclear
ribonucleoprotein A/B
Heterogeneous nuclear
ribonucleoprotein A0
Heterogeneous nuclear
ribonucleoprotein A1
Heterogeneous nuclear
ribonucleoprotein A3
Heterogeneous nuclear
ribonucleoprotein D0
Heterogeneous nuclear
ribonucleoprotein D-like
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein L-like
Heterogeneous nuclear
ribonucleoprotein Q
Heterogeneous nuclear
ribonucleoprotein U-like protein 2
Heterogeneous nuclear
ribonucleoproteins A2/B1
Histidine triad nucleotide-binding
protein 1
Histone acetyltransferase type B
catalytic subunit
Histone H1.0

P43275

Histone H1.1

P06151

P43277

Histone H1.3

Q9QUJ7-1

Long-chain-fatty-acid-CoA ligase 4

P43274

Histone H1.4

Q8JZR0

P43276

Histone H1.5

P34884

Q64523

Histone H2A type 2-C

P28667

Long-chain-fatty-acid-CoA ligase 5
Macrophage Migration inhibitory
factor
MARCKS-related protein

Q8BFU2

Histone H2A type 3

Q91ZV0

Q3THW5

Histone H2A.V

Q80UU9

P27661

Histone H2AX

O08663

Q9D2U9

Histone H2B type 3-A

Q3ULD5

P62806

Histone H4

Q99J09

P11499
Q99LI8
Q99020
Q9CX86
P49312-1
Q8BG05
Q60668-1
Q9Z130
P70333
Q921F4-1
Q7TMK9
Q00PI9
O88569
P70349
Q8BY71

O88844
P54071
P52480-2
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Isocitrate dehydrogenase [NADP]
cytoplasmic
Isocitrate dehydrogenase [NADP],
mitochondrial
Isoform M1 of pyruvate kinase PKM

P28738

Kinesin heavy chain isoform 5C

Q9Z1R2

Large proline-rich protein BAG6

Q924L1

LETM1 domain-containing protein 1

Q922Q8

Leucine-rich repeat-containing protein
59

P24527

Leukotriene A-4 hydrolase

Q99M04

Lipoyl synthase, mitochondrial
L-lactate dehydrogenase A chain

Melanoma inhibitory activity protein 2
Membrane-associated progesterone
receptor component 2
Methionine aminopeptidase 2
Methylcrotonoyl-CoA carboxylase beta
chain, mitochondrial
Methylosome protein 50
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Q9WVG6-1

Histone-arginine methyltransferase
CARM1

Q8CAQ8-1

Q99P31

Hsp70-binding protein 1

Q8K009

Q61081

Hsp90 co-chaperone Cdc37

Q9CR62

Q8JZK9
P00493

Hydroxymethylglutaryl-CoA synthase,
cytoplasmic
Hypoxanthine-guanine
phosphoribosyltransferase

Q9WVA3
Q9D2Y4-1

Q9JKR6

Hypoxia up-regulated protein 1

Q9DCG9

Q8VI75

Importin-4

Q99KX1

Q91YE6

Importin-9

Q60605

Q9D819

Inorganic pyrophosphatase

P24547
Q8K3X4
Q9CXY6

Mitochondrial 10formyltetrahydrofolate dehydrogenase
Mitochondrial 2-oxoglutarate/malate
carrier protein
Mitotic checkpoint protein BUB3
Mixed lineage kinase domain-like
protein
Multifunctional methyltransferase
subunit TRM112-like protein
Myeloid leukaemia factor 2

P08551

Myosin light polypeptide 6
Myosin phosphatase Rho-interacting
protein
NEDD4-like E3 ubiquitin-protein
ligase WWP2
Neural Wiskott-Aldrich syndrome
protein
Neurofilament light polypeptide

P08553

Neurofilament medium polypeptide

P06837

Neuromodulin

P97434-1

Inosine-5'-monophosphate
dehydrogenase 2
Interferon regulatory factor 2-binding
protein-like
Interleukin enhancer-binding factor 2

MICOS complex subunit Mic60

Q9DBH0
Q91YD9

Intersectin-2
Isocitrate dehydrogenase [NAD]
subunit gamma 1, mitochondrial
Isocitrate dehydrogenase [NADP]
cytoplasmic
Isocitrate dehydrogenase [NADP],
mitochondrial
Isoform 5 of Phosphatidylinositolbinding clathrin assembly protein

Q8BHN3

Neutral alpha-glucosidase AB

Q99KQ4

Nicotinamide
phosphoribosyltransferase

Q6GQT9

Nodal modulator 1

P15331-3

Isoform 5b of Peripherin

Q99K48

P52480-2

Q9CPT5
P25976-1

Nucleolar transcription factor 1

Q8R4R6

Nucleoporin NUP53

P28656

Nucleosome assembly protein 1-like 1

P24527

Isoform M1 of Pyruvate kinase PKM
Large neutral amino acids transporter
small subunit 1
Leucine-rich repeat-containing protein
40
Leucine-rich repeat-containing protein
59
Leukotriene A-4 hydrolase

Non-POU domain-containing octamerbinding protein
Nucleolar protein 16

D3YYU8

P06151

L-lactate dehydrogenase A chain

Q78XF5

Q9QUJ7-1

Long-chain-fatty-acid-CoA ligase 4

A2AR02

Obscurin-like protein 1
Oligosaccharyltransferase complex
subunit OSTC
Peptidyl-prolyl cis-trans isomerase g

Q5SUF2-1

Luc7-like protein 3

P35700

Peroxiredoxin-1

Melanoma inhibitory activity protein 2
Membrane-associated progesterone
receptor component 2
Mesoderm-specific transcript protein

Q61171

Peroxiredoxin-2

O08807

Peroxiredoxin-4

O08709

Methionine aminopeptidase 2

P83870

Q8CAQ8-1

MICOS complex subunit Mic60

P09411

Peroxiredoxin-6
PHD finger-like domain-containing
protein 5A
Phosphoglycerate kinase 1

Q791T5-1

Mitochondrial carrier homolog 1

Q9Z2M7

Phosphomannomutase 2

Mitochondrial carrier homolog 2
Mitochondrial import inner membrane
translocase subunit tim23
Mitochondrial RNA pseudouridine
synthase RPUSD4

Q922V4

Pleiotropic regulator 1

Q9Z0R6-1
P70404
O88844
P54071
Q7M6Y3-5

Q9Z127
Q9CRC8
Q922Q8

Q91ZV0
Q80UU9
Q07646-1
O08663

Q791V5
Q9WTQ8
Q9CWX4

Poly(RC)-binding protein 3

Q3UEB3-1

Poly(U)-binding-splicing factor PUF60
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Q9CXT8
Q9WVA3
Q9D2Y4-1
P10404
Q3V3R1
Q8BUN5

Mitochondrial-processing peptidase
subunit beta
Mitotic checkpoint protein BUB3
Mixed lineage kinase domain-like
protein
MLV-related proviral Env polyprotein
Monofunctional C1-tetrahydrofolate
synthase, mitochondrial
Mothers against decapentaplegic
homolog 3

P29341

Polyadenylate-binding protein 1

Q8BG81

Polymerase delta-interacting protein 3

P17225

Polypyrimidine tract-binding protein 1

Q9D824-1

Pre-mRNA 3'-end-processing factor
FIP1

Q99KP6-1

Pre-mRNA-processing factor 19

Q9D287

Pre-mRNA-splicing factor spf27
Probable ATP-dependent RNA helicase
DDX47
Probable ATP-dependent RNA helicase
DDX6
Profilin-1

Q8C570

mRNA export factor

Q9DCL9

Multifunctional protein ADE2

P54823

Q8C181

Muscleblind-like protein 2

P62962

Q60605

Myosin light polypeptide 6

Q9JJV2-1

Profilin-2

Q3THE2

Myosin regulatory light chain 12B
NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 6
NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 9,
mitochondrial
NADH dehydrogenase [ubiquinone] 1
beta subcomplex subunit 4
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 3, mitochondrial
NEDD8-conjugating enzyme Ubc12
Neural Wiskott-Aldrich syndrome
protein
Neuromodulin

P67778

Prohibitin

O35129

Prohibitin-2

P17918

Proliferating cell nuclear antigen

Q9CQZ5
Q9DC69
Q9CQC7
Q9DCT2
P61082
Q91YD9
P06837
Q9D0T1
Q99KQ4
Q99K48
Q99P88

Q9CWX9

Q9QUR6

Q8BHL8

Proteasomal ubiquitin receptor
ADRM1
Proteasome inhibitor PI31 subunit

Q8CIG8

Protein arginine N-methyltransferase 5

Q6PGH1

Protein BUD31 homolog

Q80VD1

Protein fam98b

P97376

Protein FRG1

Q91VH6

Protein MEMO1

Q9JKV1

NHP2-like protein 1
Nicotinamide
phosphoribosyltransferase
Non-POU domain-containing octamerbinding protein
Nuclear pore complex protein nup155

Prolyl endopeptidase

Q2YDW2-1

Protein misato homolog 1

O55125

Protein nipsnap homolog 1

Q8BVQ5

Protein phosphatase methylesterase 1

Q63850

Nuclear pore complex protein Nup50
Nuclear pore complex protein Nup98Nup96
Nuclear pore glycoprotein p62

Q01405

Protein transport protein Sec23A

Q9CPT5

Nucleolar protein 16

Q9D662

Protein transport protein Sec23B

Q8VCB1

Nucleoporin ndc1

Q3UPL0

Q6ZQH8

Nucleoporin NUP188 homolog

Q9CQS8

Q8R4R6

Nucleoporin NUP53

Q80U58-1

Nucleoporin Seh1

Q9CYI4-1

Q9JIH2
Q6PFD9

P97346

Nucleoredoxin

Q05920

Q01768

Nucleoside diphosphate kinase b

Q9D051

P28656

Nucleosome assembly protein 1-like 1

P52480

Protein transport protein Sec31A
Protein transport protein Sec61 subunit
beta
Pumilio homolog 2
Putative RNA-binding protein Luc7like 1
Pyruvate carboxylase, mitochondrial
Pyruvate dehydrogenase E1 component
subunit beta, mitochondrial
Pyruvate kinase PKM

Q6PIP5

Nudc domain-containing protein 1
Oligosaccharyltransferase complex
subunit OSTC
Paraspeckle component 1

Q61598

Rab GDP dissociation inhibitor beta

Q9CT10

Ran-binding protein 3

P34022

Ran-specific GTPase-activating protein

Q8R2U0-1

Q78XF5
Q8R326
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Q8CI51

PDZ and LIM domain protein 5

P97855

P24369

Peptidyl-prolyl cis-trans isomerase B

P63001

Q8BU03

Periodic tryptophan protein 2 homolog

Q91V41

Ras GTPase-activating protein-binding
protein 1
Ras-related C3 botulinum toxin
substrate 1
Ras-related protein Rab-14

P35700

Peroxiredoxin-1

Q9D1G1

Ras-related protein Rab-1B

Q61171

Peroxiredoxin-2

P62823

Ras-related protein Rab-3C

O08709

Peroxiredoxin-6

P61021

Ras-related protein Rab-5B

P09411

P35278

Ras-related protein Rab-5C

P35279

Ras-related protein Rab-6A

Q62193

Replication protein A 32 kDa subunit

Q3UEB3-1

Phosphoglycerate kinase 1
Phosphoribosyl pyrophosphate
synthase-associated protein 1
Phosphoribosylformylglycinamidine
synthase
Platelet-activating factor
acetylhydrolase IB subunit beta
Platelet-activating factor
acetylhydrolase IB subunit gamma
Poly(U)-binding-splicing factor PUF60

P17225

Polypyrimidine tract-binding protein 1

Q8BVY0

Q91Z31

Polypyrimidine tract-binding protein 2

Q9CYH6

Q8BHD7

Polypyrimidine tract-binding protein 3
Pre-mRNA 3'-end-processing factor
FIP1
Pre-mRNA-processing factor 19

Q7TND5

P67778

Pre-mRNA-splicing factor spf27
Probable ATP-dependent RNA
helicase DDX41
Probable ATP-dependent RNA
helicase DDX6
Probable rRNA-processing protein
EBP2
Programmed cell death 6-interacting
protein
Prohibitin

O35129

Prohibitin-2

Q99M28

Q60716

Prolyl 4-hydroxylase subunit alpha-2

P60122

Q9QUR6

Q9JK23

Prolyl endopeptidase
Proteasomal ubiquitin receptor
ADRM1
Proteasome assembly chaperone 1

Q8C650-1

Q8BHL8

Proteasome inhibitor PI31 subunit

Q9Z2Q6

Q9QUM9

Proteasome subunit alpha type-6

Q9D0M1
Q5SUR0
Q61206
Q61205

Q9D824-1
Q99KP6-1
Q9D287
Q91VN6
P54823
Q9D903
Q9WU78

Q9JKV1

P70336-1

Rho-associated protein kinase 2

Q62159

Rho-related GTP-binding protein Rhoc

P84096

Q8R4X3

Rho-related GTP-binding protein Rhog
Ribosomal L1 domain-containing
protein 1
Ribosome biogenesis regulatory protein
homolog
Ribosome production factor 1
RNA binding motif protein, X-linkedlike-1
RNA-binding protein 12

B2RY56

RNA-binding protein 25

O89086

RNA-binding protein 3

Q8VH51-1

RNA-binding protein 39

Q91VM5

Q61545

RNA-binding protein EWS

P56959

RNA-binding protein FUS

Q9CPS7

RNA-binding protein pno1
RNA-binding protein with serine-rich
domain 1
Ruvb-like 1

Q9WTM5
O35609

Ruvb-like 2
Secretory carrier-associated membrane
protein 3
Septin-10
Septin-5

P54923

Protein ADP-ribosylarginine hydrolase

P50431

Q9JIF0-1

Protein arginine N-methyltransferase 1

Q6PDM2

Septin-9
Serine hydroxymethyltransferase,
cytosolic
Serine/arginine-rich splicing factor 1

Q6PGH1

Protein BUD31 homolog

Q9R0U0-1

Serine/arginine-rich splicing factor 10

Q9CZT6

Protein CMSS1

P84104-1

Serine/arginine-rich splicing factor 3

A2ADY9

Protein DDI1 homolog 2

Q8VE97

Serine/arginine-rich splicing factor 4

P27773

Protein disulfide-isomerase A3

O35326

Serine/arginine-rich splicing factor 5

Q922R8

Protein disulfide-isomerase A6

Q9D0B0

Serine/arginine-rich splicing factor 9

Q80UG5-1
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Q9D0F3

Protein ERGIC-53

P62715

Q3TJZ6

Protein FAM98A

P62137

Q80VD1

Protein fam98b

Q9Z1Z2

Q9D945

Protein LLP homolog

P26638

Q91VH6

Protein MEMO1

O55125

Protein nipsnap homolog 1

P07724

Q8BK67

Protein RCC2

Q07417

Q9Z1M8

Protein red

P62315

Q9D662

Protein transport protein Sec23B

P62320

Q3U2P1

Protein transport protein Sec24A

P27048

Q99MR6-1

Serine/threonine-protein phosphatase
2A catalytic subunit beta isoform
Serine/threonine-protein phosphatase
PP1-alpha catalytic subunit
Serine-threonine kinase receptorassociated protein
Serine-tRNA ligase, cytoplasmic
Serrate RNA effector molecule
homolog
Serum albumin
Short-chain specific acyl-CoA
dehydrogenase, mitochondrial
Small nuclear ribonucleoprotein Sm D1
Small nuclear ribonucleoprotein Sm D3
Small nuclear ribonucleoproteinassociated protein B

P52480

Putative RNA-binding protein Luc7like 1
Pyruvate dehydrogenase E1 component
subunit alpha, somatic form,
mitochondrial
Pyruvate dehydrogenase E1 component
subunit beta, mitochondrial
Pyruvate kinase PKM

Q61598

Rab GDP dissociation inhibitor beta

P26369

P46061

Ran GTPase-activating protein 1

Q8VIJ6

Q9CT10

Ran-binding protein 3

P34022

Ran-specific GTPase-activating protein
Ras GTPase-activating protein-binding
protein 1
Ras GTPase-activating protein-binding
protein 2

O54988-1

Q91V41

Ras-related protein Rab-14

Q9WUM5

Q9D1G1

Ras-related protein Rab-1B

Q9D0K2

P62823

Ras-related protein Rab-3C

Q80TB8

Q9CQD1

Ras-related protein Rab-5A

P11983

Splicing factor U2AF 65 kDa subunit
Splicing factor, proline- and glutaminerich
Squamous cell carcinoma antigen
recognized by T-cells 3
Src substrate cortactin
STE20-like serine/threonine-protein
kinase
STIP1 homology and U box-containing
protein 1
Succinate-CoA ligase [ADP/GDPforming] subunit alpha, mitochondrial
Succinyl-CoA:3-ketoacid coenzyme A
transferase 1, mitochondrial
Synaptic vesicle membrane protein
VAT-1 homolog-like
T-complex protein 1 subunit alpha

P35278

Ras-related protein Rab-5C

P80318

T-complex protein 1 subunit gamma

Q9R0M6

Ras-related protein Rab-9A

P42932

T-complex protein 1 subunit theta

Q9QYF1

Retinol dehydrogenase 11
Rho guanine nucleotide exchange
factor 1

P80317

T-complex protein 1 subunit zeta
Thioredoxin domain-containing protein
5
Thioredoxin-dependent peroxide
reductase, mitochondrial
THO complex subunit 4

Q9CYI4-1
P35486
Q9D051

P97855
P97379-1

Q61210
P70336-1

Q3UMC0
Q64674

Spermidine synthase

Q64213

Splicing factor 1

Q8K4Z5

Splicing factor 3A subunit 1

Q9JLI8-1
Q60598

Q9WUD1

Q91W90

Rho-associated protein kinase 2

Spermatogenesis-associated protein 5

P20108

P84096

Rho-related GTP-binding protein Rhog

O08583-1

O88796

Q9QZ06

Q9JJF3

Ribonuclease P protein subunit p30
Ribonucleoside-diphosphate reductase
large subunit
Ribosomal L1 domain-containing
protein 1
Ribosomal oxygenase 1

Q9R099

Toll-interacting protein
Transcription initiation factor TFIID
subunit 9
Transcriptional activator protein Purbeta
Transducin beta-like protein 2

Q8BK35

Ribosome biogenesis protein NOP53

Q6PFR5

Transformer-2 protein homolog alpha

P07742
Q8BVY0

Q8VI33
O35295
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Q9JJA4
Q9CYH6
Q9D7H3
Q91VM5
Q8BP71-1

Ribosome biogenesis protein WDR12
Ribosome biogenesis regulatory
protein homolog
RNA 3'-terminal phosphate cyclase
RNA binding motif protein, X-linkedlike-1
RNA binding protein fox-1 homolog 2

P62996-1
Q01853
P40142
Q99LD9
Q9DAM7

Q8R4X3

RNA-binding protein 12

Q64737

O89086

RNA-binding protein 3

P17751

Q8VH51-1

RNA-binding protein 39

Q64514-1

Transformer-2 protein homolog beta
Transitional endoplasmic reticulum
ATPase
Transketolase
Translation initiation factor eif-2B
subunit beta
Transmembrane protein 263
Trifunctional purine biosynthetic
protein adenosine-3
Triosephosphate isomerase
Tripeptidyl-peptidase 2

Q61545

RNA-binding protein EWS

Q99LF4

tRNA-splicing ligase Rtcb homolog

P56959

P32921

Tryptophan-tRNA ligase, cytoplasmic

Q9ERD7

Tubulin beta-3 chain

Q8BW10

RNA-binding protein FUS
RNA-binding protein Musashi
homolog 1
RNA-binding protein NOB1

P99024

P60122

Ruvb-like 1

Q921Y2

Q9WTM5

Ruvb-like 2

Q810V0

Tubulin beta-5 chain
U3 small nucleolar ribonucleoprotein
protein IMP3
U3 small nucleolar ribonucleoprotein
protein Mpp10
U3 small nucleolar RNA-associated
protein 6 homolog
U4/U6 small nuclear ribonucleoprotein
Prp3
U4/U6 small nuclear ribonucleoprotein
Prp4
UAP56-interacting factor
Ubiquitin carboxyl-terminal hydrolase
48
Ubiquitin carboxyl-terminal hydrolase
5
Ubiquitin carboxyl-terminal hydrolase
isozyme L4
Ubiquitin-associated protein 2-like

Q61474

Q80SW1
Q8BRF7

S-adenosylhomocysteine hydrolaselike protein 1
Sec1 family domain-containing protein
1

Q8VCY6
Q922U1

Q6NZC7

SEC23-interacting protein

Q8C1B7

Septin-11

Q91Z49

Q9Z2Q6

Septin-5

Q3V0C5-1

O55131

Septin-7

P56399

Q6PDM2

Serine/arginine-rich splicing factor 1

P58321

Q9R0U0-1

Serine/arginine-rich splicing factor 10

Q80X50

Q62093

Serine/arginine-rich splicing factor 2

P61089

P84104-1

Serine/arginine-rich splicing factor 3

Q02053

Q9D0B0

Serine/arginine-rich splicing factor 9

Q922Y1

Q80X41

Serine/threonine-protein kinase VRK1
Serine/threonine-protein phosphatase
2A catalytic subunit beta isoform
Serine/threonine-protein phosphatase
2B catalytic subunit alpha isoform

Q9DBP5

Serine-tRNA ligase, cytoplasmic

Q91XD6

P62715
P63328
P26638
Q07417
P16254
Q9DBG7
P47758
P42225
P42227

Q9DAW6

P40336
Q9QZ88

Short-chain specific acyl-CoA
dehydrogenase, mitochondrial
Signal recognition particle 14 kDa
protein
Signal recognition particle receptor
subunit alpha
Signal recognition particle receptor
subunit beta
Signal transducer and activator of
transcription 1
Signal transducer and activator of
transcription 3

UMP-CMP kinase
Vacuolar protein sorting-associated
protein 26A
Vacuolar protein sorting-associated
protein 29
Vacuolar protein-sorting-associated
protein 36

O08547

Vesicle-trafficking protein SEC22b

P20152

Vimentin

P63082
P50516-1
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Ubiquitin-conjugating enzyme E2 N
Ubiquitin-like modifier-activating
enzyme 1
UBX domain-containing protein 1

V-type proton ATPase 16 kDa
proteolipid subunit
V-type proton ATPase catalytic subunit
A

Q9Z1G3

V-type proton ATPase subunit C 1

P51863

V-type proton ATPase subunit d 1
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Q64674

Small nuclear ribonucleoprotein Sm
D1
Small nuclear ribonucleoprotein Sm d3
Small nuclear ribonucleoproteinassociated protein B
S-methyl-5'-thioadenosine
phosphorylase
Sorting and assembly machinery
component 50 homolog
Spermidine synthase

Q64213

Splicing factor 1

Q8K4Z5

Splicing factor 3A subunit 1

Q921M3-1

Splicing factor 3B subunit 3

P62315
P62320
P27048
Q9CQ65
Q8BGH2

Q8JZX4

Splicing factor 45

P26369

Splicing factor U2AF 65 kDa subunit
Splicing factor, proline- and glutaminerich
Stomatin-like protein 2, mitochondrial

Q8VIJ6
Q99JB2

Q8R191

Stress-induced-phosphoprotein 1
Succinate-CoA ligase [ADP/GDPforming] subunit alpha, mitochondrial
Succinate-CoA ligase [GDP-forming]
subunit beta, mitochondrial
Succinyl-CoA:3-ketoacid coenzyme A
transferase 1, mitochondrial
Synapsin-2
Synaptic vesicle membrane protein
VAT-1 homolog
Synaptogyrin-3

Q9CXF4

TBC1 domain family member 15

P11983

T-complex protein 1 subunit alpha

P42932

T-complex protein 1 subunit theta

P80317

Q8CDN6

T-complex protein 1 subunit zeta
Thioredoxin domain-containing protein
5
Thioredoxin-like protein 1

O08583-1

THO complex subunit 4

Q9D0R2

Threonine-tRNA ligase, cytoplasmic

P39447

Tight junction protein ZO-1

Q9QZ06

Toll-interacting protein

Q60864
Q9WUM5
Q9Z2I8
Q9D0K2
Q64332
Q62465

Q91W90

Q6PFR5

Transcription elongation regulator 1
Transcription initiation factor TFIID
subunit 9
Transcriptional activator protein Puralpha
Transducin beta-like protein 3
Transformation/transcription domainassociated protein
Transformer-2 protein homolog alpha

P62996-1

Transformer-2 protein homolog beta

Q9QUI0

Transforming protein RhoA
Transitional endoplasmic reticulum
ATPase

Q8CGF7-1
Q8VI33
P42669
Q8C4J7
Q80YV3

Q01853

228

P50518

V-type proton ATPase subunit E 1

Q8BVE3

V-type proton ATPase subunit H

Q6P1B1

Xaa-Pro aminopeptidase 1

Q91YT7

YTH domain-containing family protein
2

Q9DB42

Zinc finger protein 593

Q31125

Zinc transporter SLC39A7

Chapter 8 – Appendices

Q64514-1

Transketolase
Translation initiation factor eif-2B
subunit delta
Translocon-associated protein subunit
delta
Transmembrane protein 33
Transport and Golgi organization
protein 1 homolog
Transportin-1
Trinucleotide repeat-containing gene
6B protein
Tripeptidyl-peptidase 2

P32921

Tryptophan-tRNA ligase, cytoplasmic

P68369

Tubulin alpha-1A chain

P68368

Tubulin alpha-4A chain

P99024

Tubulin beta-5 chain

Q9D1E6

Tubulin-folding cofactor B

Q61187

Tumor susceptibility gene 101 protein

P57784

U2 small nuclear ribonucleoprotein A'
U3 small nucleolar ribonucleoprotein
protein IMP3
U3 small nucleolar ribonucleoprotein
protein Mpp10
U4/U6 small nuclear ribonucleoprotein
Prp4
UAP56-interacting factor
Ubiquitin carboxyl-terminal hydrolase
14
Ubiquitin carboxyl-terminal hydrolase
47
Ubiquitin carboxyl-terminal hydrolase
5
Ubiquitin carboxyl-terminal hydrolase
isozyme L1
Ubiquitin thioesterase otub1

P40142
Q61749-1
Q62186
Q9CR67
Q8BI84-1
Q8BFY9
Q8BKI2

Q921Y2
Q810V0
Q9DAW6
Q91Z49
Q9JMA1
Q8BY87-1
P56399
Q9R0P9
Q7TQI3
P68037
Q9CZY3
Q922Y1
Q9DBP5
Q9CXL3
Q9CQE8
Q9QZ88
Q9EQH3
Q9Z1Q9
Q9WV55
P46460
P20152
Q60930

Ubiquitin-conjugating enzyme E2 L3
Ubiquitin-conjugating enzyme E2
variant 1
UBX domain-containing protein 1
UMP-CMP kinase
Uncharacterized protein c7orf50
homolog
UPF0568 protein c14orf166 homolog
Vacuolar protein sorting-associated
protein 29
Vacuolar protein sorting-associated
protein 35
Valine-tRNA ligase
Vesicle-associated membrane proteinassociated protein A
Vesicle-fusing ATPase
Vimentin
Voltage-dependent anion-selective
channel protein 2
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Q9Z1G3

Voltage-dependent anion-selective
channel protein 3
V-type proton ATPase 116 kDa subunit
a isoform 1
V-type proton ATPase catalytic subunit
A
V-type proton ATPase subunit B, brain
isoform
V-type proton ATPase subunit C 1

P50518

V-type proton ATPase subunit E 1

Q60931
Q9Z1G4
P50516-1
P62814

Q3UMB9

WASH complex subunit 4

Q9Z0H1

WD repeat-containing protein 46

Q8VCG3

WD repeat-containing protein 74

Q8BFQ4

Q6P1B1

WD repeat-containing protein 82
Wiskott-Aldrich syndrome protein
family member 2
Xaa-Pro aminopeptidase 1

Q31125

Zinc transporter SLC39A7

Q8BH43
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